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ABSTRACT 
 
A key determinant of the pathogenicity of M. tuberculosis (Mtb) is its ability to 
conserve energy and resources by altering its intermediate metabolism response to host-
derived hostile conditions. Growing evidence supports that the central carbon 
metabolism (CCM) of M.tuberculosis including glycolysis, gluconeogenesis, the pentose 
phosphate pathway, and the TCA cycle, is regulated to allow for simultaneous utilization 
of carbohydrates and fatty acids-derived carbon sources. The genes involved in CCM 
represent attractive anti TB drug-targets. Although the role of Mtb phosphoenolpyruvate 
carboxykinase (PEPCK) in gluconeogenesis pathway and pyruvate kinase (PykA) 
enzymes in glycolysis pathway are relevant for the M. tuberculosis pathogenesis, 
targeting these enzymes for the drug development is not straight forward because of the 
human orthologs existence. Here, X-ray crystallographic, biochemical, and inhibitory 
studies of Mtb PEPCK and PykA highlight distinct features of the pathogenic’s enzyme 
that differ from those of the host orthologs’ and provide opportunities to develop 
selective and potent inhibitors.  
Structural data of Mtb PEPCK has revealed that the conformation changes of the 
flexible loops in response to substrates binding differ from the one reported for host 
versions of the enzyme. GTP-competitive inhibitors of human cytosolic PEPCK bind to 
Mtb PEPCK in similar fashion, but the discovery of two unique small pockets in Mtb has 
created an opportunity for the design of a selective Mtb PEPCK inhibitor. By using 
structure-guided medicinal chemistry for GTP-competitive inhibitor series with PEPCK, 
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we are able to improve the inhibitory effect of these inhibitors against the enzyme, 
creating inhibitors with a nano-molar range IC50 and develop 10 fold selective inhibitors 
against Mtb PEPCK over human PEPCK. Structural study of Mtb PykA also 
demonstrated that adenosine mono-phosphate (AMP) is an allosteric effector, and we 
identified the binding mode and interaction of AMP in the allosteric binding site for the 
first time. Screening diverse compound libraries gave us insight into the potential 
scaffolds for the development of more potent pathogen-specific inhibitors. The structural 
and inhibitor studies of Mtb PEPCK and PykA have allowed a better understanding of 
their role in gluconeogenesis and glycolysis, and provide a framework for the 
development of selective inhibitors. 
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CHAPTER I                                                                                                    
INTRODUCTION AND LITERATURE REVIEW  
 
Introduction 
Tuberculosis, caused by the bacterium Mycobacterium tuberculosis (Mtb), is one 
of the oldest described diseases and it is still stubbornly embedded in our population as a 
leading infectious disease. One-third of the world’s population is latently infected with 
Mtb that can be activated at anytime. The 20th WHO global TB report of 2015 estimated 
that the incidence of tuberculosis was about 10 million cases, killing approximately 1.5 
million people in 2014 1. Part of the reason for the global resurgence of TB is due to the 
emergence of resistant strains of TB; multi drug-resistant TB (MDR-TB), extensively 
drug-resistant TB (XDR-TB), and totally drug-resistant TB (TDR-TB). The AIDS 
epidemic has also contributed to the resurgence of TB as people infected with 
HIV/AIDS are more susceptible to TB infection due to immunodeficiency 1. The 
currently accepted TB treatment regimen is a combination of first-line TB drugs, such as 
isoniazid, rifampicin, pyrazinamide, and ethambutol (Table 1-1) for 6-9 months 2 
(WHO) against a drug-sensitive TB strain. Second-line anti-TB drugs are used for drug-
resistant TB treatment. The second-line drugs contain aminoglycosides (kanamycin, 
amikacin, streptomycin) classified as injectable anti-TB agents, para-aminosalicylic acid 
(PAS), ethionamide, fluoroquinolones (moxifloxacin, levofloxacin), cycloserine, and 
bedaquiline and delamanid.  
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Despite the global resurgence of TB, there has been a dearth of new TB drugs in 
the market over the past 40 years. Although bedaquiline (SIRTURO®) and 
delamanid (Deltyba®) have been recently approved only for treatment of drug resistant 
TB, we still need more new TB drugs to overcome drug resistance, shorten the lengthy 
treatment times. For new TB drug discovery, understanding the molecular mechanisms 
of action and resistance of current TB drugs have provided valuable insights and 
accelerated the progress of the development of anti-TB drugs. For example, there are 
over 20 compounds in various stages of new drug development. These compounds 
include novel target drugs, re-purposed existing antibiotics, and modified existing anti-
TB drugs. A review of the literature on current TB drugs may open an avenue for 
investigation of novel drug targets and development of new effective anti-TB 
chemotherapies. Knowledge of drug/target interaction-mediated cell death and resistant 
mutations in target-encoding or related genes may also help us avoid cross-resistance. 
This thesis starts with a review of targets of existing TB drugs, problems of current a 
standard regimen, and novel targets that promise to overcome the drawbacks of exiting 
TB drugs followed by a discussion of the use of structural studies and inhibitor 
identification in suggested novel targets.  
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Table 1-1. Currently used first-line drugs and second-line drugs, target and effect. 
 
Class  Drug  Target and Effect  
First-line drugs  Isoniazide  NADH-dependent enoyl-ACP reductase 
(InhA) 
Inhibition of mycolic acid biosynthesis  
Rifampicin RNA polymerase, β subunit 
(Inhibition of transcription) 
Pyrazinamide  Multiple targets 
Ethambutol  Arabinosyl transferases  
(Inhibition of arabinogalactan synthesis)  
Second-line 
drugs  
Aminoglycoside 
(streptomycin, amikacin, 
kanamycin) 
S12 and 16S rRNA components of 30S 
ribosomal subunit 
(Inhibition of protein synthesis) 
Para-amino salicylic acid  Dihydropteroate Synthase  
(Inhibition of folate synthesis) 
Ethionamide  NADH-dependent enoyl-ACP reductase 
(InhA) 
(Inhibition of mycolic acid synthesis) 
Levofloxacin, moxifloxacin 
(fluoroquinolone) 
DNA gyrase  
(Inhibition of DNA synthesis) 
Cycloserine  D-alanine racemase and ligase  
(Inhibition of peptidoglycan synthesis) 
Bedaquiline ATP synthase 
(Inhibition of ATP synthesis) 
Delamanid Multiple targets 
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Mechanisms of currently available TB drugs   
Current TB drugs can be classified based on the molecular mechanism or on the 
targets they affect.  Most current drugs inhibit the cell wall, protein, DNA, RNA, or 
ATP, folate synthesis, while some inhibit multiple targets.  
Inhibition of cell wall synthesis; isoniazide, ethambutol, ethionamide, D-cycloserine 
The cell wall synthesis pathway is an ideal target for antimycobacterial drug 
development because those pathways are absent in the host. The unique cell wall 
architecture of Mtb is a major determinant of virulence for the mycobacterium. The cell 
is enclosed by layers of peptidoglycan, composed of extensively cross-linked peptide 
side chains consisting of L-Ala, D-Glu, meso-diaminopemelic acid, and D-Ala 3.The 
high degree of peptidoglycan cross-linking contributes the structural integrity of the cell. 
The connection between peptidoglycan and mycolic acids is covalently linked with 
heteropolysaccharide, which is composed of arabinan and galactan (arabinogalactan) 4.  
Mycolic acids are very long chain 2-alkyl, 3-hydroxy fatty acids whose length varies 
among species 5. While Corynebacterium contains mycolic acid chains of up to 40 
carbon atoms.  Mycobacterium chains are much longer, 70-90 carbons , with the addition 
of different structures such as cyclopropanations (cis or trans),  keto, or methoxy groups 
3.  This lipid-rich mycobacterial cell wall contributes to the natural antibiotic resistance 
and impermeability of the cell envelope 6. Isoniaziad, ethambutol, ethionamide, and 
cycloserine are the classes of anti-TB drugs that inhibit cell wall biosynthesis. Moreover, 
the nitroimidazole antibioticsPA-824 (Pretomanid) and OPC-67683 (Delamanid) are 
known to target the cell wall.  
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1 	  
Figure 1-1.  Chemical structure of isoniazid. 
 
 
 
Isoniazid 
Isoniazid (isonicotinic acid hydrazide, INH) (Figure1-1) is a pro-drug, activated 
by the catalase peroxidase, KatG, in Mtb to generate a hypothetical isonicotinoyl radical 
that binds to NAD(H). The active form, the INH-NAD adduct, inhibits the activity of 
NADH-dependent enoyl-ACP reductase (InhA) in the fatty acid synthesis type II system 
(FAS II), which is one of the mycolic acid biosynthetic pathways. Clinical isolates of 
isoniazid-resistant Mtb have been associated with a loss of catalase activity 7 and transfer 
of the wild-type M. tuberculosis katG (catalase-peroxidase) into INH-resistant strains 
restored INH susceptibility 8, suggesting that INH is activated by the katG gene. The 
crystal structure of the InhA complex with the INH-NAD adduct revealed that in clinical 
isolates isoniazid resistant mutations occur in the residues within or near the NADH 
binding site of InhA. Moreover, X-ray crystallography studies with mass spectrometry 
demonstrated that the KatG activated form of INH was covalently bonded to NADH in 
the active site of InhA, suggesting that the increased affinity of the INH-NAD adduct 
caused inhibition of isonicotinic acyl-NADH binding, thereby enabling the catalytic 
  
 
6 
action of InhA 9.  Since INH resistant mutations occur in KatG at a high rate, bypassing 
the activation step by creating a direct InhA inhibitor would be preferable. Therefore, 
interest is high in developing direct InhA inhibitors 10, 11. For example, GlaxoSmithKline 
performed an InhA target-based screen of a million compounds to identify inhibitors, 
and an SAR study was used optimize the hit molecules. They found that tetrahydropyran 
analogs showed great InhA inhibitory potency in the nanomolar range with in vitro 
antibacterial activity 12 and thiadiazoles had low nanomolar InhA IC50s with in vivo 
efficacy in a mouse model 13.  Those InhA inhibitors are currently under lead 
optimization in the TB drug pipeline 14.  
 
 
 
 
Figure 1-2. Chemical structure of ethambutol. 
 
 
 
Ethambutol 
Ethambutol (2,2’ ethylenediiminodi-1-butanol, EMB) (Figure 1-2) was 
discovered in 1961 by screening a collection of synthetic compounds and is  a first-line 
TB drug. The primary target of EMB is a cluster of genes (embCAB) involved in 
arabinogalactan biosynthesis, it disrupts the polymerization of arabinan in the 
  
 
7 
mycobacterial cell wall, resulting in cell death. Metabolic labeling of cells with D-[14C] 
glucose exposed to EMB, revealed the accumulation of β-D-arabinofuranosyl-1-
monophosphodecaprenol, which is the major intermediate of arabinogalactan 
biosynthesis 4. Also, labeled [14C]-mycolic acid in the cell wall extracted from [14C]  
acetate grown cultures of M. smegmatis indicated that EMB inhibits the incorporation of 
mycolic acid into the cell wall 15. Overexpression of the embAB gene leads to EMB-
resistance due to a higher level of arabinosyl transferase activity 16. Also, 
characterization of a clinical EMB-resistant Mtb isolates found mutations on the EmbB 
protein, and in EMB-resistant M.smegmatis there was a single point mutation on the 
embB gene 17. Although, EMB has a modest effect against whole cells with an MIC of 
10 µM, its low toxicity and synergistic effect with other drugs keep EMB in the first-line 
TB drugs. Therefore, significant efforts to develop EMB analogs have been made over 
the past 40 years to improve potency. SAR studies showed that the distance between the 
two nitrogens and the chirality of EMB is critical for activity. For example, the dextro 
(S,S) isomer shows 500 fold more efficacy than the (R,R) isomer 18. Using combinatorial 
chemistry, diamine derivatives were synthesized, leading to identification of a novel 
EMB analog, SQ109, which exhibits a 35-fold greater potency than EMB 19. SQ109 
inhibits cell wall assembly using a different mechanism from EMB. SQ109 was 
discovered, it targets MmpL3, a transporter of trehalose monomycolate (TMM) 20 and 
clinical development is underway 14.   
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Figure 1-3. Chemical structure of ethioamide. 
 
 
 
Ethionamide  
Ethionamide (ETH) (Figure 1-3) is an important component of second-line 
therapy for the treatment of MDR and XDR-TB. There is structural similarity between 
ETH and INH, and over-expression of inhA confers resistance to both ETH and INH in 
Mtb 21, indicating that InhA is ETH’s target and is involved in mycolic acid biosynthesis, 
the same as INH. X-ray crystallographic data of InhA revealed that the ETH-NAD 
adduct binds in a similar position to INH-NAD 22. Like INH, ETH is also a prodrug, but 
it is activated by EthA, a monooxygenase 23, and INH-resistant strains are susceptible 
when treated with ETH. This fact supported by overexpression EthA gene leads to ETH 
hypersensitivity and loss of function mutant strains were shown to be resistant to ETH 24. 
Baulard and his colleagues found that ethA gene expression is regulated by the ethR 
(Rv3855) gene, which is a transcriptional repressor for ethA gene 24. Low expression of 
ethA is responsible for the need for high dose treatment, leading to severe adverse 
effects. Therefore, Baulard and his colleagues attempted to identify EthR inhibitors to 
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increase ETH activation, and one of inhibitors resulted in reduced therapeutic dose of 
ETH 25.   
 
 
 
 
Figure 1-4.  Chemical structure of D-alanine and D-cycloserine. 
 
 
 
D-cycloserine 
D-cycloserine (DCS) is a second-line antituberculosis drug for the treatment of 
MDR- and XDR-tuberculosis. DCS is a structural cyclic analogue of D-alanine, which is 
isolated from Streptomyces orchidaceus and Streptomyces garyphalus (Figure 1-4). 
Shoolery and Rogers (1958) observed the accumulation of the uridine nucleotide, UDP-
GNAc-lactyl-L-Ala-D-Glu-L-Lys, in growth inhibition of S.aureus by DCS and 
Strominger (1960) showed that D-alanine racemase (AlrA) and D-alanine: D-alanine 
ligase (Ddl) are competitively inhibited by DCS 26-28. Also, Walter (1963) and Morrison 
(1962) reported that D-alanine rescued growth activity in presence of DCS growth 
inhibition in Mycobacterium butyricum and Mtb, respectively 29 30.  Overexpression of 
the AlrA and Ddl genes in M. smegmatis supported that these overexpressed genes 
conferred resistance to D-cycloserine in M. smegmatis 31. Therefore, it is thought that 
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DCS targets the AlrA and Ddl enzymes. AlrA catalyzes the conversion of L-Ala to D-
Ala, and Ddl catalyzes the ATP-dependent ligation between two D-alanine to produce the 
D-alanyl-D-alanine dipeptide. Since D-alanine is one of the central components for the 
cross-linking, step of peptidoglycan assembly, inhibition of D-alanine racemase (AlrA) 
and D-alanine: D-alanine ligase (Ddl) blocks the peptidoglycan cross-linking and affects 
cell wall integrity. The severe adverse effects of DCS are attributed to non-specific 
inhibitions. It has been reported that DCS acts as a neuronal N-methyl-d-aspartate 
(NMDA)-receptor partial agonist 32, and thus its side effects are associated with neural 
disorders including depression, memory loss, seizures, and suicidal tendencies, which 
makes it difficult for patients to complete the course of TB treatment 33. Therefore, 
finding the primary target of DCS is critical to develop less toxic and specific inhibitors 
and improve DCS’s properties as an anti-TB drug. The arguments about this issue were 
found in several studies. Overexpressing the Ddl gene in M.smegmatis confers a lower 
level of resistence to DCS than overexpressing the alr gene, suggesting that Ddl is not 
the lethal target of DCS in M.smegmatis 34.  In contrast, analysis of metabolomics, D-
alanine:D-alanine, and Ala (D-, L-), from an H37Rv cell treated at the same DCS 
concentration, revealed that Mtb Ddl activity is strongly inhibited by DCS that is higher 
than Alr 35. Although the crystal structure of Mtb Ddl is available, the Mtb Ddl complex 
structure with DCS has not been solved, thus an SAR study has not yet been developed. 
The severity of the side effects limit its use, however, DCS remains a useful second-line 
TB drug because of its efficacy against MDR-,and XDR-TB and its lack of cross 
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resistance with existing anti-TB drugs. Improving the specificity of DCS could be an 
important toll in the treatment of TB.  
Inhibition of protein synthesis: aminoglycosides 
The ribosome is a complex molecular machine for protein synthesis. Significant 
structural differences between the bacterial and human counterparts makes the ribosome 
an attractive drug target for new antibiotics 36. The bacterial ribosome is composed of 
two subunits, the 50S and 30S, and each subunit is composed of a variety of ribosomal 
RNA and proteins. The 50S subunit catalyzes the formation of peptide bonds in 
polypeptide chains, and the 30S subunit is responsible for proofreading by 
discrimination of mismatched amino acyl transfer RNAs based on the mRNA codon 37.   
 
 
 
 
Figure 1-5. Chemical structure of aminoglycosides. 
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Aminoglycosides (Figure 1-5) are second-line antibiotics for MDR-TB treatment 
which inhibits bacterial protein synthesis by targeting the ribosome. They were isolated 
from soil microorganisms, and consist of an amino-modified sugar structure. The 
currently used aminoglycosides are streptomycin, kanamycin, and amikacin. 
Streptomycin was first introduced as a TB treatment in the early 1940s 38 . Streptomycin-
resistant clinical isolates harbored mutations in components of the 30S subunit of 
ribosome, 16S ribosomal RNA (or 16S rRNA, encoded by rrs) and ribosomal protein 
S12 (encoded rpsL) 39 40. Early experiment have demonstrated streptomycin interferes 
with the ribosome proofreading process 41. A structure of the 30S subunit in complex 
with streptomycin showed that streptomycin binds to the phosphate backbone of 16S 
rRNA nucleotides, and also makes contact with protein S12. Binding to the ribosome 
causes non specific interaction with non-cognate tRNAs, resulting the protein 
mistranslation 37.  The mechanism of action of amikacin and kanamycin action are same 
as that of streptomycin, but the efficacy of each aminoglycoside is reportedly different in 
practice. Due to the high frequency of streptomycin resistance in MDR-TB patients, 
streptomycin is not recommended to use for MDR-TB treatment. Kanamycin and 
amikacin are lower cost and less toxicity than streptomycin, thereby, both agents are the 
first choice of an injectable drugs 42. The mutations in the rrs gene conferred a high-level 
of drug resistance to aminoglycosides. Recent studies on the mechanism of kanamycin 
resistance in Mtb identified a mutation in whiB7, a transcriptional activator, which 
increased the gene expression of both eis (Rv2416c) and tap (Rv1258c). Enhanced eis 
gene expression is associated with inactivation of kanamycin and increased tap gene 
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expression, a putative drug efflux encoding gene, also shows a low-level of streptomycin 
resistance 43. This study suggests that intrinsic mutations in whiB7 can cause cross-
resistance against clinically used aminoglycosides. However, not all resistant strains 
have mutations on whiB7, indicating that the mechanism of action of aminoglycoside 
antibiotic resistance is not clearly identified 44.  Aminoglycosides have significant 
adverse effects, such as nephrotoxicity and ototoxicity in clinical use, resulting in patient 
non-compliance 45. The disadvantages of aminoglycosides make them a less than ideal 
MDR-TB treatment underscoring the requirement for more effective treatments.  
Inhibition of DNA replication: fluoroquinolones (levofloxacin, moxifloxacin) 
 The process of DNA replication requires that the challenges arising from the 
topological issue of the circular double-stranded DNA helix structure be overcome. 
DNA topoisomerases overcome these challenges through breaking and rejoining DNA 
strands. There are two types of topoisomerases, types I and II. The type I topoisomerase 
breakes one DNA strand, while type II breaks double DNA strands at the same time. 
They are sub-divided into types IA, IB IIA, and IIB enzymes based on structure and 
mechanism. During DNA breakage, a covalent phosphotyrosyl bond between DNA and 
the enzyme  forms to produce the covalent protein-DNA complex intermediates after 
nucleophilic attack by  a tyrosine hydroxyl group in the active site toward the DNA 
phosphate 46,47.  
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Figure 1-6. Chemical structure of fluoroquinolones. 
 
 
 
The quinolones are synthetic molecules derived from nalidixic acid, a byproduct 
of the synthesis of chloroquine. It was discovered in 1962 and used to treat of Gram-
negative urinary tract infections 48 . Creating a fluoroquinolone by introducing of 
fluorine at the C6 position of the quinoline ring significantly improved bactericidal 
activity. The fluoroquinolones (levofloxacin and moxifloxacin) (Figure 1-6) are used for 
treatment of MDR-TB as second-line anti-TB drugs which target DNA-topoisomerase 
complexes formed by the type II DNA topoisomerase DNA gyrase 49.  Stabilizing the 
covalent DNA-protein intermediate by fluoroquinolones arrests DNA replication by 
trapping topoisomerase at the DNA cleavage stage and preventing the resealing of the  
DNA breaks 50. Clinical isolates with mutations in gyrA or gyrB are associated with 
resistance to fluoroquinolone 51. Due to its potential found in murin models of TB to 
shorten the length of treatment and active on both replicating and non-replicating 
tubercle bacilli, co-treatment of moxifloxacin with rifampin, pyrazinamide, was able to 
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eradicate Mtb from infected mice lung within 2 month 52.  Currently, novel TB regimen 
of PaMZ (PA-824, moxifloxacin pyrazinamide) for TB treatment is in clinical 
development 14, 52. However, the concern of fluoroquinolone-resistance leads to make 
efforts of finding new class of inhibitors targeting DNA gyrase are in progress, as DNA 
gyrase is a clinically validated therapeutic target.    
Inhibition of RNA polymerase: rifamycins 
Transcription by DNA-dependent RNA polymerase (RNAP), is a key step in 
gene expression and an essential step for bacterial growth and survival and the 
complexities of bacterial RNAPs differ from eukaryotic RNAPs 53, making bacterial 
RNA polymerase an attractive drug target. Most bacteria have a single RNAP with a 
core structure consisting of a multi-subunit, α2ββ'ω that forms a crab claw-like structure 
54. The catalytic site of the enzyme is formed by the cleft between the β and β' subunits, 
which accommodates DNA templates to make phosphodiester bond during transcription 
elonagation.   
 
 
 
 
Figure 1-7. Chemical structure of rifamycins. 
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Rifamycins (Figure 1-7) are a part of the ansamycin family of antibiotics, whose 
backbone structure consists of a naphthoquinone core connected with an ansa poly-
hydroxylated bridge. It exhibits more potent activity on Gram-positive bacteria than on 
Gram-negative especiallyit isstrongly affecting on mycobacteria. Rifamycins are an 
outstanding class of anti-tubercular drugs in that they shorten the treatment duration 
from 18 to 9 months, and have a sterilizing activity. Thereby, rifamycins are the 
mainstay of antituberculosis therapy, especially rifampin, one of rifamycins, which is 
currently used as a first-line of anti-TB drug. However, there are two major drawbacks 
to rifamycins (1) drug-resistance is rapidly acquired through mutations to the target 
enzyme, and (2) drug-drug interactions (with antiretroviral agents and bedaquiline) by 
inducing cytochromes P450 in the liver. For this reason, there have been numerous 
efforts to development analogs that minimize these drawbacks.  
Understanding of the mechanism of action of rifamycins is critical for the 
development of novel agents or rifamycin analogs. Two different models from structure-
function studies have been proposed to account for the mechanism of action of 
rifamycins: the steric occlusion model and the allosteric modulation model. Rifamycins 
target the β-subunit (encoded by rpoB) of DNA-dependent RNA polymerase (RNAP). 
The determination of the crystal structure of the Thermus aquaticus RNAP-rifampicin 
complex showed that rifampicin binds in a deep pocket 20Å away from the active center 
in the RNAP β-subunit. This study suggested the steric occlusion model for the 
mechanism, in which rifampicin sterically blocks the transcription elongation of RNA 
when the chain becomes 2 to 3 nucleotides long, but is not effective against longer 
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chains so it is only effective at a certain stage of transcription 55. However, the the steric 
model could not explain all the mutations related to rifamycin-resistance. The mutations 
β-D516N and β-D516V on RNAP were found in the rifamycin-resistant strains, but do 
not decrease the affinity of rifamycins for RNAP. Moreover, rifabutin and rifalazil do 
not share cross-resistance with rifampin, indicating a different subset of resistant 
mutations 56. These observations prompted Artsimovitch et al. to propose the, allosteric 
modulation mechanism in which rifabutin and rifapentin bind allosterically to modulate 
a loss of affinity for catalytic Mg2+ binding in the active site resulting in transcription 
inhibition 57.  However, Feklistov et al. re-tested the evidence in support of the allosteric 
modulation mechanism and found that the steric-interference model is the most likely 
real mechanism. Directly testing the affinity of rifamycins to Mg2+ in solution showed 
rifamycin had no effect on metal binding in the RNAP active site. Their study also 
showed that the rifmycin-resistant mutants, β-D516N and β-D516V, quantitatively affect 
on rifampicin-RNAP interaction, decreasing rifamycin affinity for RNAP.  These results 
implY that tighter binding interactions between rifamycin analogs and the RNAP 
enzyme may have a chance to overcome rifamycin-resistant mutations. Of the numerous 
modifications and structure-activity relationships (SAR) studies on rifamycins, the most 
promising analogs are the piperidine ring-substituted rifabutin analogs and the rifalazil 
analogs because of their activities against a variety of rifampin-resistant clinical isolates 
of TB. Because these drugs target RNAP, it is being used as a target to search for 
additional novel compounds.   
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Another major problem of using rifamycins in TB treatment is its susceptibility 
to drug-drug interactions due to its ability to induce drug transporter proteins, P-
glycoproteins and drug-metabolising enzymes, particularly cytochrome P450 (CYP) 3A4 
in the liver and small intestine 58. These interactions cause rifampicin to decrease the 
plasma concentration of several drugs, especially HIV protease inhibitors, leading to 
treatment failure. A 600mg daily dose of rifampicin with a single protease inhibitor 
reduced the area under the concentration-time curve (AUC): indinavir was reduced by 
92% , nelfinavir by 82% , and saquinavir by 70% 58. However, different rifamycins 
display different degrees of CYP induction; for example, co-administering with rifabutin 
(300 mg daily dose) improved the reduction of indinavir to only 34% below its original 
AUC 59.  Co-adiministration with CYP3A inhibitors (HIV protease inhibitors) can 
increase the plasma concentration of rifabutin by inhibiting rifabutin metabolism by 
CYP3A4. Thereby, the different rifabutin profiles can alter the effectiveness of TB 
treatment for HIV co-infected patients. Though it may be possible to overcome two 
major drawbacks of rifamycins through structural modifications, rifamycin analogs still 
face the problem of drug-drug interaction with drugs other than antiretrovirals, such as 
other TB drugs (moxicloxacin 60 , bedaquiline 61) creating more challenges to their use. 
Therefore, rifamycin-free regimes are being developed.   
Inhibition of ATP synthase: bedaquiline 
ATP synthase has a complex structure and reaction mechanism. It is composed of 
two domains, a membrane- bound F0 domain, which is involved in proton translocation, 
and a cytoplasmic located hydrophilic F1 domain that catalyzes ATP hydrolysis 62. 
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Bacterial ATP production by F1F0-ATP synthase is essential in a number of vital cellular 
processes. In aerobic bacteria, ATP synthase is involved in ATP generation through 
oxidative phosphorylation. In anaerobic bacteria, ATP synthase maintains pH 
homeostasis via generation of the proton motive force by pumping protons under non-
respiratory growth conditions 63. In mycobacteria, ATP synthase is essential in both the 
replicating and non-replicating states. Hypoxic, non-replicating Mtb is requires ATP 
synthesis activity to maintain ATP homeostasis 64. Deleting the atpD gene in 
M.smegmatis makes the bacterium incapable of growth on fermentable and non-
fermentable carbon sources 65, and makes it a potential  target for promising new 
antibacterial drugs.  
 
 
 
 
Figure 1-8. Chemical structure of bedaquiline. 
 
 
 
Bedaquiline (BDQ) (Figure 1-8), the diarylquinoline TMC207 (also known as 
R207910), was approved by the FDA in 2012, specifically for MDR-TB treatment. It is 
effective not only on active, replicating Mtb but also against the dormant, non-
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replicating state. The lead compound was discovered from a whole-cell screen, and then 
optimized into a series of diarylquinolines; the most potent compound, R207910, 
showed potent in vitro activity against M. tuberculosis H37Rv and clinical isolates, with 
MICs in the range of 0.030 to 0.120 µg/ml (rifampicin; 0.500 µg/ml and isoniazid 0.120 
µg/ml). Its mechanism of action differs from pre-existing antitubercular drugs by in that 
it targets the energy metabolism of mycobacteria by inhibiting ATP synthase, leading to 
ATP depletion and causing an imbalance in pH homeostasis 66 67. Point mutations in the 
atpE gene, a part of the F0 subunit of ATP synthase, conferred resistance to R207910 67. 
However, these target-based mutations were only observed in about 30% of the BDQ 
resistant isolates, indicating that multiple mechanisms of resistance existed 68. Rv0678, a 
transcriptional repressor of the gene encoding the MmpS5-MmpL5 efflux pump, was 
reported to be associated with non-target based resistance to BDQ. The BDQ resistant 
strains that lacked  mutations on the atpE gene, showed cross-resistance to clofazimine 
(CFZ), and the sensitivity of CFZ and BDQ against the cell was increased in the 
presence of efflux inhibitors, verapamil and reserpine. Therefore, the MmpS5-MmpL5 
efflux pump could be involved in non-target based acquired resistance of BDQ 69.  
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Figure 1-9. Chemical structure of para-aminosalicyclic acid (PAS). 
 
 
 
Inhibition folate synthase: para-aminosalicylic acid (PAS) 
para- aminosalicyclic acid (PAS) (Figure 1-9) was introduced as a 
antituberculosis agent in 1940s 70, and is one of the second-line drugs used for MDR-TB 
treatment. PAS-resistant transposon mutants of M. bovis BCG harbor insertions in the 
thymidylate synthase (thyA) gene, which is involved in controlling intracellular folate 
levels and clinical PAS-resistant isolate strains contain mutations in thyA, showing that 
PAS action is associated with the folate pathway 71. However, the detail mechanism of 
its action was not discovered over 60 years since it was introduced in TB treatment 
regimen. In 2013, Zheng, J. et al. has reported that PAS is a prodrug, its metabolite 
through the folate pathway working with dihydropteroate synthase (DHPS) and 
dihydrofolate synthase (DHFS) targets dihydrofolate reductase (DHFR, encoded by 
dfrA), inhibiting enzyme activity. They also showed that converted to the active form by 
enzymes in the folate pathway where it serves as an alternative substrate for 
dihydropteroate synthase (DHPS), resulting in an inhibition of folate metabolism 72 73. In 
addition, they found overexpressing RibD enzyme, known as a functional analogue of 
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DHFR, is resistant to PAS, suggesting that clinical isolates of PAS-resistance strains 
may contain mutations in dfrA and ribD gene 72. Due to PAS does not share cross-
resistance with existing drugs; it can be still in second-line drugs for MDR- and XDR-
TB treatment.  
 
 
 
 
Figure 1-10. Chemical structure of PA-824 (Pretomanid) and OPC-67683 (Delamanid). 
 
 
 
Inhibition of multiple targets: nitroimidazole, pyraziamide 
The novel antibacterial agents, PA-824 and OPC-67683 (Figure1-10), are a series 
of bicyclic nitroimidazoles, which were found to have anti-tubercular activity. These 
agents were developed using SAR studies by creating structural analogs of a 
radiosensitizer (CGI-17341) used in cancer chemotherapy. Due to the mutagenicity 
associated with bicyclic nitroimidazoles, its potential antibacterial properties were not 
investigated 74. However, Novartis found the lead compound PA-824 from screening 300 
nitroimidazooxazines derivatives, which is active against Mtb without the mutagenicity. 
Otsuka Pharmaceuticals discovered and developed a seriese of nitroimidazooxazoles, 
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leading to the compound OPC-67683, Delamanid (Deltyba®), a potent compound against 
drug–susceptible TB and MDR-TB which first received approval for the treatment of 
MDR-TB in the European Union (EU) in April 2014.    
PA-824 and OPC-67683 exhibit anti-tuberculosis activity against both non-
replicating and actively replicating Mtb, which is shortens the duration of TB treatment. 
Moreover, they do not share cross-resistance with current anti-TB drugs as seen by 
comparable susceptibility against MDR-TB strains 75. Both compounds are pro-drugs 
activated by a deazaflavin (cofactor F420) dependent nitroreductase (Ddn, Rv3547), and 
mutations in this gene confer resistance to both agents 76. Also, loss of a specific 
glucose-6 phosphate dehydrgenase (FGD1) or deazaflavin cofactor F420 is related to 
PA824 resistance, indicating they are necessary for sensitivity to nitroimidazole analogs 
75.  After intracellular bioreductive activation, the molecules inhibit mycolic acid 
synthesis under aerobic conditions, disrupting the formation of ketomycolates as seen by 
accumulation of hydroxymycolates. However, this mode of action does not explain the 
mechanism for killing non-replicating Mtb, since mycolic acid synthesis is not necessary 
for non-replicating Mtb 77. Singh et al. showed the PA-824 dependent production of 
HNO2 by Ddn and demonstrated the des-nitro product from PA-824 activated by Ddn 
was correlated to the anaerobic killing activity of PA-824 78.  The crystal structure of 
Ddn from Mtb and its homolog from Nocardia farcinica provided insights into the 
binding mode of PA-824 and allowed the development of novel analogues that bind to 
the mutant Ddn structure 79, 80.  Analysis of 14C-labled fatty acid and mycolic acid 
showed that OPC-67683 inhibits especially the synthesis of methoxy- and keto-mycolic 
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acid, with IC50 values of 0.021-0.036 µg/ml, while INH inhibits non-specific mycolic 
acid subclasses (IC50 = 0.630-1.851 µg/ml). Moreover, no effect of this compound on 
CYP enzymes was reported, indicating it can be used safely in HIV co-infected patients 
81. In clinical trials, the WHO reported that co-administration of delamanid with anti-
retroviral drugs showed no clinically significant drug-drug interaction 82.  
  Although the novel mechanism of bicyclic nitroimidazoles is an advantage 
against MDR- and XDR-TB treatment, the high rate of drug resistance is a major 
problem with these series of drugs. It has been reported that the mutation frequency to 
PA-824 resistance is comparable to that of INH 76, and two mutations in coenzyme F420 
genes, fbiA and fgd1, conferred delamanid resistance as soon as delamanid was 
introduced to the regimen for MDR-TB treatment 83. However, the feature of 
nitroimidazoles activity on non-replicating strain is considered as important to be used in 
combination of other drugs for the TB treatmement. Novel TB regimen including PA-
824 is currently in clinical phase III, and results in shoten the lengcy of treatment, safer 
to use in patients with HIV and TB than a standard regimen. 
 
 
 
 
  
 
25 
 
Figure 1-11. Chemical structure of pyrazinamide. 
 
 
 
Pyrazinamide (PZA) (Figure 1-11) is a first-line anti-TB drug discovered in 1952 
84, and it is effective against semi-dormant TB within an acidic environment, 
contributing to shortening the required time for TB chemotherapy 85. Multiple targets of 
PZA in Mtb have been reported.  PZA is a pro-drug, which is metabolized intercellularly 
to the active form pyrazinoic acid (POA) by pyrazinamidase/nicotinamidase (encoded by 
pncA). Mutations in the pncA gene result in PZA resistance in Mtb by preventing PZA 
conversion into POA 86, 87. The ability of POA to disrupt the proton motive force and 
ATP synthesis has been observed 88, 89, but the mechanism of action remains elusive.  
Ribosomal protein S1 (RpsA) was reported as a putative molecular target of POA in 
2011 based on its binding activity to POA. RpsA is responsible for translation initiation 
of mRNAs and IS involved in trans-translation. Trans-translation in bacteria is a key 
process in high fidelity protein synthesis, arresting any  ribosome with damaged mRNA 
free by removing the mRNA and the product of polypeptide chains 90. Trans-translation 
is performed by transfer-messenger RNA (tmRNA), which has the functions of both 
tRNA and mRNA. The RpsA C-terminus is involved in trans-translation by specifically 
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binding to the tmRNA and it has been proposed that POA binds to the C-terminal region 
of Mtb RpsA and disrupts the formation of the RpsA-tmRNA complex 91. A structure of 
RpsA complexed with POA demonstrated that POA binds to the same RpsA residues 
involved in tmRNA binding 92, thereby disrupting the interaction between RpsA and 
tmRNA, and causing inhibition of trans-translation. Recently the study to identify 
anothertarget of PZA/POA reveals that the mutations in the Mtb panD gene (encoding 
aspartate decarboxylase) from Mtb, but not in in the pncA and rpsA genes, conferred 
resistance to POA and PZA 93, 94.  Overexpression of the wild-type Mtb PanD resulted in 
POA resistance and the enzyme activity was inhibited by POA, but not by PZA. Mtb 
PanD catalyzes L-aspartate to β-alanine, which is required for pantothenate (vitamin B5) 
and CoA synthesis. The sterilizing effect of POA can be explained by the action of POA 
inhibiting this energy metabolism by targeting PanD 94. A complex structure of Mtb 
PanD with POA could elucidate the structural basis for inhibition of PanD by POA.  
Most frequent drug resistance mutant, M117I, in C-terminal of PanD is not involved in 
enzyme activity. From the structure of PanD from E.coli published in 2015, it reveals 
that C-terminus of PanD is critical for interacting with PanZ, which activates PanD 95. 
Therefore, it suggests that POA interrupts the important protein-protein interaction 
between PanD and other activators, leading to POA-resistance. However, the structure of 
PanD from Mtb has not been reported yet, thus it is unclear to demonstrate the molecular 
mechanism of POA/PZA action.  
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Problems of current TB treatment  
Despite the availability of effective anti-TB drugs that addressed above, the 
treatment that completely could lead to the elimination of the disease has proven to be 
very difficult for a number of complex factors.  
Currently used TB treatment regimes require at least 6 months for success 
clinical cure using combination drugs. This lengthy multidrug treatment is attributed to 
patient difficult to complete the cource and adherence to drugs, leading treatment failure, 
relapse of infection and development of drug resistance. The global incidence of MDR- 
and XDR-TB cases has contributed that TB treatment becomes more challenging. MDR-
TB is defined as a TB strain which is not sensitive to isoniazid and rifampicin, the first-
line anti-tubercular agents. XDR-TB is a multi drug-resistant strain that is resistant to 
first-line and the most effective second-line anti-TB drug, fluoroquinolone, together with 
one of injectables (i.e., amikacin, kanamycin, or capreomycin). TDR is a TB strain that 
is resistant to all of anti-TB drugs 96. The occurrence of drug-resistant strains has 
gradually increased with estimated 10 million TB cases in 2014; of those an estimated 
300,000 cases are multi-drug resistant (MDR), and that 9.7% individuals are extensively 
drug resistant (XDR-TB) 1. The treatment for MDR-TB requires up to 18-24 months 
treatment duration with a combination of eight to ten pills daily, leading 30% of MDR-
TB patients fails to complete this course 97, 98. Only 50% of successful results of MDR-
TB treatment has been reported, and an estimated 190,000 people died from MDR-TB in 
2014 1.  XDR-TB is virtually untreatable and it is estimated that 70% of XDR-TB 
patients die within a month of diagnosis 1. Most MDR- and XDR- TB drugs cause high 
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rates of adverse events including, ortotoxicity, uncontrolled psychiatric disorders, and 
gastrointestinal effects 99, 100, leading of discountinuation of MDR- and XDR TB 
therapy.  
People with untreated latent TB infection and HIV infection are much 
more likely to develop active TB disease during his or her lifetime than people without 
HIV infection. One-third of the more than 33 million people living with HIV/AIDS are 
also infected with tuberculosis, one-fourth of HIV positive people die due to TB 
infection 96. Co-infection of TB and HIV complicates the anti-TB treatment because of 
drug-drug interaction and overlapping drug toxicities. For example, the problem of drug-
drug interaction between TB drugs (rifampicin) and anti-retroviral (ARV) drugs makes 
TB treatment for people with HIV/AIDS difficult. Rifampicin induces the expression of 
cytochrome P450 (CYP) 3A4 enzyme in the liver and intestines. This enzyme is drug-
metabolising enzyme that can metabolize protease inhibitors, results in reduced of the 
therapeutic concentration of the protease inhibitors. Therefore, the use of rifampicin with 
these HIV protease inhibitors contributes HIV treatment failure and development of drug 
resistance 101.   
Heterogeneity of bacterial population and variety of niches they reside in the host 
is the reason that current therapy regimen does not completely eradicate all Mtb in the 
body. Although RIF and PZA have shorten the treatment duration from 12-18 months to 
6 months, persisting after treatment subpopulation can be re-activated when host 
immune system is compromised. Those bacteria remain in non-replicating state, leading 
to latent TB infection. Mitchison has classified four Mtb subpopulations depending on 
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drug susceptibility, 1) actively growing bacilli which are most effectively killed by INH, 
2) slow growing bacilli that have spurts of metabolism, which are killed by RIF, 3) less 
metabolically active bacilli present in the acid pH environment that are killed by PZA, 
and 4) dormant bacilli which are not killed effectively by current drugs 102.  Therefore, 
sterilizing effect of TB drugs is important to prevent re-activation of subpopulation, and 
activation of latent-TB among one third of global population.  
Moreover, TB has complex pathology, and as a result bacilli reside in 
compartments with very different characteristics: cellular compartment enriched by 
macrophages and easily accessed by plasma and caseous necrotic core, rich in lipids, 
with limited diffusion from plasma. It is challenging to produce a drug with such 
physical-chemical properties that it will readily distribute in both very distict 
compartments. Recent study showed that despite favorable pharmacokinetics of all 
current drugs in blood, only RIF and PZA were able to achieve sufficient concentrations 
across both compartments of lesions 103. It clearly suggests that use of any single anti-TB 
drugs is not sufficient to kill all Mtb bacilli, concomitant drug treatment is necessary to 
increase the success rate of TB therapy.  
These challenges to control TB with current antituberculosis drugs highlight the 
urgent need for developing new anti-TB drugs that satisfy several important 
requirements for effective treatment. First, new TB drugs should have no cross-
resistance with the first-line drugs to kill effectively MDR- and XDR-TB. For this, it is 
important to develop new drugs that inhibit novel targets that are different from those of 
currently used drugs. Second, new drug should be effective against dormant Mtb and 
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shorten the lengthy TB therapy to improve patient compliance. The drugs should have 
limited toxicity, suggesting the target of inhibition should be only present in bacteria or 
have sufficient structural difference between host and pathogen. Also, the new drugs 
should be affordable to ensure accessibility to people in the developing conturies, where 
is the majority of the high TB burden resides 104. Lastly, drug-drug interactions between 
TB drugs and antiretroviral drugs should be eliminated or minimal to be useful for 
therapy for co-infected HIV and TB patients. 
 
New regimen(PaMZ) for efficient TB treatment 
The new regimen developed by TB Alliance which includes moxifloxacin, PA-
824, and pyrazinamid, called PaMZ, is currently being evaluated in phase III clinical 
trials and expected to chages a paradigm of standard TB treatment. In phase 2b trial done 
in 2015, this novel TB regimen showed improved treatment of both drug-susceptible and 
MDR-TB.  In clinical study of PaMZ with over 200 patients, cultured sputum of 71% 
patients with 2 month course of PaMZ treatment shows no TB, while sputum of only 
38% patients with standard treatment shows no TB 105. Moreover, this regimen treatment 
shortens the duration treatment time for both drug-susceptible and MDR-TB. A standard 
treatment currently takes 6 months for drug-susceptible TB and 18-24 months for MDR-
TB. Due to powerful bactericidal activity, this regimen is shortened to 4 months for 
drug-susceptible TB and to 6 months for MDR-TB. It also proved to be efficient in 
patients co-infected with TB/HIV. In addition, this novel regimen is not required the 
injectable agents, so it is easy to store, distribute and administer which is crucial for the 
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third world countries where the burden of TB is highest.  Therefore, the PaMZ regimen 
promises simpler, shorter, more affordable and safer therapy for both drug-susceptible 
and MDR-TB infected patients.  
 
Central carbon metabolism in M.tuberculosis for targets for new TB drug 
development 
As shown the new regimen, that includes new anti-TB drugs, dramatically 
improved TB treatment. Over past 50 years, only two drugs are approved recently. 
Therefore, we need more drugs to combat with TB. To date, there are over 20 potential 
compounds in the stage of lead optimization, and clinical development. They include re-
purposed drugs, new classes drugs with unknown targets, and new drugs targeting novel 
pathways 14.  As we reviewed above, current targets of existing drugs are very limited.  
To pursuit finding promising new anti-TB drugs, especially in respect to overcome the 
problem of drug-resistance in TB treatment, it should be exploited the novel 
targets/pathways that are essential for TB survival and persistence not only in vitro, but 
also in vivo.   
Increased research on pathogenicity of Mtb suggested that enzymes of Mtb’s 
CCM are essential for Mtb survival, and important to be validated as potential drug 
targets 106. Mtb central carbon metabolism (CCM) comprised glycolysis, 
gluconeogenesis, and the pentose phosphate pathways, as well as the glyoxylate shunt, 
the methylcitrate cycle, and the tricarboxylic acid (TCA) cycle has been shown to be 
regulated in a way distinct from other well studied bacteria, like E.coli 107. Mtb resides in 
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phagosomes of human macrophages, and it’s CCM has evolved to survive this unique 
environment, which made it unlike other bacterial pathogens 106. Most bacteria can 
selectively utilize the carbon source that supports the fastest growth through regulating 
the expression and/or function of enzymes involved in metabolism of secondary carbon 
sources, a regulatory mechanism known as carbon catabolite repression (CCR) 108. In 
contrast, Mtb can co-catabolize mixed carbon sources through the CCM to distinct 
metabolic fates. As demonstrated in 13C trace experiments, Mtb’s preferred carbon 
source is dextrose for the intermediates of glycolysis and the pentose phosphate 
pathway, while it prefers to use acetate for TCA cycle intermediates. Mtb also 
maintained a low level of acetate-derived 13C through gluconeogenesis 109.  
Growing body of evidence support the conclusion that ability to reconfigure flux 
through CCM in response to environmental changes is closely linked to virulence and 
persistence of Mtb 110, 106, 111. Mtb strains lacking the gluconeogenic enzyme or 
components of the glyoxylate shunt were defective in replication and showed attenuated 
growth during the chronic phase of infection in a mouse model of pulmonary TB. During 
infection in a carbon limited conditions, Mtb upregulates ICL, first enzyme of the 
glyoxylate shunt of the tri-carboxylic acid (TCA) cycle to use fatty acids as a carbon 
source 112. The glyoxylate shunt allows the cycle to bypass the loss of two CO2 
molecules and allows for the condensation of the C2 intermediate (Acetyl Co-A) from β-
oxidation and glyoxylate (C2 unit) to produce C4 intermediates, which incorporate 
through gluconeogenesis to reach glycolysis- or pentose-phosphate-derived metabolites 
113. The Mtb glyoxylate shunt pathway contains a malate synthase (GlcB) and two 
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isozymes of isocitrate lyase (Icl1/Icl2). ICL upregulation was demonstrated under low 
oxygen conditions, associated with non-replicating stage of Mtb as well as during 
infection 114, and is an important enzyme not only for the utilization of fatty acid but also 
for propionl-CoA metabolism because it also function as methyl-citrate lyase 115. An Mtb 
ICL knock-out mutant failed to establish an infection in mice, supporting the 
requirement of ICL for in vivo growth and virulence 112. Together with the absence of 
this pathway in mammalian cells, the Mtb ICL and GlcB enzymes have been spotlighted 
as attractive drug targets for new anti-TB chemotherapies. ICL possesses a small 
charged active site which makes it a difficult target, thus not many efficacious ICL 
inhibitors have been found 116, 117. Structure guided inhibitor studies of GlcB have shown 
that phenyl-diketoacids (PDKA) inhibit Mtb growth on acetate and in mice 118. Similar 
to ICL, phosphoenolpyruvate carboxykinase (PEPCK), which is the first committed step 
enzyme in the gluconeogenesis pathway, is also up-regulated during Mtb growth on fatty 
acids 119. A PEPCK-deficient Mtb strain was not able to grow on fatty acids as a sole 
carbon source in vitro, and failed to establish and maintain infection in mice, indicating 
that the gluconeogenesis pathway is required for Mtb virulence 120. Using Mtb PEPCK as 
a of target for development is hampered by the existence of a highly conserved human 
homolog. Thus, a detailed structural study of Mtb PEPCK is required to create inhibitors 
selective for the pathogen over human enzyme. The importance of gluconeogenesis in 
Mtb virulence was also confirmed by a fructose bisphosphatase (FBPase, rv1099c) and 
an alternative FBPase (rv3214) knock-out study. In the Mtb H37Rv genome, two genes, 
glpX (rv1099c) and gpm2, working together has FBPase activity that maintains 
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gluconeogenesis in Mtb. While GLPX is annotated as an FBPase, inhibiting it alone is 
not sufficient to block FBPase activity as GPM2 can maintain gluconeogenesis in the 
absence of GLPX activity; deletion of both glpX and gpm2 disrupts gluconeogenesis and 
results in attenuation of Mtb growth  in a mouse model of infection 121. In addition, a 
glucokinase null mutant in Mtb revealed the role of glucose metabolism in Mtb 
pathogenesis. The glucokinase genes, ppgK (Rv2702) and glkA (Rv0650), are 
functionally related to glucokinases, that is, they are involved in the first reaction in 
glycolysis and allow Mtb to incorporate glucose into the glycolysis pathway. An Mtb 
with deletion of both genes failed to persist in mouse lungs, meaning that Mtb uses 
glucose during infection via glucose phosphorylation to persist during chronic infection. 
These results suggest that the Mtb CCM has made a distinct metabolic adaptation to the 
host and has shown to be flexible in its use of diverse host-derived carbon sources. 
Therefore, the metabolic plasticity of the Mtb CCM has emerged as one of key 
determinants to its pathogenicity.  
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Figure 1-12. Tricarboxylic acid cycle and associated fatty acid degradation pathway (β-
oxidation). Modified from Schnappinger 122. 
 
 
 
PEP-oxaloacetate-pyruvate node in Mtb CCM 
It has been reported by Sauer and Eikmanns that the junction between 
gluconeogenesis and glycolysis (interconversion of the intermediates PEP, pyruvate, and 
oxaloacetate) is important for carbon flux distribution in bacteria 123. The intermediates 
PEP, pyruvate, and oxaloacetate are major metabolic precursors for the biosynthesis of 
several amino acids. As shown in Figure 1-12, oxaloacetate (OAA) can be used to 
synthesize aspartate and pyruvate can make alanine, valine, and leucine. Alanine is also 
crucial for peptidoglycan cross-linking, which is required for the rigidity of cell wall in 
Mtb that contributes its virulence 124. PEP is used in the synthesis of the aromatic amino 
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acids phenylalanine and tryptophan 125. In addition, they are also important energy 
precursors, entering the TCA cycle to produce cofactors NADH and FADH2 that are 
used for respiratory ATP formation.  
The PEP-oxaloacetate-pyruvate node is composed of several enzymes; 
Phophoenolpyruvate carboxykinase (PEPCK), Pyruvate kinase (PykA), Pyruvate 
carboxylase (PCA), and Malic enzyme (MEZ) (Figure 1-12). PEPCK, preferentially 
catalyze PEP-production from oxaloacetate (OAA), and also can do the reversible 
reaction, OAA-formation from PEP by fixing CO2. Pyruvate can be synthesized by the 
malic enzyme (MEZ) from malate, or by the pyruvate kinase (PykA) from PEP. In 
addition, pyruvate can be converted to oxaloacetate and malate by pyruvate carboxylase 
(PCA) and malic enzyme, respectively.  
A carbon flux study of the Mtb CCM indicates that the major metabolic change 
in response to the macrophage environment occurs at the PEP-pyruvate-oxaloacetate 
node 109,110,120,121,126,127, suggesting that the enzymes involved in this node represent good 
potential novel drug targets 106. Hypoxia arrests the growth of Mtb and contributes to 
transition to the non-replicating state when granulomas develop. Low oxygen 
concentration induces up-regulation of PEPCK and malic enzymes, resulting in 
facilitating CO2 fixation to replenish intermediates into TCA cycles 128. Under slow 
growth rate conditions induced by limited nutrients, instead of fully turning TCA cycle, 
Mtb operates the GAS (Glyoxylate shunt and Anapleurotic reactions for oxidation of 
pyruvate, and Succinyl CoA synthetase) pathway for the generation of succinyl CoA. 
The pathway is represented by glyoxylate shunt, anaplerotic reaction for oxidation of 
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pyruvate, and succinyl CoA synthetase reaction, indicating that CO2 fixation achieved by 
PEPCK, MEZ, and PCA is important for Mtb’s virulence 126.   
In this dissertation, we chosen PEPCK and PykA enzymes as potential drug 
targets for the development of efficient anti-TB chemotherapies. The PEPCK enzyme 
exists across all species and has a highly conserved active site, and Mtb PEPCK is highly 
homologous to the human enzymes (cytosolic and mitochondrial versions). Thus, a 
detailed structural study of Mtb PEPCK is required to support a selective inhibitor 
development, which would be active against Mtb PEPCK and not to be toxic to the host. 
Unlike PEPCK, the essentiality of Mtb PykA in infection has not been thoroughly 
studied. PykA is located at the junction of glycolysis and gluconeogenesis. This point is 
a pivot to switch between both pathways, and the enzyme is likely to be tightly regulated 
by the relevant intermediates. Transcriptional regulation for Mtb PykA has not been 
observed in response to different carbon sources, which can be interpreted that either 
Mtb PykA function change is not required for adaptation of Mtb to the host environment 
or that the activity can be regulated on a different level, such as phosphorylation, 
acetylation, or allosteric regulation by effectors. Transposon mutagenesis study in 
H37Rv grown on glycerol and fatty acids resulted in no mutations in the Mtb PykA gene 
129, suggesting that Mtb PykA is required for in vitro growth on glycerol and fatty acids 
and it has good potential as a drug target for TB chemotherapy. Interestingly, 
Mycobacterium bovis (M. bovis) harbors an inactivate version of pyruvate kinase despite 
sharing over 99.95% of its genome with Mtb 130. As a result, glycerol and glucose are not 
sufficient to support the growth of M. bovis in the absence of a pyruvate. An Mtb mutant 
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with disrupted PykA gene (pykA) also failed to grow on glycerol, but it grows on either 
pyruvate or oleic acid as a carbon source. Increased expression of proteins associated 
with fatty acids β-oxidation was observed in Mtb lacking PykA, suggesting that it shifts 
to fatty acid degradation upon the loss of the pykA gene 130. In addition, there was an 
increase in the expression of isocitrate dehydrogenase (Icd2: Rv0066c) and a decrease in 
expression of isocitrate lyase (Icl: Rv0467) upon the loss of the pykA gene. Flux balance 
analysis also indicates increased flux through the TCA cycle in the pykA-deficient Mtb 
130. The considerable changes of the proteomic profile in response to the loss of pykA 
suggest that a better understanding of the role of pykA in the metabolic flux of the CCM 
is required.  
Mtb PykA catalyzes the production of ATP from ADP during the conversion of 
PEP to pyruvate. Interestingly, PykA in Trypanosomatidae has been identified as a 
potential drug target because Trypanosoma brucei heavily relies on the glycolysis 
pathway for ATP production 131.  In Mtb, functional icl is required to reduce the 
intracellular ATP concentration which is associated with successfully entering the non-
replicating state, suggesting a link between the CCM and the regulation of the 
intracellular ATP level 132. An Mtb PEPCK knock-out mutant is still capable of 
producing pyruvate and alanine via the malic enzyme. Thus, Mtb PykA is not required to 
maintain intracellular level of pyruvate, but under certain conditions, ATP production 
via Mtb PykA may be important for maintenance of its intracellular ATP level. As Ehrt 
and co-workers described, pyruvate cannot be a precursor for PEP synthesis in Mtb, as 
PEPCK is the sole enzyme capable of PEP biosynthesis 127. It is possible that one more 
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important role of Mtb PEPCK is to provide the PEP intermediate which enables Mtb 
PykA to contribute to the maintenance of intracellular ATP levels. Despite Mtb PEPCK 
and PykA are critical for pathogenicity roles in Mtb’s metabolic adaptation to the host 
environment are critical to pathogenicity, these enzymes were not considered as drug 
targets due to the existence of their highly conserved host orthologs. Finding the 
differences in the atomic structures and regulatory mechanisms of these enzymes 
compared to those of the host orthologs would provide insights into the development of 
potent and specific inhibitors. 
For the rest of chapter II and IV, we focused on the X-ray crystal structural 
studies for Mtb PEPCK (Rv0211) and Mtb PykA (Rv1617) to examine the structural 
differences between human and Mtb versions of these enzymes. We discovered regions 
that are distinct from human orthologs and can be exploited for the design of selective 
inhibitors. Moreover, biochemical studies for two enzymes provided information on 
regulatory events mechanism for better understanding of their role in CCM. Chapter  III 
and V present the results and discussion of inhibitor study on two enzymes; for example, 
high-throughput screening was employed to identify their inhibitors followed by SAR 
study based on co-crystal structure with inhibitors were performed, especially for Mtb 
PEPCK. We develped selective Mtb PEPCK inhibitors over human enzyme and 
described the basis for selectivity in chapter III. For the inhibitor study on Mtb PykA, the 
interactions between a hit from HT screening and the enzyme were analyzed to propose 
a design of selective and potent inhibitors. This result may initiate the SAR study to 
develop more potent inhibitors. Our works represented in this dissertation contribute to 
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TB drug discovery and development, positioning PEPCK and PykA as potential drug 
targets and laying out an initial ground for development of selective inhibitors.  
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CHAPTER II                                                                                                       
STRUCTURAL STUDY OF PHOSPHOENOLPYRUVATE CARBOXYKINASE 
FROM MYCOBACTERIUM TUBERCULOSIS 
 
Introduction 
Phosphoenonlypyruvate carboxykinase (PEPCK) is the first and rate limiting 
enzyme in the M.tuberculosis gluconeogenic pathway, a part of the central carbon 
metabolism, that incorporates intermediates from the TCA cycle into glucose, amino 
acids, DNA, and RNA133.  The Mtb PEPCK enzyme is essential for TB growth and 
persistence during infection and is an attractive anti-TB target 120. Since the PEPCK 
enzyme analogs are conserved in the host, detailed structural study of Mtb PEPCK is 
needed for selective inhibitor design to specifically target the pathogenic enzyme.   
PEPCK reaction  
PEPCK (EC 4.1.1.32) reversibly catalyzes both the gluconeogenic (PEP-
forming) and anaplerotic (OAA-forming) reactions. It preferentially operates the 
gluconeogenic PEP-forming reaction, the conversion of oxaloacetate (OAA) to 
phosphoenolpyruvate (PEP) in the presence of divalent metals and GTP. There are two 
steps in synthesis of PEP by PEPCK, first, the OAA is decarboyxlated to become enolate 
anion intermediate, and then the γ-phosphoryl group of GTP transferred to make PEP. 
The metals play important roles to stabilize anion intermediate and GTP conformation 
134. This reaction is only pathway that the intermediate (oxaloacetate) from the TCA 
cycle can be incorporated into the intermediate (PEP) in gluconeogenesis pathway. C13 
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tracing analysis shows that the knock-out PEPCK Mtb strain does not make the PEP, 
serine, and hexose-P intermediates when grown on an acetate carbon source, indicating 
gluconeogenesis is the only pathway to produce those intermediates 120. In the reverse, 
anaplerotic, reaction PEP is converted to OAA in the presence of divalent metals and 
GDP (Scheme 2-1). This reaction is required for M.tuberculosis survival under in vitro 
glycerol limited growth conditions, similar to the in vivo conditions of the macrophages, 
to maintain the availability of substrates for central carbon metabolism 126,135. During 
cell growth, intermediates from the TCA cycle are constantly withdrawn to supply 
necessary anabolic pathways; depleting the supply of C4 intermediates which must be 
restored. Replenishment of OAA into TCA cycle in most organisms can be 
accomplished, irreversibly, by phosphoenonlypyruvate carboxylase (PEPC) (EC 
4.1.1.31) or by the reversible PEPCK (EC 4.1.1.32). Interestingly, PEPC is found in 
most plants and bacteria, and even in other mycobacteria such as M. smegmatis, M. 
avium and M. leprae, but not in M. bovis and M. tuberculosis. Furthermore, it has been 
reported that PEPCK alone is sufficient for anaplerosis of OAA in Saccharomyces 
cerevisiae and Corynebacterium glutamicum 136,137. It is possible that M.tuberculosis 
relies on PEPCK for OAA anaplerosis due to the absence of PEPC, which makes this 
reaction important for M.tuberculosis survival during infection.  
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Scheme 2-1. Mtb PEPCK’s reactions: PEP-forming reaction (gluconeogenic reaction) 
and OAA-forming reaction (anaplerotic reaction). 
 
 
 
PEPCK isoforms 
There are two types of PEPCKs, GTP-dependent and ATP-dependent, named for 
nucleotide specificity 138. E. coli, yeast, and plants have the ATP-dependent PEPCK 
isozymes , while eukaryotes, such as human, rats, and chickens, have the GTP-
dependent PEPCK isoform 139. Despite low sequence homology between the primary 
sequences of ATP- and GTP-dependent PEPCK, their overall folded structure is highly 
similar and all active site residues are conserved 140. Mtb PEPCK is an exception, it is 
classified as a GTP-dependent PEPCK [EC 4.1.1.32] with an approximately 70% 
sequence similarity with eukaryotic PEPCKs and optimal activity in the presence of 
GTP 141.  Human GTP-dependent PEPCK has two isoforms; cytosolic PEPCK 
(cPEPCK) and mitochondrial PEPCK (mPEPCK). In the human liver, 30-50% of the 
PEPCK is the cytosolic isoform and 50-70% is the mitochondrial isoform.  
PEPCK regulation 
Human c PEPCK (GTP-dependent PEPCK) gene transcription is induced by 
starvation and its synthesis can be regulated by a variety of hormonal stimuli such as 
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glucagon, glucocorticoids, adrenaline, retinoic acid and thyroide hormone but reduced 
by insulin 142.  There is little evidence to suggest that enzyme can be regulated by protein 
modification 143. Recent study revealed human cPEPCK has a post-translational 
mechanism of regulation by lysine acetylation 144. In mycobacteria, the transcription of 
PEPCK is up-regulated when Mtb growth on fatty acid as a carbon source 119. Moreover, 
it has been reported that hypoxic conditions, protein-protein interactions with 
thioredoxin, and Fe2+ ions induce Mtb PEPCK activity in the direction of the anaplerotic 
reaction (OAA-formation) 145,146. PEPCK catalyze the anaplerotic reaction in pyruvate 
kinase-deficient mutant of B.subtilis, and also functions CO2 fixing enzyme in anaerobic 
bacteria. On the other hand, the preferred reaction in mammalian PEPCK is thought to 
be gluconeogenesis. This evidence suggests that PEPCK can play both gluconeogenesis 
and anaplerotic reaction in highly varied species. It implies structural difference between 
organisms may provide the key point to understand those differences.  
Metals in PEPCK activity 
 Two divalent metal ions are required for optimal PEPCK activity. Kinetic studies 
have been carried out with various metals in different organisms and indicate the effect 
of divalent cations differs widely. Mn2+ is the preferred activator in mitochondrial 
PEPCK in many species 147,148, 149,150.  In C. glutamicum PEPCK, Mn2+ and Co2+ both 
highly activated the enzyme reaction, while Cr3+ and Zn2+ showed an inhibitory effect 
151. Incubation of a low concentration of Fe2+, Co2+, Mn2+, or Cd2+ with rat liver PEPCK 
in the presence of Mg2+ showed improved enzyme activity in the PEP-forming reaction 
but maximal activity was obtained combining with Mg2+ and Mn2+ in the PEP-forming 
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reaction of PEPCK from cytosolic rat liver.  The synergetic effect of Mg2+ and Mn2+ has 
been reported for GTP-dependent PEPCKs 152. In a crystal study of E. coli PEPCK, 
Mn2+ placed in the catalytic active site to stabilize the transition state and Mg2+ lay in the 
nucleotide binding site to create the Mg2+-ATP complex 153. A crystal study of human 
cPEPCK also defined these two metals as Mn2+ in the catalytic site and Mg2+ in the 
GTP-binding site based on their maximal activity 140.  
Dynamics in PEPCK 
Crystallographic studies of GTP-dependent PEPCK have revealed the presence 
of a three flexible loop architecture; the P-loop, the Ω-loop (the active site lid), and the 
R-loop whose movements are important to function 154. The P-loop is the phosphate 
binding region, which is a common structure found in nucleotide binding proteins, such 
as protein kinase and glutathione synthetase which have an ATP-binding domain 155. The 
R-loop is composed of residues 84-92 in rat cPEPCK, containing an arginine residue 
(R87 in human cPEPCK) that binds directly to the ligand (OAA/PEP) through 
electrostatic interaction. Significant movement of this loop has not been observed in the 
wild-type PEPCK enzyme. However, the absence of the Ω-loop in a mutant PEPCK 
structure shows that the conformational changes are preserved while the enzyme activity 
is abolished 156. The P- and R-loop participate directly in substrate binding: the 
phosphate group of the GTP or GDP molecule binds to the P-loop, and the OAA or PEP 
molecules bind to the R-loop. On the other hand, the flexible, Ω-loop on the protein 
surface, rather than directly interacting with the substrate, changes from an open to a 
closed conformation upon substrate binding, acting like an active site lid 154. 
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 The Ω-loop consists of 11 residues (A464-V474 residue in rat cPEPCK) whose 
conformational changes between an open and closed form are depending upon ligand 
binding in the active site. In the rat cPEPCK, Ω-loop closure occurs when all substrates 
form a Michaelis complex in the active site. Closing of the Ω-loop helps to stabilize and 
protect of the reactive intermediate resulting in an increase in enzyme accuracy 
(specificity). 
 The R-loop in Mycobacterium consists of residues 79-86. In Mycobacterium 
smegmatis, PEPCK mutations to D75, D78 and E83 (D75A, D78A, and E83A) were 
generated and the D78A and E83A mutants decreased enzyme activity in both directions 
157. In Dr. Sabine Ehrt’s group in Cornell University, one of our collaborators, especially 
study on Mtb PEPCK enzyme. They generated these mutants in order to see whether 
these mutants can support Mtb growth on different carbon source. As shown Figure 2-1, 
the growth of the wild-type PEPCK shows normal growth on glycerol and butyrate, but 
the E83A and D78A mutants cannot support bacterial growth on butyrate, but D75A 
supports growth as with the wild-type bacteria. Therefore, the E83A and D78A mutants 
in Mtb are expected to display impaired enzyme activity. Further studies are needed to 
completely understand the role of these residues, and of the R-loop, in Mtb PEPCK.  2 
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Figure 2-1. The growth curve over time of three mutants (D75A, D78A, and E83A) on 
different carbon sources, glycerol or butyrate. Data was provided from Dr. Sabine’s 
group.  D78A and E83A mutants are not able to support TB growth on butyrate as a sole 
carbon source, while D75A mutant shows similar growth rate to wild-type PEPCK.  
 
 
 
Sequence similarity between the Mtb and human PEPCK isozymes (cytosolic PEPCK 
and mitochondrial PEPCK)  
The gluconeogenesis pathway is shared between host and pathogen, and all 
PEPCKs have a similar overall structure with a conserved active site; both Mtb PEPCK 
and the human cPEPCK/mPEPCK are also GTP-dependent, indicating a high 
conservation. Mtb PEPCK contains 606 amino acid residues while the human protein has 
622 residues for the cytosolic isoform, and 640 residues for the mitochondrial isoform. 
The sequence identity of Mtb PEPCK is 52% and 51% with the human cPEPCK and 
mPEPCK, respectively, and the similarity is approximately 67% and 65% for cPEPCK 
and mPEPCK. Therefore, a detailed comparison of Mtb and human PEPCK structures is 
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required to develop selective molecules to inhibit only Mtb PEPCK without affecting the 
host enzymes.  
In this study, the crystal structures of Mtb PEPCK in the apo form and in 
complex with substrates were determined at high-resolution. The structural data of Mtb 
PEPCK reveal that the behavior of the flexible loops upon substrate binding differs from 
the reported rat cPEPCK structure. A unique interaction between the P-loop and the Ω-
loop in Mtb PEPCK increases the efficiency of catalysis in the direction of the 
anaplerotic reaction. Since Mtb PEPCK has disparate flexible loop properties in the 
active site, they provide an opportunity to design ligands that can selectively inhibit Mtb 
PEPCK over the human enzyme. 
 
Result and discussion 
Overall structure of Mtb PEPCK and substrate binding site  
The Mtb PEPCK structure displays high conservation with known PEPCK 
structures. It consists of an N-terminal and a C-terminal domain with an α/β topology 
that brings the termini into close proximity. The co-purified GDP-metal complex is 
shown in Figure 2-2, the active site of Mtb PEPCK is located in the cleft between the 
two domains as reported in other GTP-dependent PEPCK structures 140. The key 
residues in the active site involved in substrate binding and metal ion coordination are 
highly conserved in the Mtb PEPCK enzyme. 
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Figure 2-2. Overall fold of Mtb PEPCK-GDP-Mn2+-Zn2+ complex structure.  GDP is 
bound to the C-terminal domain, the phosphate ion is bound to the N-terminal domain, 
and there are two divalent metals between the two domains.  
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Figure 2-3. The active site of Mtb PEPCK in complex with GDP-Zn2+-Mn2+-PO4-. The 
anionic substrate, PEP or OAA, binds respectively to the N-terminal domain in the (A) 
PEP-GDP or (B) OAA-Mn2+ complex structure. The nucleotide substrate, (C) GTP or 
GDP, binds to the C-terminal domain. Two divalent metals are located between the N- 
and C-terminal domains.  
 
 
 
Mtb PEPCK has two separate substrate binding pockets, PEP or OAA binds in 
the N-terminal domain, while the nucleotide (GTP, GDP) binds in the C-terminal 
domain, there are also two metal binding sites located between the N- and C-terminal 
(Figure 2-3). In the oxalate-Mn2+ Mtb PEPCK complex structure, the two oxalate 
oxygens interact via hydrogen bonding to the H –Nω of the side chains of R81 (2.9 Å) 
and R389 (2.7 Å ). The rest of the oxalate oxygens chelate a catalytic metal at distances 
of 2.6 Å and 2.4 Å. In the PEP-GDP complex structure, the two PEP phosphate oxygens 
interact with the H –Nω of the R81 and R389 side chains at 3.1 Å and 2.8 Å, 
respectively. The carboxyl oxygen of PEP hydrogen bonds to the backbone amide 
hydrogen atom of the G222 and R81 residues, which is consistent with the human 
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cPEPCK-PEP complex. However, the interaction with N387 and the movement of Y220 
observed in human cPEPCK were not observed in Mtb PEPCK structures.  
In the Mtb PEPCK-GDP complex structure, the guanine base of the nucleotide is 
surrounded by the three benzene rings of the phenylalanine residues, F515, F510, and 
F502, in the C-terminal domain. The carbonyl oxygen atom from the guanine base ring 
hydrogen bonds to the side chain -NH2 group of N518 (3.0 Å) and the backbone amide 
group of F515 (2.90 Å). The oxygen atom of the ribose ring hydrogen bonds to the ω –
NH2 group of the R420 side chain (3.1 Å). The GDP phosphate group is stabilized by the 
backbone amides of residues from the P-loop (S271-N277) including A272 (2.9 Å), 
G274 (3.1 Å), T276 (3.0 Å), and N277 (2.9 Å). This nucleotide interaction is also 
observed in the recently reported Mtb PEPCK-GDP-bound structure 146. 
Identification of co-purified metals with Mtb PEPCK suggests Zn2+ bound in the 
catalytic site and Mn2+ bound in the nucleotide binding site 
The PEPCK enzyme is dependent upon divalent metal ions for activity. Although 
the active site is very highly conserved, including the two metal sites found in PEPCKs 
across species from bacteria to humans, studies of metal usage have not provided a 
cohesive picture of PEPCK’s metal requirements. Kinetic data for divalent metals in 
different PEPCKs show a highly divergent effect from different divalent cations. Mn2+ 
has been used as an efficient activator in mitochondrial PEPCKs of many species 
139,147,158, while maximal PEPCK activity in cytosolic rat liver was obtained using a 
combination of Mg2+ and Mn2+ for the PEP-forming reaction 152. Two metals in reported 
crystal structures were not previously identified but have now been denoted Mn2+ and 
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Mg2+ based on activity observations, metal coordination geometry, or crystallization 
conditions 140,153. Recently, the structure of Mtb PEPCK in complex with GDP -Mn2+ 
was released. That paper showed that the Electron Paramagnetic Resonance (EPR) from 
Mn2+ could tightly bind to the nucleotide metal binding site, but not the catalytic metal 
binding site 146. The factors governing PEPCK metal selection requires more study for 
insight into its activity. As we did not include any metals during purification or 
crystallization, we made an effort to identify the metals we observed bound to Mtb 
PEPCK.  
The density for both metal sites shows similar coordination. The metal density in 
the catalytic site is octahedrally coordinated with the Nε2 atom of H249 at a distance of 
2.3 Å, the Nζ atom of K229 at 2.4 Å, one oxygen from the side chain of D296 at 2.2 Å, 
and with three water molecules at an average distance of 2.3 Å. The nucleotide binding 
site metal is also octahedrally coordinated with the hydroxyl oxygen from the side chain 
of T276 at 2.2 Å, one oxygen atom from the β-phosphate of GDP at a distance of 2.3 Å, 
and four water molecules at an average distance of 2.3 Å.  
To identify the two co-purified metals in the structure, we used inductively 
coupled plasma mass spectrometry (ICP-MS) in combination with anomalous scattering. 
The ICP-MS analysis of the trace metals in the protein sample, purified directly from E. 
coli without added metals, showed a mixture of divalent metals bound: Ni, Zn, Mg, Fe, 
Mn, and Cu, each with a less than 1:1 molar ratio with the enzyme. They were found at 
relatively high concentrations in the order, Ni, Zn, Fe, Mn, Mg, and Cu, as shown in 
Table 2-1.  
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Anomalous difference scattering generated at a wavelength of 1.54 Å showed a 
strong anomalous signal for the metal in the nucleotide binding site. Mn2+, Fe2+, and 
Co2+ were the only metals from our analysis that had a significant anomalous signal at 
1.54 Å, as shown in Figure 2-4. At 0.97 Å, a strong anomalous scattering signal was 
seen in the catalytic metal site, with no anomalous signal observable in the nucleotide 
binding metal site. The only transition metals corresponding with anomalous scattering 
at this wavelength are: Cu2+, Ni2+, and Zn2+ (Figure 2-5). We designated the catalytic 
metal Zn2+ due to the relatively high concentration seen in ICP-MS, Ni2+ was 
disregarded as being most likely an artifact of the His tag purification step. The 
probability of binding of Mn2+ and Fe2+ in the nucleotide binding site is similar and it is 
difficult distinguish them due to their similar properties as transitional metals, but we 
designated it Mn2+ based on the ICP-MS result, which showed a slightly higher molar 
ratio than Fe2+.  
 Identifying zinc as the catalytic binding site metal binding site was surprising as 
it is not the preferred metal for activity in other PEPCK enzymes. In the literature, the 
PEPCK enzyme from Thermococcus kodakaraensis showed no activity in the presence 
of Zn2+ 152 and Zn2+ has an inhibitory effect on C. glutamicum PEPCK 151. Since we 
found that Zn2+ binds to the catalytic metal binding site, we attempted to test Mtb 
PEPCK activity using Zn2+ or Mn2+ as the solo divalent cation across a range of pHs 
from 5.8-8.5 (Figure 2-6). We noticed that the HEPES molecule in the buffer showed 
50% inhibition at 50 mM HEPES at pH 7.0, thus we used Tris buffer, which has no 
inhibition (data not shown). Mn2+ and Zn2+ show similar activity, about 0.5 
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µmole/mg·min at pH 7.0, but at pHs below 7.0, Zn2+ shows higher activity than Mn2+. 
Above pH 7.0, the reverse is true and Mn2+ is preferred to Zn2+. This result suggests that 
Mn2+ and Zn2+ activity for Mtb PEPCK is comparable at pH 7.0, indicating a similar 
probability of binding to the catalytic site. Since we purified Mtb PEPCK in a pH 7.0 
buffer condition, it is likely that the mixture of metals in the catalytic metal site 
contained Zn2+.  
 
 
 
 Table 2-1. Trace metal content of Mtb PEPCK by atomic absorption spectroscopy. 
 
Metal ppb(µg/l) µM Molar ratio, metal/enzyme 
Ni 64 1.090 0.153 
Zn 52 0.795 0.111 
Fe 12 0.215 0.030 
Mn 12 0.218 0.031 
Mg 12 0.494 0.069 
Cu 6 0.094 0.013 
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Figure 2-4. Absorption K- and L-edges for metals in X-ray energy range from 6 to 
20keV. This chart is made by Ethan Merritt 159. 
 
 
 
 
Figure 2-5. Anomalous difference map. (A) The anomalous signal appeared in the 
catalytic metal site, which coordinated with D296, K229, and H249, and water 
molecules (data collected at 0.97 Å), and (B) The anomalous signal appeared in the 
nucleotide binding metal site with GDP, T276, and water molecules (data collected at 
1.54 Å). 
  
 
56 
 
Figure 2-6. Zn2+ vs Mn2+ activity in Mtb PEPCK dependent upon pH. 
 
 
 
Overall structural comparison of Mtb PEPCK and human cPEPCK reveals intriguing 
differences in flexible loops 
Structural differences in the active site of PEPCK between the host and pathogen 
are of particular importance for the design of selective inhibitors that specifically target 
Mtb without affecting the host. The sequence identities in the active and substrate 
binding site are significantly conserved between the pathogen and host enzyme. Mtb 
PEPCK contains 606 amino acid residues while the human protein has 622 for the 
cytosolic isoform, and 640 for the mitochondrial isoform. The sequence identity of Mtb 
PEPCK is 52% and 51% with the human cytosolic PEPCK(cPEPCK) and mitochondrial 
PEPCK(mPEPCK), respectively, and the similarity is approximately 67% and 65% for 
cPEPCK and mPEPCK. The structure of human cPEPCK is only available in PDB 
website. A superposition of the PEPCK structures of the pathogen (GDP-bound Mtb 
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PEPCK) and host (1KHB, human cPEPCK) shows that the overall fold of Mtb PEPCK is 
almost identical to that of the human enzyme. The root mean square displacement 
(r.m.s.d.) of the Mtb PEPCK is about 1.0 Å over 491 Cα atoms. The reported rat 
cytosolic PEPCK crystal structure (91% sequence identity with human cPEPCK) 
contains three flexible elements in the active site, the P-loop, Ω-loop, and R-loop, which 
are important components for enzyme catalysis 156. In our study, the apo -Mtb PEPCK 
structure with colored B-factors exhibits these three flexible loops in the active site; the 
P-loop (residues 269-277), Ω-loop (active site lid, residues 448-458), and R-loop 
(residues 79-86) (Figure 2-7).  
 
 
 
 
Figure 2-7. Active site in apo-Mtb PEPCK crystal structure, loops are colored by B-
factor. Three flexible loops, P-loop, R-loop, and Ω-loop have relatively high level of B-
factor. 
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The major structural differences between human and the Mtb enzyme occur in 
the two active site loops, the Ω-loop and R-loop. The Ω-loop in human cPEPCK was not 
visible in the electron density, indicating it was disordered in GTP analog complex form 
(PDB: 1KHE), whereas it forms ordered/closed conformation with full electron density 
in Mtb PEPCK-GDP bound structure (Figure 2-8).  The R-loop flips over toward solvent 
area in Mtb PEPCK-GDP bound structure, however this loop was buried in human 
cPEPCK 140. The intriguing differences in these flexible loops may provide an 
opportunity for drug development targeting Mtb PEPCK, therefore we look into in depth 
of “cause of effect” on these loops movements in this chapter. 
 
 
 
 
Figure 2-8. Superimposed crystal structure of human cPEPCK GTP-bound (PDB : 
1KHE)  and Mtb PEPCK-GDP bound forms. The R-loop and Ω-loop show different 
conformations. The Ω-loop in Mtb PEPCK adopts closed conformation, while its 
conformation in human cPEPCK is disordered. The R-loop in Mtb PEPCK stays way 
from the active site while it is packed inside of the active site in human cPEPCK. 
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Figure 2-9. Superimposition of the apo and GDP-bound Mtb PEPCK structures. It 
represents the P-, Ω- (active site lid), and R-loops adopt different conformation upon 
GDP binding.   
 
 
 
The Mtb PEPCK Ω-loop undergoes a conformational change upon GDP binding  
Superimposition of the Mtb PEPCK apo and GDP-bound crystal structures 
reveals different conformational changes in the Ω-loop (residues 448-458) as shown 
Figure 2-9. Density for the Ω-loop was different between the apo and GDP-bound Mtb 
PEPCK structures. In the apo Mtb PEPCK structure, there was no density for residues 
450-457 (part of the Ω-loop) meaning it was disordered, while in the GDP-complex Mtb 
PEPCK structure, density was fully observable for the entire loop and is in a closed 
position over the active site.  In the GDP-bound structure, the GDP phosphate group 
binds to the P-loop (residues 269-276) and the GDP ribose binds to the guanidinium 
group of R420, which also links to the P-loop. Specifically, the amino -NH2 group of the 
R420 side chain hydrogen bonds to the ribose ring oxygen (3.1 Å), and the H-NƐ of 
R420 hydrogen bonds to the backbone carbonyl oxygen of A272 (3.0 Å) from the P-
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loop. Consequently, the P-loop moves 1.9 Å (measured from the Cα of A272) to the 
other substrate (OAA, PEP) binding sites. This movement allows two additional residues 
(E447 and Q448) on the Ω-loop to form hydrogen bonds: the carbonyl oxygen atom of 
E447 side chain interacts with the backbone amide hydrogen from K422 (2.9 Å), the  
hydrogen atom in the –NH2 group of the Q448 side chain forms a hydrogen bond with 
the backbone carbonyl oxygen atom of S271 (2.9 Å), and the carbonyl oxygen of the 
Q448 side chain hydrogen bonds with the P-loop via a hydrogen atom on the sulfhydryl 
group of the C273 side chain (3.1 Å) (Figure 2-10). In the apo structure, the side chains 
of E447 and Q448 instead protrude into the solvent.  
Comparison of the apo and GDP-bound structures reveals that the P-loop 
movement upon GDP binding facilitates closure of the Ω-loop through hydrogen bonds 
between the P-loop and Ω-loop mediated by Q448 of the Ω-loop. The C273 residue is 
highly conserved in all PEPCKs and is known as a “hyper-reactive” residue, but the 
Q448 residue is not conserved in eukaryotic GTP-dependent PEPCKs including human 
cPEPCK, rat cPEPCK, and chicken mPEPCK (mitochondria), which instead contain an 
alanine in this position as shown in sequence alignments (Figure 2-11). Thus, the 
interaction between the P-loop and the Ω-loop cannot occur in other species, making it a 
unique feature of Mtb PEPCK. 
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Figure 2-10. The interaction between Ω-loop and P-loop. (A) GDP-bound structure 
(magenta), apo structure (blue); (B) The interaction between Q448 in the closed Ω-loop 
and the backbone carbonyl of S271 (2.90 Å), and the thiol group of C273 (3.17 Å) from 
the P-loop. 
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Figure 2-11. Multiple sequence alignment of GTP-dependent PEPCKs color coded 
according to sequence similarity to Mtb PEPCK. (A) Human cytosolic type 
(cPEPCK_human), chicken mitochondria (mPEPCK_chicken), and rat cytosolic type 
PEPCK (cPEPCK_rat). (B) Sequence alignment of residues 446 to 459 in the Ω-loop 
(numbering in Mtb PEPCK), shows that the Q448 residue in Mtb PEPCK is not 
conserved in other GTP-dependent PEPCKs.  
 
 
 
Stability of the Ω-loop is achieved differently between the rat and Mtb PEPCKs. 
The Mtb PEPCK stabilizes the closed Ω-loop conformation through the interactions 
between the P-loop and Ω-loop. However the rat cPEPCK crystal structure seems to pull 
the Ω-loop closer through interactions between the Ω-loop and R-loop. In the rat 
cPEPCK structure, there are hydrogen bonds between the two oxygens of the E469 side 
chain in the Ω-loop and two hydrogens from the backbone amides of E89 and S90 in the 
R-loop at distances of 2.7 Å and 3.1 Å, respectively. Another hydrogen bond occurs 
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between the Nε2 atom of H249 and a carbonyl oxygen of the E89 side chain (3.0 Å) 156 
which stabilizes Ω-loop closure. This interaction between the Ω-loop and R-loop is 
absent in the Mtb PEPCK structure.  
Both the R-loop and P-loop are directly involved in substrate binding in Mtb 
PEPCK, as the P-loop interacts with GTP or GDP while the R-loop binds OAA or PEP 
in the active site. The Ω-loop does not make any direct substrate contacts, but it has 
significant roles during catalysis through 1) placing substrates in the active site at a 
reasonable distance for catalysis to occur, 2) protecting intermediates from solvent 156. 
Therefore, the interaction between the Ω-loop and R-loop in rat cPEPCK likely makes 
Ω-loop closure dependent on substrate binding (PEP or OAA) in the active site, while 
the interaction between the Ω-loop and P-loop in Mtb PEPCK induces Ω-loop closure 
upon nucleotide binding alone. This implies that eukaryotic PEPCK activity relies on 
PEP or OAA concentration for catalysis whereas Mtb PEPCK activity may depend on 
nucleotide concentration.  
Ω-loop closure supports the precise positioning of PEP in the Mtb PEPCK active site 
In order to understand the importance of Ω-loop closure in Mtb PEPCK, we 
examined the substrate-complex structures of Mtb PEPCK. In the structure of Mtb 
PEPCK with PEP alone, the electron density for PEP was not in a position consistent 
with catalysis, instead, the PEP phosphate group overlapped with the catalytic metal 
binding site position despite the high amount of metal in the soaking condition. In figure 
2-12, the PEP phosphate oxygen interacts with three metal binding residues, the Nε2 
atom from H249 (2.9 Å), the Nζ atom from K229 (3.0 Å), and an oxygen from the D296 
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side chain (2.7 Å). The PEP carboxyl group binds with the side chains of Asp462 and 
Arg460 through water mediated hydrogen bonds at distances of 2.4-2.8 Å (Figure 2-
12B). In addition, the density for part of the Ω-loop, residues 450 to 457, was not visible 
in the electron density map and the Q448 residue pointed to the solvent area, suggesting 
that the Ω-loop was open.  
Unlike the structure with PEP alone, the Mtb PEPCK PEP-GDP complex 
structure clearly shows PEP in the catalytic position, consistent with reported PEPCK 
structures (Figure 2-12C). The crystal structure of the PEP-GDP complex was obtained 
by soaking a mixture of PEP and GDP into the E83A mutant crystal. We used the E83A 
mutant crystal to prevent catalysis during soaking. In the PEP-GDP-bound structure, the 
PEP carboxylate group hydrogen bonds to the -NH on the backbone of G222 (3.0 Å) and 
R81 (3.0 Å), and the PEP phosphate interacts with the side chain of R81 and R389 (2.7-
3.1 Å) with no density observed for the metal ions, indicating that metal coordination is 
not critical for PEP positioning in the catalytic site, and the binding of GDP was solely 
responsible for PEP repositioning. The GDP induced Ω-loop closure resulted in a 2.3 Å 
shift of the P-loop (measured from the Cα of the A272) toward the catalytic metal 
binding site, making contacts between the sulfhydryl group of C273 on the P-loop and 
the carbonyl group from the side chain of Q448 on the Ω-loop (3.2 Å). This P-loop 
position overlaps the PEP binding position in the absence of GDP, consequently, the 
non-catalytic PEP binding site observed in the Mtb PEPCK PEP complex structure 
becomes unavailable after nucleotide binding. In the human cPEPCK PEP complex 
structure, PEP takes position in the catalytic site without requiring conformational 
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changes to the active site.  
 
 
 
 
Figure 2-12. Different position of PEP in Mtb PEPCK structure. (A) Superimposed PEP 
complex structures, PEP_1 is misplaced vs PEP_2 correctly positioned. (B) The PEP 
complex crystal structure shows PEP misplaced in the absence of GDP [C] PEP binds in 
the correct catalytic position in the presence of GDP.  
 
 
 
The structure of Mtb PEPCK in complex with oxalate (OAA analog) and Mn2+ 
shows that oxalate can be positioned in the catalytic site by directly coordinating to a 
metal (Figure 2-3) even in the absence of GTP and when the Ω-loop is disordered. The 
Mn2+ is coordinated by K229, H249, and D296. The two oxalate ion oxygens bind Mn2+ 
at distances of 2.4 Å and 2.6 Å. The negative charge of the oxalate oxygen atoms is 
stabilized by the side chains of R389 and R81. The binding mode of oxalate in Mtb 
PEPCK is identical to that reported in other GTP-PEPCK structures. OAA directly 
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coordinates with the divalent metal in the active site as three residues support metal 
interactions, indicating that the metal facilitates OAA positioning for catalysis. However, 
PEP does not directly coordinate with the catalytic metal, instead using metal outer 
sphere coordination to bind in the active site 160. In the human cPEPCK PEP complex 
structure, two of the water molecules mediate the interaction between the Mn2+ ion and 
the oxygen atoms of PEP’s phosphate group140. Therefore, structural information point 
out that the factors influencing substrate position depend on the direction of the reaction; 
we hypothesize that the divalent metal coordinates OAA positioning for the 
gluconeogenic reaction, while Ω-loop closure of in the active site are critical to correctly 
orient PEP for the anaplerotic reaction.  
Loss of interaction between the P-loop and Ω-loop affects Ω-loop closure, decreasing 
the anaplerotic activity of Mtb PEPCK  
To test our hypothesis that the position of the anaplerotic substrate (PEP) is 
significantly controlled by the conformation of the Ω-loop in Mtb PEPCK, we disrupted 
Ω-loop closure by removing the hydrogen bonding interaction between the P-loop and 
Ω-loop. The mutation of Q448 residue to an alanine causes loss of interaction between 
the P-loop and Ω-loop. Kinetic experiments were performed to determine the effect of 
the mutation in both directions of the gluconeogenic and anaplerotic reaction (Table 2-
2).  
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Table 2-2. Kinetics data of the wild-type and the Q448A mutant for the gluconeogenic 
and anaplerotic reactions.  
 
 Vmax (µmol min-1 mg-1) Kcat (s-1) 
Gluconeogenic reaction (PEP-formation) 
Wild-type 9.2 ± 0.6 10.6 ± 0.7 
Q448A 14.1 ± 0.5 16.2 ± 0.6 
Anaplerotic reaction (OAA-formation) 
Wild-type 9.8 ± 0.8 11.3 ± 0.9 
Q448A 2.8 ± 0.3 3.2 ± 0.3 
 
 
 
By abolishing the hydrogen bond between the P-loop and the Ω-loop, the Q448A 
mutant demonstrated that Ω-loop closure has a distinct effect on the kinetics of the 
anaplerotic reaction. For the gluconeogenic reaction, the Q448A mutant results in an 
approximately 1.3-1.6 fold increase in the Kcat compared to wild-type PEPCK. 
 In the direction of the anaplerotic reaction, the Q448A mutant in Mtb PEPCK 
showed a significant three fold reduced Kcat, meaning that the wild-type enzyme is three 
times more efficient at catalyzing the anaplerotic reaction than the mutant. The kinetic 
data also demonstrates that Ω-loop closure is more important for PEP positioning than 
for OAA positioning as the mutant showed only a decrease in the rate of the anaplerotic 
reaction. The reduced turnover rate of the mutant shows the importance of the hydrogen 
bond between the P-loop and Ω-loop for Ω-loop closure and it suggests that the catalytic 
step of the Ω-loop closing is the rate-limiting step of the anaplerotic reaction.  
There is a possibility that the Q448A mutant affects GDP binding affinity in 
direction of the OAA forming reaction. However, there is no difference between the Kd 
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value of the wild-type and the Q448A, indicating that the loss of GDP affinity (Table 2-
3) is not the reason for the loss of enzyme activity in direction OAA formation. 
 
 
 
Table 2-3. The Kd value (M) of GDP for WT (wild-type), Q448A mutant and human 
cPEPCK. 
 
 WT Q448A Human cPEPCK 
Kd 0.0015 0.0015 0.0028 
 
 
 
Moreover our results are in agreement with a recent study that found that a 
C273S mutant displayed greater efficiency in anaplerotic activity145. Our understanding 
is that the interaction between the Q448 residue and S273 in the C273S mutant is 
stronger than in the wild-type because serine makes a tighter hydrogen bond than 
cysteine resulting in a more efficient Ω-loop closure. Therefore, the interaction between 
the P-loop and the Ω-loop, unique to Mtb PEPCK, accelerates Ω-loop closure and is 
important for the anaplerotic reaction because it plays a role in effectively positioning 
PEP for catalysis. 
The flexible loops play a key role in the anaplerotic reaction of Mtb PEPCK 
The eukaryotic GTP-dependent PEPCK preferentially catalyzes the reaction only 
in the forward, PEP-forming reaction, due to the Km values of the forward reaction 
substrates, GTP and OAA, is in the range of the physiologic intracellular concentration. 
Also the presence of pyruvate carboxylase, which is better suited to OAA formation 
from pyruvate than PEPCK, so the role of PEPCK in reverse-reaction, OAA formation 
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has not been focused among eukaryotic PEPCKs 161. Most bacteria and yeast are ATP-
dependent enzymes, but the crystal structure of Mtb PEPCK reveals that it is a GTP-
dependent PEPCK. The PEPCK gluconeogenesis reaction in Mtb is critical to utilize the 
macrophage’s fatty acid carbon source for maintenance and persistence during infection 
120. However, under slow growth conditions Mtb PEPCK has been observed catalyzing 
the anaplerotic reaction, converting PEP to OAA 126.  Slow growth in vitro mimics the 
conditions of macrophage during the course of infection 110. Therefore, the anaplerotic 
reaction of Mtb PEPCK might also play a key role in Mtb pathogenicity.  
The conformational changes of the Ω-loop closure upon GDP binding differs 
from the host enzyme due to the unique interaction between the Ω-loop and P-loop in 
Mtb PEPCK. Disruption of that interaction resulted in a three-fold decrease rate of the 
anaplerotic reaction compared to the wild-type. This interaction is critical for the PEPCK 
anaplerotic reaction and is not present in other GTP-dependent PEPCKs, including the 
host enzyme, representing a unique feature of Mtb PEPCK. Mtb PEPCK improved 
anaplerotic reaction is the result of a one amino acid difference from the host, an 
important metabolic adaption in response to the host-driven environment. This structural 
and biological evidence provides better insight into the anaplerotic role of Mtb PEPCK 
in Mtb pathogenencity.    
The flexibility of the R-loop (residues 79-86) is unique to Mtb PEPCK among wild-
type PEPCK enzymes  
The R-loop in Mtb PEPCK is more flexible than that in the human PEPCK due to 
differences in key interactions. In the apo Mtb PEPCK structure, the R-loop packs into 
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the active site by adopting a closed conformation, while in the GDP-bound structure it 
forms an open conformation that is exposed to solvent (Figure 2-13). The superimposed 
apo and GDP-bound structures reveal that the displacement of the R-loop is about 4.3 Å 
(measured from the Cα of R81). This R-loop contains catalytic residue R81, which binds 
directly to the substrate (OAA or PEP), and the flexibility of this loop has never been 
observed indicating that the R-loop was not flexible in the reported structures of rat 
wild-type cPEPCK and human cPEPCK. However, in a rat cPEPCK mutant missing the 
Ω-loop, the R-loop moved away from the active site and adopted an open conformation. 
In the wild-type rat cPEPCK structure, H470 from the Ω-loop interacts via a hydrogen 
bond with E89 from the R-loop (3.0 Å), but this interaction becomes unavailable in the 
mutant rat cPEPCK structure. The absence of the interaction between the R-loop and Ω-
loop makes the R-loop in the rat cPEPCK adopt an open conformation. Superimposing 
the human cPEPCK and Mtb PEPCK structures (Figure 2-13) reveals that G454 in Mtb 
PEPCK is in the equivalent position to H470 in the rat protein and is unable to sustain 
the same R-loop/Ω-loop interaction. Furthermore, the salt bridge interaction between 
E89 and R483 (3.1 Å) in the human cPEPCK seems to determine the rigidity of the R-
loop regardless of substrate presence. Mtb PEPCK has L467 instead of the human 
cPEPCK’s Arg in the same position, preventing the formation of a salt bridge in Mtb 
PEPCK. Thus, structural evidence demonstrates that the R-loop in Mtb PEPCK is more 
flexible than its human PEPCK counterpart due to the absence of both the salt bridge and 
the R-loop/Ω-loop interaction. Further detailed study is required to address about the 
importance of the R-loop’s flexibility on catalysis.  
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Figure 2-13. The interaction between the R-loop and Ω-loop in human cPEPCK.  
Superimposed GDP complex and Mtb PEPCK structure (violet) with human cPEPCK 
structure (green). The salt bridge interaction between E89 and R438 in human cPEPCK 
is missing in the Mtb PEPCK structure due to the equivalent L467. Mtb PEPCK has 
G454 instead of histidine, removing the interaction between the R-loop and Ω-loop. 
 
 
 
 Differences in the conformational changes of the R-loop in Mtb PEPCK 
compared to other GTP-dependent PEPCKs led us to investigate the catalytic role of the 
R-loop in Mtb PEPCK. Mutations of the M. smegmatis PEPCK, E83A, and D78A, 
reduced enzyme activity in both the OAA and PEP forming reactions 157. Dr. Sabine’s 
group demonstrated the E83A and D78A mutants do not support Mtb growth on butyrate 
as a carbon source (Figure 2-1). The Mtb PEPCK E83A and D78A mutants showed 
almost no enzyme activity compared with the WT enzyme (Figure 2-14), while the 
D75A mutant retains the full activity of the wild-type PEPCK (data not shown). It is in 
agreement with previously published M.smeg mutants and Dr. Sabine’s data 
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(unpublished). Intriguingly, the reported CD data from M.smeg mutants 157 indicates the 
protein structure of the D75A, D78A, and E83A mutants show no major differences 
compared to wild-type enzyme (Table 2-4). These results suggest that those residues are 
critical for Mtb PEPCK activity but not for the structure. However, those residues do not 
directly interact with substrates in the OAA/PEP binding site, begging the question of 
how they contribute to enzyme activity. 
 
 
 
Table 2-4. Secondary structure data of wild-type and mutant M.smegmatis PEPCK 
enzymes 157. 
 
Enzyme α-Helix β-Sheet β-Turn Other NRMSD 
WT 30 34 16 20 0.001 
E83A 31 34 15 20 0.001 
D78A 32 29 18 21 0.001 
D75A 29 32 17 22 0.001 
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Figure 2-14. Activity of wild-type, E83A and D78A mutant of Mtb PEPCK. The 
increased absorbance (340 nm) over time represents the enzyme activity, E83A and 
D78A mutant shows no activity.  
 
 
 
 
Figure 2-15. Interaction of D78 and E83 residues in R-loop with adjacent residues. 
Superimposed structures of apo- (blue) and GDP bound Mtb PEPCK (pink) shows 
different conformation of R-loop. The D78 and E83 residues contribute to the 
conformational maintenance.  
 
 
E83A	  and	  D78A 
WT 
  
 
74 
The crystallographic evidence of the loop’s flexibility made us postulate that 
stabilizing the mobile R81 loop helps the R81 residue bind substrates during the 
reaction. In Figure 2-15, the D75 residue is located in the surface area, pointing out 
toward solvent without interacting with the adjacent residues. However, the D78 residue 
has an intermolecular interaction with the S218 and G219 residues. The carbonyl oxygen 
of the D78 side chain functions as hydrogen bond acceptor interacting with the backbone 
amide of the G219 residue (distance 2.8 Å) and it also hydrogen bonds to the oxygen 
atom of the D78 side chain (distance 2.6 Å). Considering no significant structural 
changes on the D75A, D78A, and E83A mutants 157, the D78 residue may play a key 
role in maintaining R-loop conformation during catalysis, while the D75 residue plays 
no significant role.    
  We aimed to determine the effect of mutations on R81 loop conformation with 
crystal structures of mutants, E83A and D78A. Unfortunately, only E83A mutant was 
crystallized, while D78A mutant was aggregated during purification. The purified E83A 
Mtb PEPCK was crystallized with co-purified GDP molecule as same as wild-type Mtb 
PEPCK enzyme. This fact indicates that the loss of activity in the E83A mutant is not 
due to the loss of nucleotide binding and GDP bound E83A PEPCK shows only minor 
differences from the WT structure. In GDP bound E83A Mtb PEPCK structure, the 
electron density for the R81 side chain was not clearly visible. In contrast, the structure 
of the E83A mutant with the PO4 ion bound to the hydrogen of HNƐ- R81 side chain 
(distance 2.9Å) shows full density for the R81 residue with an additional coordinated 
water molecule to –NH of R81 side chain (distance 2.9Å), which binds in place of the 
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oxygen of the E83 carboxylate (Figure 2-16). Comparison of known PEPCK structures 
with our ligand complex structures (PO4 and oxalate) shows that the R81 side chain 
(R87 in human cPEPCK and rat cPEPCK) always adopts an identical rotameric 
conformation in the active site.  
 
 
 
 
Figure 2-16. The interaction between E83 and R81 side chain maintains catalytic 
efficient rotameric conformation of R81 side chain in the active site. (A) Rat cytosolic 
PEPCK in complex with OAA (PDB entry 2QF1), (B) E83A mutant structure with full 
density for R81 in the presence of ligand and water. 
 
 
 
In Figure 2-15C, the carboxyl oxygen of the E83 side chain accepts hydrogen of 
H-N1 of the R81 side chain to form a hydrogen bond (distance 3.2 Å), and NƐ-R81 is 
positioned for substrate binding, oxygen of oxalate ion hydrogen bonds to –NH of R81 
side chain (distance 2.8 Å). However, the R81 residue forms differently when there is no 
interaction with E83 as shown in Figure 2-15A. In addition, the R87 residue (numbered 
81 in Mtb PEPCK) in rat cPEPCK structure forms two main interactions with substrate 
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and E89 residue (numbered 83 in Mtb PEPCK). The oxygen atom of carboxyl group on 
oxaloacetate (OAA) accepts H-NƐ of R87 side chain to form H-bond interaction 
(distance 2.8Å) and the carbonyl oxygen of E89 side chain also accepts hydrogen from –
NH of R87 side chain at distance 3.3Å (Figure 2-16A). Therefore, the E83 residue is 
required to maintain the correct conformation of the R81 side chain for substrate binding 
and the flexibility feature of R-loop might make the role of E83 residue more important 
for efficient catalysis.  
Glycerol binding pocket between the R-loop and Ω–loop of the Mtb PEPCK active site 
would be explored for the design of species-specific drug  
The Mtb crystal structures contained a glycerol molecule (from the cryo-solution, 
10% glycerol) bound close to the R-loop as shown in Figure 2-17. We found that water-
mediated interaction between the -OH group of glycerol and the NH group of the R81 
side chain in the R-loop at 3.0 Å and 2.9 Å. In addition, the glycerol -OH groups also H-
bond to the backbone amide of P468 and N101, 2.9 Å and 2.8 Å distance, respectively. 
Also, the other -OH group of glycerol interacts H-bonding to carbonyl oxygen of N100 
side chain at 3.0 Å. 
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Figure 2-17. Glycerol binding pocket in Mtb PEPCK structure. 
 
 
 
At 20%, the concentration of glycerol did not inhibit enzyme activity during the 
enzyme assay. However, this novel glycerol binding site is not present in the human 
cPEPCK crystal structure. The N100 in Mtb PEPCK is substituent with G114 in human 
cPEPCK, which is not able to H-bond to the -OH group of glycerol (Figure 2-18). This 
unique glycerol binding site in Mtb PEPCK could be useful for novel and selective 
inhibitor design. For example, potent and selective inhibitors of Mtb dihydrofolate 
reductase (DHFR) were designed to take advantage of the glycerol binding pocket in the 
active site which was absent in human DHFR 162. Therefore, the same logic applied in 
this situation could provide opportunities for developing new selective inhibitors of Mtb 
PEPCK.   
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Figure 2-18. Comparison of a glycerol binding pocket of Mtb PEPCK and human 
cPEPCK.  Glycerol (green), human cPEPCK (blue), Mtb PEPCK (grey).  
 
 
 
Conclusion 
We obtained and refined a substrate bound crystal of Mtb PEPCK at high 
resolution. We found mobile loops in the active site that show conformational changes 
upon substrate binding. Comparisons between Mtb PEPCK and other GTP-dependent 
PEPCKs reveal that the flexible loops in Mtb PEPCK behave differently because of the 
differences in the residues adjacent to those involved in loop interactions. Notably, the 
unique interaction between the P-loop and Ω–loop in Mtb PEPCK allows the Ω–loop to 
close upon GDP binding, which was not observed in other GTP-dependent PEPCKs. 
The Ω–loop closure helps position PEP in the catalytic site and is required for efficient 
turnover especially for the anaplerotic reaction. Moreover, the R-loop shows increased 
flexibility in Mtb PEPCK while it is restricted in other GTP-dependent PEPCKs. In 
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addition, a glycerol binding pocket was found in the Mtb PEPCK, which is absent in the 
human cPEPCK. Despite the conservation of the overall structure and active site 
between host and Mtb PEPCK enzyme, we explored structural differences in Mtb 
PEPCK, which provides an opportunity to develop selective inhibitors for targeting the 
pathogenic enzyme.   
 
Experimental procedures 
Cloning, protein expression, and purification of M. tuberculosis PEPCK (Rv0211) 
The plasmid of M. tuberculosis PEPCK (Rv0211) was given by Sabin Ehrt’s 
group. To overexpress PEPCK, pckA (1,838 bp) was amplified by PCR and cloned into 
the pET28a vector (Novagen) using the restriction sites NdeI and HindIII. Primer 
sequences are available upon request. The plasmid transformed into Escherichia coli 
BL21(DE3) (Novagen) for expression. The cells were grown to an OD600 of 0.7-0.8 at 37 
°C in Luria-Bertani medium containing 50 µg ml-1 kanamycin. Mtb PEPCK expression 
was induced with 0.5 mM isopropyl 1-thio-β-D-galactopyranoside (IPTG). Cell growth 
continued at 291 K for 18 h after IPTG induction, and the cells were harvested by 
centrifuging at 4200g for 15 min at 277 K. The cell pellet was suspended in ice cold 
lysis buffer (20 mM Tris-HCl pH 7.0, 500 mM sodium chloride, 5 mM imidazole and 1 
mM phenylmethylsulfonyl fluoride (PMSF)) and the cells were lysed by French press. 
The cell debris was centrifuged at 36000 x g for 30 min at 277 K. Recombinant PEPCK 
with an N-terminal poly-His tag in the supernatant fraction was purified by nickel 
affinity chromatography (Ni-NTA resin (Qiagen)) followed by gel filtration (HiLoad XK 
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16 Superdex 200 prep-grade column (GE Healthcare)). It was then concentrated to 22 
mg/ml in 20 mM HEPES (pH 7.0), 50 mM NaCl using a Spin-X UF concentrator 
(Corning). The protein concentration was estimated by measuring the absorbance at 280 
nm, employing the calculated extinction coefficient of 26600 M-1 cm-1 (SWISS-PROT; 
http://www.expasy.ch/). 
Site-directed mutagenesis of Q448A, R377A, a double mutant (Q448A, E447A) and 
D72A, D75A, E83A mutants 
Site-directed mutagenesis of the M. tuberculosis PEPCK gene was performed 
with the QuikChange II Site-Directed Mutagenesis kit (Stratagene). Pfu Turbo DNA 
polymerase (Stratagene) was used for PCR reactions in the course of 30s at 95 °C; 1min 
at 58 °C; 7 min at 68 °C for 25 cycles. The pET28-pckA was used as template to 
construct the PEPCK single point mutants (Q448A, and R377A), while plasmid of 
Q448A mutant was used as template for double mutant (Q448A, E447A). PCR products 
were digested with Dpn I for 50 min at 37 °C to digest the DNA templates. 
Subsequently, plasmids containing the desired mutation were transformed to into One 
shot® TOP10 cells (Invitrogen) for plasmid propagation and extraction, and then 
transformed into Escherichia coli BL21 (DE3) (Novagen) for expression. The sequence 
of mutant DNA was confirmed by determining the plasmid DNA sequencing at the Gene 
Technology Lab of Texas A&M University. For the Q448A mutant, the forward primer 
(5'- CTG GGT AGC GAG GCG ACC GCC GCG G-3') and reverse primer (5'- CCG 
CGG CGG TCG CCT CGC TAC CCA G-3') were used. For R377A, forward (5'- CAA 
CGA CTG GTA CTT CGC GGA GAC GGA AAC CAA TG -3'), and reverse (5'- CAT 
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TGG TTT CCG TCT CCG CGA AGT ACC AGT CGT TG-3') primers were used. For 
double mutant, Q448A and E447A, forward (5'- CCC TGG GTA GCG CAG CGA CCG 
CCG C -3') and reverse (5'- GCG GCG GTC GCT GCG CTA CCC AGG G-3') primers 
were used. The plasmids containing mutants, D72A, D75A, E83A, of the M. 
tuberculosis PEPCK was provided by Sabine’s group. Expression and purification of the 
mutants was performed following the protocol used for the wild-type protein.  
Enzyme assay of M. tuberculosis PEPCK (Rv0211) 
The gluconeogenic reaction (PEP-formation) 
The activity of Mtb PEPCK in direction of gluconeogenic reaction was 
determined using the pyruvate kinase and lactate dehydrogenase (PK/LDH) coupled 
enzyme assay (Figure 2-19). The PEP produced by PEPCK was taken by pyruvate 
kinase to produce pyruvate. The LDH enzyme converts pyruvate to lactate with 
oxidation NADH to NAD+. The reduction in absorbance at 340nm can be monitored as 
a rate of PEP formation by Mtb PEPCK.  Use extinction coefficient for NADH (Ɛ340 = 
6220M-1cm-1) to determine rate of PEP production.  
 
2 
 
 
Figure 2-19. The coupled enzyme reactions (PK/LDH) used for the measurement of Mtb 
PEPCK enzyme activity. 
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The assay mixture contained 0.4 mM GTP, 4 mM MgCl2, 0.5 mM MnCl2, 1 mM 
DTT, 2 mM ADP, 6 unit PK/LDH enzymes, 0.25 mM NADH, and 2 µg/ml Mtb PEPCK 
enzyme in 20 mM Tris-HCl, pH 7.5, with 50 mM NaCl. The enzyme reaction was 
started by adding varied OAA concentration (0-1 mM). To determine Kcat and Vmax in 
Table 2-2, GraphPad Prism version 6.00 (GraphPad Software, La Jolla California USA) 
were used. 
The anapelrotic reaction (OAA-formation) 
PEPCK converts PEP to OAA by fixing CO2 in presence of GDP and metals. 
The produced OAA by PEPCK was consumed by MDH to generate L-malate in order to 
maintain its equilibrium (Figure 2-20).  During this process, MDH converts reduced 
NADH to NAD+, thus enzyme activity can be monitored by detecting decreased NADH 
absorbance, spectrophotometrically, at 340 nm. The assay mixture contained 20 mM 
Tris-HCl, 50mM NaCl, 2 units of MDH, 2mM MgCl2, 0.1 mM MnCl2, 100 mM 
NaHCO3, 5 mM DTT, and 0.25 mM NADH with varied GDP and PEP concentrations 
depending upon the experiment. To determine Kcat and Vmax in Table 2-2, GraphPad 
Prism version 6.00 (GraphPad Software, La Jolla California USA) were used. 
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Figure 2-20.  The enzyme reaction of coupled malate dehydrogenase (MDH) enzymes. 
It is used for detecting anaplerotic reaction (OAA-formation, CO2 fixation) of Mtb 
PEPCK enzyme.   
 
 
 
Metal-dependent activity assay 
To detect metal activity of enzyme, the PEP forming activity of Mtb PEPCK was 
detected using the malate dehydrogenase (MDH) coupled enzyme (Figure 2-20) due to 
the activity of PK/LDH coupled enzyme was also metal dependent. The assay mixture 
contained 20 mM Tris-HCl buffer, 50 mM NaCl, 100 µM GTP, 1 mM malate, 1 mM 
NAD, and 6 units of MDH. The PEP forming activity of Mtb PEPCK was measured 
using MDH, followed by monitoring the increased NADH absorbance at 340nm. The 
reaction was started by adding metal for the pH-dependent experiment at room 
temperature. The effects of Zn2+ and Mn2+ on the kinetic parameters of Mtb PEPCK was 
performed an activity comparison at 62.5 µM of the metal over a pH range of 5.8 - 8.5.  
Crystallization and data collection of M. tuberculosis PEPCK  
Mtb PEPCK was crystallized by hanging drop vapor diffusion at 16 °C. 
Crystallization was achieved in a 4 µl drop consisting of 2 µl well solution [10% -16% 
(w/v) PEG 3350, 0.2 M KH2PO4] and 2 µl of protein. PEPCK in complex with co-
purified GDP grew within 24 h. The apo PEPCK was formed after one month in the 
same drop. Crystals of Mtb PEPCK in complex with oxalate, non-hydrolyzable GTP 
  
 
84 
analog (Guanosine 5′-[β,γ-imido]triphosphate trisodium salt hydrate), and PEP, were 
obtained by soaking the apo crystal in 2 mM oxalate or PEP in the presence of 5 mM 
MnCl2. We were unable to obtain a wild-type PEPCK complex with PEP-GDP because 
the compound turns over in the active site.  The crystallization trial of mutant Q448A 
was unsuccessful. The mutant E83A PEPCK in complex with co-purified GDP was 
grown under the same conditions as WT PEPCK, and mutant E83A PEPCK in complex 
with PEP-GDP was obtained by soaking with the apo E83A crystal in 0.5 mM PEP in 
the presence of 5 mM MnCl2 and 0.5 mM GDP. Crystals were cryo-protected by dipping 
them into a solution [10% (w/v) PEG3350 and 20% glycerol (v/v)]. Diffraction data 
were collected at a wavelength of 1.542 Å using a Rigaku R-Axix IV ++ at home source 
and at the Advanced Photon Source beamline 23-ID using a MAR 300 CCD detector 
(MarMosaic from Marresearch Charged Coupled Device) (Rayonix LLC, Evanston, IL). 
The HKL2000 program package (HKL Research, Inc., Charlottesville, VA) was used for 
integration and scaling.  
Structure determination and refinement of M. tuberculosis PEPCK  
The molecular replacement program PHASER (University of Cambridge, 
Cambridge, U.K.) was used to determine the structure of Mtb PEPCK using the crystal 
structure of human cPEPCK (PDB entry 1KHG) as a search model with water and ions 
removed. The GDP-bound Mtb PEPCK structure represented C2221 space group with 
a=103.32, b=125.17, c=122.15, α=90.00, β=90.00, and γ=90.00, while apo-Mtb PEPCK 
structure showed C2 space group with a=103.24, b=122.43, c=64.38, α=90.00, 
β=116.89, and γ=90.00. Except GDP-bound Mtb PEPCK structure, all other structures 
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are scaled into C2 space group. Therefore, the apo structure of Mtb PEPCK used as a 
search model for substrates-bound structures and E83A mutant structure. Rigid body 
refinement, followed by simulated annealing at 5000 K, was conducted using PHENIX 
(Python-based Hierachical Environment for Integrated Xtallography). Subsequently, 
refinement was conducted in alternating cycles of manual model building in COOT 
(Crystallographic Object Oriented Toolkit), followed by refinement in PHENIX until the 
R factors converged. Data collection and refinement statistics for Mtb PEPCK in 
complex with substrates were shown in Table 2-5. 
Anomalous difference scattering experiment of M. tuberculosis metal co-purified 
PEPCK  
The Mtb PEPCK crystal with co-purified metals was collected at 1.542 Å using 
Rigaku the R-AXIS IV++ home source; the same crystal was collected again at the 
wavelength of 0.9199 Å at the Advanced Photon Source. The data were processed in 
HKL2000 and the Sfall program in CCP4 was used to calculate Fcalc and PHIcalc. The 
anomalous difference maps were created using the program FFT (Fast Fourier 
Transform) in CCP4.  
ICP-MS analysis of M. tuberculosis metal co-purified PEPCK 
Mtb PEPCK co-purified with metals was used for trace metal analysis. Protein 
samples were digested in 1-4% HNO3, 20 mM HEPES pH 7.0, 50 mM NaCl at 70 °C for 
24 h and then diluted with deionized water. The trace metals in the sample were 
determined using an inductively coupled plasma mass spectrometer (ICP-MS; ELAN 
6100 DRC-2 Perkin-Elmer, Concord, Ontario, Canada), a Meinhardt microcentric 
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nebulizer, and a quartz cyclonic spray chamber. Rhodium (Rh) 103 was used as an 
internal standard with external calibration. 
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Table 2-5. Data collection and refinement statistics for Mtb PEPCK in apo-form and 
complex with substrates. 
 
Mtb 
PEPCK-
apo 
Mtb PEPCK-
oxalate-Mn2+ 
Mtb PEPCK-
nhGTP 
Mtb PEPCK-
Zn-Mn-GDP 
Mtb PEPCK-
PEP 
E83A Mtb 
PEPCK-PEP-
GDP 
PDB ID 4WIE 4WIU 4WL8 4WOU 4WPT 4WPU 
Wavelength 
(Å) 1.54 1.54 1.00 0.92 0.95 1.54 
Resolution 
range (Å) 
50 - 2.18 
(2.22 - 
2.18) 
50 - 2.02 
(2.05 - 2.02) 
50 - 1.61 
(1.64 - 1.61) 
50 - 2.12 
(2.16 - 2.12) 
50 - 1.13 
(1.15 - 1.13) 
50 - 2.26 
(2.3 - 2.26) 
Space group C 1 2 1 C 1 2 1 C 1 2 1 C 2 2 21 C 1 2 1 C 1 2 1 
Unit cell 
103.958 
122.564 
64.555 
90 
117 
90 
103.969 
122.739 
64.697 
90 
116.98 
90 
105.616 
123.009 
64.035 
90 
116.97 
90 
103.316 
125.172 
122.147 
90 
90 
90 
103.574 
122.813 
64.556 
90 
116.66 
90 
104.636 
122.715 
63.861 
90 
116.61 
90 
Total 
reflections 157035 173856 368099 382393 708883 123037 
Unique 
reflections 37534 45080 92528 44382 90212 33627 
Multiplicity 4.2 (4.1) 3.9 (3.9) 4.0 (2.3) 8.5 (7.0) 1.9 (1.1) 3.7 (3.2) 
Completeness 
(%) 
99.98 
(99.76) 94.98 (90.31) 98.02 (83.54) 98.47 (93.61) 95.21 (96.46) 99.61 (96.44) 
Mean 
I/sigma(I) 24.8 (5.05) 35.3 (7.6) 21.0 (1.2) 27.8 (3.4) 6.51 (2.67) 17.4 (2.2) 
Wilson B-
factor 24.9 23.82 20.28 35.48 16.89 33.16 
R-merge 0.146 (0.912) 0.107 (0.215) 0.128 (0.77) 0.11 (0.708) 0.087 (0) 0.121 (0.508) 
R-work 0.1350 (0.1613) 
0.1551 
(0.1809) 
0.1642 
(0.2680) 
0.1767 
(0.2643) 
0.1692 
(0.2198) 
0.1670 
(0.2008) 
R-free 0.1888 (0.2472) 
0.1953 
(0.2243) 
0.1869 
(0.3058) 
0.2107 
(0.3064) 
0.1946 
(0.2735) 
0.2231 
(0.2803) 
Number of 
atoms 5409 5377 5415 5014 5572 5142 
macromolecul
es 4791 4787 4770 4657 4787 4769 
ligands 7 13 39 41 21 44 
water 611 577 606 316 764 329 
Protein 
residues 600 600 599 595 600 599 
RMS(bonds) 0.007 0.008 0.008 0.007 0.007 0.008 
RMS(angles) 1.04 1.02 1.16 1.11 1.12 1.14 
Ramachandran 
favored (%) 98 97 99 97 98 97 
Ramachandran 
outliers (%) 0 0 0 0.17 0 0.33 
Clashscore 2.45 1.28 2.44 3.26 3.18 4.18 
Average B-
factor 24.6 24.7 23.1 41.6 20.10 34.3 
macromolecul
es 23.7 23.8 21.8 41.5 18.40 33.9 
ligands 28.5 35.3 30.6 37.4 26.50 39.2 
solvent 32.1 31.5 33 44.2 30.60 39.3 
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Additional results 
Pyruvate-kinase activity of Mtb PEPCK 
PEPCK catalyzes the decarboxylation of oxaloacetate for pyruvate formation in 
the presence of nucleoside diphosphate. A study of the rat liver PEPCK revealed that 
Inosine 5’-diphopshate (IDP) and a divalent metal ion are required for the formation of 
pyruvate from oxaloacetate 148,163,164. As shown in Figure 2-21, pyruvate-kinase activity 
in Mtb PEPCK shows better activity (2.5 fold) in the presence of GDP than without 
GDP. The apparent Km of OAA in the pyruvate forming reaction is 376 µM in the 
absence of GDP and 168 µM in the presence of GDP. This activity was observed a 
decade ago, however, the reason for the disparate activity was unknown. In our 
structural study of Mtb PEPCK, we observed conformational changes of the Ω–loop 
upon GDP binding; it closed in presence of GDP. Therefore, Ω–loop closure may 
participate in catalysis of pyruvate production.    
 
 
 
 
Figure 2-21. Comparison pyruvate-kinase activity of Mtb PEPCK in absence and 
presence of GDP molecule. 
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Crystal contacts in the Mtb PEPCK structure 
The GDP molecules seem to make crystal packing contact that block the active 
site of Mtb PEPCK. The guanidinium group of the R377 side chain on the neighboring 
molecule forms electrostatic interaction with the phosphate groups of the GDP molecule 
(distance 3.0 Å), as shown in Figure 2-22. To discriminate between biologically relevant 
interfaces and artificial crystal packing contacts in the crystal structures, the Mtb PEPCK 
enzyme sample after incubation with the GDP molecule ran the gel-filtration, however 
the peak was correlated to a monomeric sized peak. Thus, the contacts the between two 
monomers in the crystal structure are symmetry related crystal packing contacts.     
 
 
 
 
Figure 2-22. Crystal contacts in Mtb PEPCK crystal structure. (A) Two monomeric 
molecules in crystal structure, and (B) GDP molecule is located between two molecules. 
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CHAPTER III                                                                                                                 
STRUCTURAL ANALYSIS OF PEPCK INHIBITOR COMPLEX AND 
DEVELOPMENT OF SELECTIVE INHIBITORS 
 
Introduction 
The Mtb PEPCK enzyme is essential for Mtb growth on fatty acids in vitro 43 and 
for TB persistence during infection in mice 25 making it an attractive target for anti-TB 
drug development. Despite the conservation of the overall structure and the highly 
conserved active site, there are structural differences that provide opportunities to 
develop selective inhibitors targeting Mtb PEPCKs over the host enzyme in CHAPTER 
II.  
3-mercaptopicolinic acid (3-MPA) is the classic reversible PEPCK inhibitor, 
known to inhibit gluconeogenesis by blocking the PEPCK enzyme in the rat and guinea-
pig 64. Its IC50 against human cPEPCK was reported in the 20 µM range 65. Recently, the 
3-MPA binding site was found in a substrate binding site (PEP/OAA) and also in an 
allosteric site near the nucleotide binding site 66. Moreover, a variety of substrate 
analogues (OAA/PEP) exhibited poor enzyme inhibition even though they bind tightly to 
the substrate-binding site 67.   
Mammalian GTP-dependent PEPCK has a regulatory role in hepatic 
gluconeogenesis, making it a target for type 2 diabetes drug development. Transcription 
of the PEPCK gene is inhibited by insulin, resulting in a decreased rate of 
gluconeogenesis in the liver and in rat hepatoma cells 68. Overexpressed PEPCK 
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contributes to an increase in the rate of gluconeogenesis and the development of fasting 
hyperglycemia in transgenic mice 69, and PEPCK siRNA treatment of diabetic mice 
decreased the quantity of hepatic PEPCK enzyme and eliminated hyperglycemia. These 
data demonstrate the involvement of the PEPCK enzyme in the development of 
hyperglycemia, and suggest that inhibiting the human cPEPCK enzyme should decrease 
blood glucose levels in type 2 diabetic patients 70. Therefore, numerous efforts to find 
PEPCK inhibitors have been made to treat type 2 diabetes.  
A variety of reversible GTP-competitive inhibitors were designed and developed 
by the Roche research center based on the human cPEPCK nucleotide binding pocket. 
The first scaffold developed from an HTS hit is 1-ally-3-butyl-8-methylxanthine (IC50 = 
225 ± 25 µM).  
3 3	  
 
 
 
Figure 3-1. The first scaffold from HTS hit is 1-ally-3-butyl-8-methylxanthine (IC50 = 
225 ± 25 µM) against human cPEPCK. 
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Figure 3-2. The modifications of Roche compounds targeting the human cPEPCK. 
Based on a xanthine ring, the series of compounds contain diversity on N1, N3, and C8.  
 
 
 
 
 
Figure 3-3. The binding mode of a GTP-competitive PEPCK inhibitor. (A) (N-{4-[1-(2-
FLUOROBENZYL)-3-BUTYL-2,6-DIOXO- 2,3,6,7-TETRAHYDRO-1H-PURIN-8-
YLMETHYL]-PHENYL}-ACETAMIDE or Axon1165) in human cPEPCK (PDB code: 
1NHX), and (B) chemical structure of Axon1165.  
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Roche made a variety of xanthine analogues with modifications on the N1, N3, 
and C8 positions (Figure 3-2). Potency from the initial HTS hit was improved about 100 
fold (IC50 = 2.11 ± 0.60 µM) through the substituent of 2-fluorobenzyl at N1 and N-
Acetyl-4-aminobenzyl at C8 (chemical structure shown in Figure 3-3). This compound, 
Axon1165, is commercially available from the Axon Medchem Company. Figure 3-3A 
shows how the human PEPCK-Axon1165 structure (PDB: 1NHX) explains the 
interaction mode of this compound. The xanthine ring makes a π-stacking interaction 
with F530 at 3.4 Å and with F517 at 3.3 Å in a sandwich configuration, and there is 
another π-π interaction between the benzyl ring on the C-8 xanthine ring with F525 in a 
parallel offset configuration. The favorable edge-to-face interaction between F530 and 
the phenyl ring of the C-8 benzyl unit is also seen in the X-ray structure. The C-2 
carbonyl of the xanthine ring hydrogen bonds to the amide of the N295 side chain at a 
distance of 3.0 Å. The 2-fluorobenzyl group makes π-interactions with the peptide bond 
between N295 and L293 and the fluoro group hydrogen bonds to the N533 side chain 
amide at 3.1 Å. In this chapter, the structural differences between the complex structures 
of Axon1165 with human and Mtb PEPCK are addressed in detail and used for the 
identification of a lead compound that shows selective inhibition against the pathogenic 
enzyme. In addition, the Roche GTP-competitive human cPEPCK inhibitor library 
(xanthine analogues) was intensively tested against Mtb PEPCK to find potent and 
selective inhibitors.  
In addition, to find new molecule scaffolds that inhibit the Mtb PEPCK enzyme, 
800 fragments (low molecular weight, <300 Da, compounds) and SRI hit 1120 anti-
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tuberculosis active compounds 71 were screened against the Mtb PEPCK enzyme using 
affinity testing with differential scanning fluorimetry (DSF) as initial screening method. 
Also, medically relevant compounds were screened against Mtb PEPCK to search for 
molecular scaffolds via enzyme inhibition assay against the Mtb PEPCK enzyme. For 
this, 4700 anti-tuberculosis active compounds were selected for inhibiting Mtb growth 
on acetate, as a sole carbon source (from among 51K compounds).  
 
Result and discussion 
Crystal structure of Mtb PEPCK bound to Axon1165 (GTP-competitive inhibitors for 
human cPEPCK) and comparison with the human cPEPCK structure (PDB:1NHX) 
 Axon1165 (CAS_628279-07-2) is a GTP-competitive human cPEPCK inhibitor 
that is commercially available. The complex structure of human cPEPCK with 
Axon1165 is available in the PDB (PDB:1NHX) and its IC50 against human cPEPCK is 
2.11 ± 0.60 µM 65. The interaction mode is as described in the beginning of this chapter. 
This compound has an IC50 of 3.54 µM against Mtb PEPCK and we successfully created 
a complex structure of Mtb PEPCK with Axon1165. The information from this structure 
allows us to investigate the difference in the binding interactions between the human and 
Mtb PEPCK enzymes.  
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Figure 3-4. The binding site of Axon1165 in Mtb PEPCK. (A) Superimposed complex 
structure of Axon1165 in Mtb PEPCK (blue) and human cPEPCK (grey) (PDB:1NHX), 
(B) different residues placed near the Axon1165 binding area between Mtb and human 
PEPCK enzyme, (C) the structure of Axon1165, and (D) the Fo-Fc omit map contoured 
at 5.0 σ of the Axon1165 ligand in the Mtb PEPCK structure. 
 
 
 
In Figure 3-4, a superimposed complex structure of the Mtb PEPCK and human 
Axon1165 structures reveals that the binding mode of Axon1165 is highly conserved 
between two structures. In the Mtb PEPCK-Axon1165 structure, the xanthine ring makes 
a π-stacking interaction with the benzyl ring of the F515 side chain at 3.5 Å and with 
that of the F502 residue at 3.7 Å. There is another π-π interaction between the benzyl 
ring on the C-8 xanthine ring and the ring of F510 side chain is in a parallel offset 
configuration. The favorable edge-to-face interaction between the benzyl ring of the 
F515 side chain and the phenyl ring of the C-8 benzyl unit is also seen in the X-ray 
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structure. The C-2 carbonyl of the xanthine ring accepts a hydrogen from the amide 
group of the N277 side chain at a distance of 2.9 Å. The 2-fluorobenzyl ring makes π-
interactions with the peptide bond between the N277 and L278 residue and the fluoro 
atom accepts hydrogen from the N518 side chain amide for a H-bonding interaction 
(distance 2.9 Å). These interactions are identical to those found in the human cPEPCK 
structure.  
 
 
 
 
Figure 3-5. Comparison of binding interaction with Axon1165 in Mtb PEPCK and 
human cPEPCK (PDB ID: 1NHX). This figure was generated by using Ligplot program. 
The different residues are pointed with arrows.  
 
 
 
Despite the highly conserved binding interactions, there are two interesting 
differences in the xanthine analog binding area which could be exploited for the design 
of selective Mtb PEPCK inhibitors. First, the 2-fluorobenzyl ring of Axon1165 is 3.4 Å 
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from M296 in the human cPEPCK (Figure 3-4 B, Figure 3-5); the equivalent residue in 
the Mtb PEPCK complex structure is L281. Both L281 in Mtb PEPCK and M296 in 
human cPEPCK are hydrophobic residues, but modification of the fluorobenzyl group of 
Axon1165 could extend near the L281 residue and create potent and selective Mtb 
PEPCK inhibitors.  
Another important structural difference between the Mtb and human PEPCK 
occurs close to the acetamide of the C8 benzyl ring, in an area denoted the small binding 
pocket (pocket size is about 10 Å). As shown in Figure 3-6, the electrostatic surface 
model of the Mtb PEPCK represents a number of polar residues in this small pocket and 
is sufficiently large to accommodate the larger inhibitors that are extended from the C8 
benzyl ring. However, this pocket in human cPEPCK structure contains fewer polar 
residues and is smaller than that of Mtb PEPCK. 
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Figure 3-6. Comparison of the electrostatic surface of the small pocket near the inhibitor 
binding site. (A) Mtb PEPCK structure in complex with Axon1165, (B) human cPEPCK 
(PDB:1NHX).  
 
 
 
 
Figure 3-7. Superimposed inhibitor binding pocket of the human cPEPCK and Mtb 
PEPCK structures.  
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The superimposed structure of human cPEPCK (PDB:1NHX) and Mtb PEPCK 
in complex with Axon1165 (Figure 3-7) highlights several key residues that create the 
larger pocket in Mtb PEPCK, but not in human cPEPCK. The side chain of the Mtb 
PEPCK R509 residue faces the outer pocket and hydrogen bonds with the side chains of 
D560 (3.0 Å) and D507 (2.8 Å). The equivalent residue in human cPEPCK is K524 
which does not interact with adjacent residues and seems to have free rotation. These 
differences may offer opportunities to develop selective Mtb PEPCK inhibitors. To find 
a lead molecule that binds to this area, we screened a variety of xanthine analogs with 
extended groups at the C-8 position. 
Screening Roche 104 compounds (1st set of Roche library) 
104 human cPEPCK inhibitors (GTP-competitive inhibitors), mostly with 
modifications on the C8 position were screened against Mtb PEPCK at a final 
concentration of 10 µM, resulting in 80 compounds that showed inhibition in the range 
of 50-90%, results are shown in Table 3-1.  
 
 
 
Table 3-1. 104 compound screen against the Mtb PEPCK enzyme. 
 
Enzyme Inhibition at 10 µM Number of compounds 
> 90% inhibition 5 
>70% inhibition 30 
>50% inhibition 45 
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A group of 104 compounds were tested against Mycobacterium tuberculosis 
H37Rv for whole cell inhibition by the tuberculosis research lab in University Illinois 
Chicago (UIC). The data related to the compounds (sulfonoamide, amide, and 
benzylamine linkage analogues with a xanthine core) are summarized in Table 3-2 and 
Table 3-3. Screening of the first set of Roche compound libraries suggested that 
sulfonamide derivatives are effective against the enzyme at 10 µM, but they have poor 
activity against TB whole cells, probably because the polarity of compounds prevents 
entry to the bacterium. The N-methyl amide derivatives shows increased Mtb PEPCK 
activity compared to the amide analogues. The benzylamine derivatives are most potent 
against the cell and enzymes with a low µM range of activity for MIC and IC50, as 
shown Table 3-2. It suggests that benzylamine derivatives possess better permeability 
against cell. However, though RO4355651 has poor inhibition against the enzyme (no 
enzyme inhibition at 10 µM), it shows MABA MIC is 25 µM, thus the possibility of 
nonselective target inhibition cannot be ruled out.   
We selected five compounds that were potent against both the enzyme (IC50 of 4 
of 5 compounds in range of 0.5-1.5 µM) and whole cells (99-100% at 50 µM) (Table 3-
2). Those five compounds were taken to X-ray crystallography to figure out binding 
modes, resulted in four compounds, RO4355622, RO4355668, RO4355703, and 
RO505244, PEPCK-inhibitor complex structures were solved for all of them at 2.0 Å 
resolutions.   
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Table 3-2. Chemical structures, IC50, and MIC value of selected five compounds.  
 
 
 
 
 
 
 
 
 
 
Compound 
ID 
Structure 
Xanthine analogs - Benzylamine 
ENZYME 
IC50(µM) 
MABA MIC 
(µM) 
RO4355622 
 
0.626 22.7 
RO4355651 
 
No inhibition 
<10µM 25 
RO4355668 
 
0.752 16.4 
RO4355703 
 
1.26 7.6 
RO0505244 
 
1.21 28.3 
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Figure 3-8. Superimposition of PEPCK-inhibitor complex structures with RO4355622, 
RO4355668, RO4355703, and RO505244.  
 
 
 
 All four compounds bind to the GTP-binding site in a similar fashion as Axon 
1165, the π-π interactions of xanthine core and C-8 benzyl ring with the phenyl ring of 
the F530, F517, and F525 side chains are conserved. However, interestingly, the 
extended ring systems of C-benzyl ring do not interact with any enzyme residues (Figure 
3-8). Instead, the human cPEPCK is in complex with a sulfonamide compound 
(PDB:2GMV) and shows that the imidazole ring extends from the sulfonamide linkage 
positioned on top of the phenyl ring from the F530 side chain for a π-π interaction 
(Figure 3-9).  
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Figure 3-9. Superimposed inhibitor complex structures of Mtb PEPCK with 
RO4355622, RO4355668, RO4355703, and RO505244 and human cPEPCK with N-(4-
{[3-butyl-1-(2-fluorobenzyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-
yl]methyl}phenyl)-1-methyl-1H-imidazole-4-sulfonamide (orange color) (PDB 
code:2GMV). 
 
 
 
The difference between conformation of K524 (human cPEPCK) and R509 (Mtb 
PEPCK) may induce the differences in the binding mode of the extended ring from the 
C-8 benzyl on R8. As shown in Figure 3-9, the different placement of a sulfonamide 
derivative in the human PEPCK structure might be due to the steric hindrance caused by 
the K524 residue. It is possible that the steric hindrance caused by K524 facilitates this 
turn, while R509 of Mtb PEPCK can accommodate any extended ring system near the 
small binding pocket, which represents a different environment compared to the human 
one. Therefore, the bulky group of the sulfonamide linkage in certain compounds could 
be critical to confer selectivity against the Mtb PEPCK enzyme. The xanthine analogs, 
sulfonamide, and amide derivatives with MABA MIC and percent inhibition at 10 µM of 
compounds against the Mtb PEPCK enzyme are represented in Table 3-3. Despite the 
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compounds have inhibitory effect on enzyme at 10 µM, whole cell activity is very poor. 
Probably, the polarity of sulfonamides and amides makes compounds difficult to enter 
into cell.  
 
 
 
Table 3-3. Chemical structure of xanthine analogs, sulfonamide, and amide derivatives 
with MABA MIC and percent inhibition at 10 µM of compounds against the Mtb 
PEPCK enzyme. 
a data from TB research center at UIC 
Compound 
ID 
Structure 
Xanthine analogs - Sulfonamides 
MABA MIC 
(µM)a 
% Enzyme Inhibition 
at 10 µM 
RO0504005 
 
> 50 91 
RO0503982 
 
 
> 50 87 
RO0505928 
 
> 50 4 
RO0282693 
 
41.8 80 
RO0505787 
 
49.2 92 
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Table 3-3. Continued. 
 
Compound 
ID 
Structure 
Xanthine analogs - Amides 
MABA MIC 
(µM)a 
% Enzyme Inhibition 
at 10 µM 
RO0282340 
 
 
 
> 50 40 
RO0503883 
 
 
> 50 77 
RO0506405 
 
49.9 53 
RO0506263 
 
48.2 81 
RO0506834 
 
>50 90 
RO0507332 
 
 
46.4 89 
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Screening of 2nd set of Roche libraries selected based on structural information of 
complex structure of Mtb PEPCK with inhibitors, revealed the improved activity with 
respect to both cell and enzyme inhibition 
 The complex structures of Mtb PEPCK with compounds from the 1st set of Roche 
compounds revealed the small binding site with different residues between human and 
Mtb PEPCK, and provided opportunities for the development of selective inhibitors for 
anti-TB drugs. The 2nd set of Roche libraries contained selected 472 compounds with a 
variety of modifications on the C8 position and could potentially bind to the small 
binding site. The results of screening 2nd of Roche inhibitors revealed the improved 
activity with respect to both cell and enzyme inhibition. Of these compounds, 65 showed 
over 70% enzyme inhibition at 10 µM. These 65 compounds were retested in dose-
response for IC50 value. The 20 compounds had IC50 values ranging from 0.2 µM to 2.5 
µM and MIC values were less than 10 µM. Benzylamines continue to show very good 
activity in both the enzyme assay and MABA, and more potent N-methyl amides were 
identified. The IC50 and MABA MIC values of the hit compounds are summarized in 
Table 3-4. 
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Table 3-4. The IC50 and MABA MIC values of the hit compounds with chemical 
structure. 
 
Compound 
ID 
Structure 
Xanthine analogs – 2nd Roche compounds 
MABA 
MIC 
(µM)a 
ENZYME 
IC50(µM) 
RO4355653 
 
 
1.9 5 
RO4355629 
 
4.3 0.6 
RO4355660 
 
2.8 2.5 
RO4355664 
 
2.8 3 
RO4355707 
 
 
0.38 1.8 
RO4355630 
 
6.1 2.3 
RO0504732 
 
 
4.8 0.2 
RO0506952 
 
 
4.6 1.8 
RO0507002 
 
 
9.8 0.8 
RO0507694 
 
 
5.1 0.7 
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Structural study of 2nd Roche compound library hits revealed important interactions 
for binding to C-8 binding pocket  
We identified a small pocket in Mtb PEPCK whose amino acid composition 
differs from the human one, providing us an opportunity to find selective inhibitors 
against pathogenic enzyme. Thus, we screened several Roche 2nd compounds using X-
ray crystallography and identified inhibitors that interact with the binding pocket.  
Structural analysis of Mtb PEPCK with RO4355707, which has the most potent 
activity against the cell (MIC = 0.38 µM), reveals that the benzo-d-imidazole ring of 
RO4355707 contacts a hydrophobic interaction with the guanidinium group of the R509 
residue in Mtb PEPCK (distance 3.6 Å) (Figure 3-10). The piperidine ring might make a 
better linker for entering the cell than the sulfonamides, and extending the benzo-d-
imidazole ring successfully captured the interaction of the R509 side chain. Further 
modification of this compound could improve potency and selectivity against the 
enzyme.  
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Figure 3-10. The binding mode of RO4355707 in Mtb PEPCK-RO4355707 complex 
structure.   
 
 
 
 
Figure 3-11. The binding mode of RO0506473 in Mtb PEPCK and chemical structure of 
RO0506473. 
 
 
 
 
In the crystal complex structure of Mtb PEPCK-RO0506473, the molecule binds 
to the small pocket by interacting with the D560 residue through water mediated 
interactions as shown in Figure 3-11. The hydroxyl group interacts with the water 
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molecule through hydrogen bonds, and the water interacts with the carbonyl group of the 
D560 side chain, at 3.2 Å and 2.7 Å, respectively. This compound shows an IC50 of 2.5 
µM against Mtb PEPCK, but cell data is not available. Binding small pocket through 
water interaction shows no improved and selective activity on Mtb PEPCK. The water 
mediated interaction with D560 may not support a strong interaction to improve 
inhibitory effect. This molecule probably interacts with phenylring F530 of human 
cPEPCK to show an increased activity against human PEPCK (IC50 = 1.48 µM).    
 
 
 
 
Figure 3-12. The binding mode of RO0506333 in Mtb PEPCK-RO0506333 complex 
structure and chemical structure of RO0506333. 
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Figure 3-13. The binding mode of RO0505787 in Mtb PEPCK-RO0505787 complex 
structure and chemical structure of RO0505787. 
 
 
 
 
Figure 3-14. The binding mode of RO0504449 in Mtb PEPCK-RO504449 complex 
structure and chemical structure of RO504449. 
 
 
 
The complex structures of RO506333, 0505787, and 0504449 inhibitors (Figures 
12, 13, and 14) with Mtb PEPCK reveal that the pyrazole ring is positioned near the 
R509 residue in C-8 binding pocket, not on the top of the benzyl ring of the F515 side 
chain. The 2-N atom of the pyrazole ring functions as a hydrogen bond acceptor 
interacting with the backbone of amide of the F510 residue. Crystallographic evidence 
suggests that the H-bond interaction between the molecule and the backbone of amide of 
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F510 is critical to position the extended ring near R509.  These pyrazole derivatives 
showed very potent inhibition on Mtb PEPCK, RO506333 (IC50=0.30 µM), RO050787 
(IC50= 0.96 µM), RO0504449 (IC50=0.80 µM). Therefore, this H-bond interaction is 
important to improve enzyme inhibitory activity against Mtb PEPCK. However, they 
showed no selective inhibition. It is possible that these compounds can still interact with 
phenyl ring of F530 side chain in human PEPCK to have π-π interaction showing strong 
inhibition.  
 
 
 
 
Figure 3-15.  Mtb PEPCK-RO507000 complex structure and chemical structure of 
RO507000. 
 
 
 
The nitrogen atom on the pyridine ring of RO507000 hydrogen bonds to the 
backbone carbonyl group of the G514 residue through a water molecule (Figure 3-15). 
The carbonyl group of the G514 backbone interacts with water (distance 2.9 Å) and the 
water interacts with the nitrogen of the pyridine ring (distance 2.7 Å) for a H-bonding 
interaction, this makes the pyridine ring turn closer to the F515 residue, unlike the 
pyrazole ring. The IC50 value of RO507000 is 0.76µM, indicating not much different 
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activity were shown between the interaction closer to the R509 and the interaction closer 
to the F515 residue.  
The crystal complex structures of Mtb PEPCK with the Roche inhibitors 
demonstrate clearly the importance of the H-bonding interaction between the compound 
and the backbone amide group of F510 to position the extended ring near the R509 
residue. This localization of inhibitors near R509 is expected to increase selective 
activity against Mtb PEPCK because the lysine residue at the equivalent position may 
cause steric hindrance and thus would exhibit less activity against the human enzyme. 
This interaction also improved inhibitory efficacy on Mtb PEPCK. We tested the 
inhibitors against a cloned human cPEPCK enzyme using identical conditions to those 
used for the Mtb PEPCK enzyme. None of compounds showed selectivity against Mtb 
PEPCK, they all represent better activity on human enzyme (Table 3-5). It is plausible 
that the compounds interact with the benzyl group of the F530 side chain via π-π 
interactions as discussed in Figure 3-9, with a similar degree of enzyme inhibition. 
Therefore, further direction for the design of selective inhibitors against Mtb PEPCK: (1) 
keep H-bonding interaction between the compound and the backbone amide group of 
F510 to position the extended ring near the R509 residue, (2) have bulky groups that can 
reside near R509 residue in Mtb PEPCK, but induce steric hinderance with K524 in 
human cPEPCK, (3) avoid a π-π interaction with phenylring of F530 side chain in 
human cPEPCK would be valued strategies.  
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Table 3-5. The chemical structure of Roche compounds with the IC50 value against 
human cPEPCK and Mtb PEPCK. 
 
Compound 
ID 
Structure 
 
Mtb PEPCK 
IC50 (µM) 
Human cPEPCK 
IC50 (µM) 
RO4355707 
 
 
2.29 1.40 
RO0506473 
 
2.50 1.48 
RO0506333 
 
0.30 0.22 
RO0505787 
 
0.96 0.16 
RO0504449 
 
 
0.80 0.80 
RO0507000 
 
0.76 0.70 
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Sulfonamides derivatives show selective cell growth inhibition depending on carbon 
sources, indicating that the compounds may be targeting on Mtb PEPCK   
 In order to figure out whether growth inhibition is via PEPCK inhibition or not, 
newly synthesized of sulfonamides analogs (by Wuxi AppTec) were tested against 
H37Rv for whole cell inhibition by the tuberculosis research lab in University Illinois 
Chicago (UIC), using different carbon source, palmitate and glycerol containing media 
(Table 3-6). The compounds which show better cell inhibition on 7H12 (in presence 
palmitic acid as a sole carbon source) were presented here with IC50 value of human and 
Mtb PEPCK enzyme. 
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Table 3-6. Xanthine analogs – sulfonamides are tested on mc27000 under different 
carbon source.  
 a,b Cell data were provided by the tuberculosis research lab in University Illinois 
Chicago (UIC). 
 
Compound 
ID 
Structure 
Xanthine analogs - Sulfonamides 
7H12a 
 
7H12 
without 
palmitic 
acid 
add 0.2% 
glycerolb 
Mtb 
PEPCK 
IC50 
(µM) 
Human 
cPEPCK 
IC50 (µM) 
ES2888-133-
P1 
 
 
3.9 13.1 0.44 0.20 
ES652-550-P1 
 
9.6 21.0 0.24 0.26 
ES2888-132-
P1 
 
 
5.6 12.2 0.58 0.22 
 
 
 
In vitro, Mtb PEPCK enzyme is essential for TB growth in fatty acids condition 
as a carbon source 25. Therefore, inhibitors targeting on Mtb PEPCK would be specific to 
palmitic acid medium rather than specific to glucose. In Table 3-6, three potent 
inhibitors inhibit growth very efficiently on palmitic acid medium. This suggests that 
their growth inhibition could be via PEPCK inhibition. However, they are also active on 
glycerol condition, thus, the possibility of multiple target inhibition of those compounds 
cannot be ruled out.  
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Modification to the N1 binding pocket of xanthine analogues shows selectivity against 
the Mtb PEPCK enzyme over the human counterpart 
Our collaborators, Schröndinger and the TB alliance modified the N1 position of 
the xanthine analogues to design PEPCK-0057 (N-(4-((3-(cyclopropylmethyl)-1-(2-
fluoro-4-(methylsulfonyl)benzyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-
yl)methyl)phenyl)methanesulfonamide) and PEPCK-0058 (N-(4-((3-
(cyclopropylmethyl)-1-(2-fluoro-4-(2-oxooxazolidin-3-yl)benzyl)-2,6-dioxo-2,3,6,7-
tetrahydro-1H-purin-8-yl)methyl)phenyl)methanesulfonamide) (Figure 3-16). There is a 
second pocket that can be explored for selective inhibitor development, located at L281 
in Mtb PEPCK, and M296 in the human PEPCK enzyme (Figure 3-17). In Mtb PEPCK 
two water molecules hydrogen bond with residues adjacent to L281. One water molecule 
interacts with the amide backbone of Q282 at a distance of 3.0 Å and the other water 
molecule interacts with the carbonyl backbone of N277 at a distance of 2.8 Å. Those two 
water molecules are connected via a hydrogen bond (2.7 Å). PEPCK-0057 and PEPCK-
0058 contain a methyl sulfonyl and oxooxazolidinyl group in the N1 position, 
respectively, which should act to replace the two water molecules.  
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Figure 3-16. The chemical structures of PEPCK-0057 and PEPCK-0058.  
 
 
 
 
Figure 3-17. Superimposed structure of Mtb PEPCK (blue) and human PEPCK (pink) 
complex with Axon1165.  
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Figure 3-18. The selectivity of PEPCK-0057 and PEPCK-0058 against Mtb PEPCK 
over human cPEPCK. (A) Dose-response graph for PEPCK-0057 and PEPCK-0058 
against both human and Mtb PEPCK enzymes. (B) IC50 of PEPCK-0057 and PEPCK-
0058 on human and Mtb PEPCK enzymes.  
 
 
 
PEPCK-0057 and PEPCK-0058 exhibited enzyme inhibition with IC50s of 200 
nM and 157 nM, respectively, which shows about a 10-fold greater selectivity for the 
Mtb PEPCK enzyme than the human analog (Figure 3-18). As shown Figure 3-19, the 
complex structure with PEPCK-0057 indicates that the oxygen of the methyl sulfonyl 
group from the fluorobenzyl ring on xanthine replaced a water molecule by forming a 
hydrogen bond to the backbone amide of Q282 (distance 2.9 Å). This interaction induces 
a minor shift, 0.4 Å, of the Cα atoms of Q282, whereas the remaining residues 
interacting with the inhibitor remained in their original positions. This minor shift to 
interact with the methyl sulfonyl group of the inhibitor is not favorable in human 
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PEPCK. These differences can be explained by the presence of the longer M296 side 
chain in the human PEPCK compared to the shorter L281 in Mtb PEPCK. In addition, a 
high degree of flexibility in M296 may cause steric hinderance to the methyl sulfonyl 
group of the inhibitor (Figure 3-20). In Figure 3-21, the PEPCK-0058 complex of the 
Mtb PEPCK structure indicates that the oxygen of the oxazolidone ring carbonyl group 
interacts with the backbone amide of Q282 at a distance of 2.9 Å. Also, the side chain of 
L281 supports hydrophobic interaction with the oxazolidine ring at a distance of 3.4 Å. 
The superimposed structure of Mtb PEPCK and human PEPCK reveals that the side 
chain of M296 in human PEPCK is too close to have this hydrophobic interaction at 2.1 
Å. The co-crystal structures provide an explanation of the selectivity observed and these 
data suggest that the site binding the methyl sulfonyl group and oxazolidine ring of the 
inhibitors is a promising one for the design and development of selective inhibitors 
against the Mtb PEPCK enzyme.  
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Figure 3-19. The complex structure of Mtb PEPCK with PEPCK-0057. 
 
 
 
 
Figure 3-20. The superimposed structures of the PEPCK-0057-Mtb PEPCK complex 
(blue) and the Axon 1165-human PEPCK complex (pink). PEPCK-0057 is shown in 
orange and Axon 1165 in light pink. 
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Figure 3-21. The superimposed structures of the PEPCK-0058- Mtb PEPCK complex 
(pink) and the Axon 1165-human PEPCK complex (tan). 
 
 
 
Conclusion 
The Roche inhibitors that bind near the R509 residue in C-8 binding pocket and 
near L281 in N-1 binding pocket have been identified through X-ray structure studies. 
Moreover, the IC50 values against the human and Mtb PEPCK enzymes have been 
compared to determine the selectivity of the inhibitors. We discovered an important 
interaction which resulted in improved activity and led us to place a ring near the R509 
residue. We also identified potent whole-cell inhibitors, specific to growth on fatty acids. 
These compounds could be used for proof of concept (POC) for the development of an 
anti-TB drug targeting Mtb PEPCK. The xanthine inhibitors with modification to the N1 
position (PEPCK-0057 and PEPCK-0058) were designed by Schröndinger and the TB 
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alliance to bind near the L281 residue. They show both potency and selectivity against 
Mtb PEPCK. The co-crystal structure of PEPCK-0057 and -00058 with Mtb PEPCK 
revealed that the minor shift created through the hydrogen bond might be not favorable 
in the human enzyme. The longer methionine residue in the human PEPCK instead of 
the leucine in Mtb PEPCK, may cause steric hindrance upon binding these inhibitors. 
Therefore, this site near the L281 residue is a promising site that can be explored for the 
development of selective and potent inhibitors against Mtb PECPK. The detailed 
characterization of the inhibitors presented here provides further insight into design 
strategies for pathogen-specific inhibitors.  
 
Experimental procedures 
Enzyme assay for high-throughput screening for identification of M. tuberculosis 
PEPCK inhibitors 
To identify inhibitors through high-throughput screening (HTS), PK/LDH 
coupled assay was used. The standard assay mixture contained 0.3 mM GTP, 2 mM 
MgCl2, 0.1 mM MnCl2, 1 mM DTT, 1 mM ADP, 2 unit PK/LDH enzyme, 0.25 mM 
NADH, and 2 µg/ml Mtb PEPCK (28nM) enzyme in 20mM Tris-HCl, pH 7.5, with 
50mM NaCl. The enzyme reaction was started by adding 0.2 mM OAA after 20 minute 
incubation with inhibitors. The enzyme assay was monitored the decreased NADH 
absorbance at 340 nm during 5min. The % inhibition was calculated from this equation, 
%inhibition = (1- (decreased absorbance slope)/control slope (no inhibitor, only 
DMSO)))*100. The value of IC50 was calculated by using Prism. Activity assays were 
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performed with a Thermo Scientific Multiskan GO spectrometer. The plate used in the 
enzyme assay was a 96-well, half area, UV-star plate, (Greiner bio-one).  
Differential Scanning Fluorimetry (DSF) assay of M. tuberculosis PEPCK  
The real time (RT)-PCR machine (Stratagene Mx3005P) was set to equilibrate 
samples at 25°C for 5minutes and then gradually increase temperature to 95°C at a rate 
of 1°C/minute. The excitation and emission of SYPRO orange can be monitored using 
filters: FAM (492nm) and ROX (610nm). The RT-PCR instrument (MxPro software) 
calculated  first derivative plot, indicating the lowest point is melting point of the protein 
105, 106. The master mix contained 40µg/ml protein in buffer (20mM Tris-HCl pH 7.5, 
50mM NaCl) and 5X SYPRO orange (diluted from 5000X concentrate). Each well of a 
96-well plate has 10µl solution contained 9µl master mix and 1µl of 1mM inhibitors 
stock (final concentration 100 µM). For the fragment screening, final 5mM inhibitors 
were used. It is not recommended exceed DMSO amount not over 2% (v/v), but this 
case, 10% DMSO does not influence the results.  
Crystallization of Mtb PEPCK in complex with inhibitors and data collection 
Crystallization was accomplished by the hanging-drop vapor diffusion method. 
Co-crystal of inhibitors was obtained by soaking the apo crystal of the mutant E83A 
PEPCK in 125µM inhibitors for 2 days in the presence of 10% PEG3350, 20%Glycerol, 
and 0.5mM MnCl2. Crystals were cryo-protected by dipping them into a solution [10% 
(w/v) PEG3350 and 20% glycerol (v/v)]. Diffraction data were collected at a wavelength 
of 1.542 Å using a Rigaku R-Axix IV ++ at home source and at the Advanced Photon 
Source beamline 23-ID using a MAR 300 CCD detector (MarMosaic from Marresearch 
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Charged Coupled Device) (Rayonix LLC, Evanston,IL). The HKL2000 program 
package (HKL Research,Inc., Charlottesville,VA) was used for integration and scaling.  
Structure determination and refinement of M. tuberculosis PEPCK in complex with 
inhibitors  
To determine the co-crystal structure of Mtb PEPCK with inhibitors, the apo 
structure of the mutant E83A Mtb PEPCK used as a template for refinement by using 
PHENIX (Python-based Hierachical Environment for Integrated Xtallography). Rigid 
body refinement, followed by simulated annealing at 5000 K, was conducted. 
Subsequently, refinement was conducted in alternating cycles of manual model building 
in COOT (Crystallographic Object Oriented Toolkit), followed by refinement in 
PHENIX until the R factors converged. Inhibitors were manually built in the active site 
of the model by examining the FO-FC map in Coot (Paul Emsleya and Kevin Cowtan, 
2004). The full data collection and refinement statistics are given in Table 3-7.  
 Cloning, expression and purification of human cytosolic PEPCK (cPEPCK) 
cDNA of human cPEPCK purchased from Origene Technologies was amplified 
by PCR (30s at 94°C; 30s at 55°C ; 4min at 72°C; 10min at 72°C) and then digested 
with NdeI and BamHI enzymes. Digested PCR products ligated into pET19b (+) vector 
contained Nde and BamH restriction sites. The ligate product was transformed into ONE 
Shot Top10 cells (Invtriogen). After confirmed DNA sequence, isolated the plasmid 
DNA was transformed into BL21 (DE3) (Novagene) for over-expression. The 
expression and purification of the human cPEPCK was performed following the protocol 
used for the M. tuberculosis PEPCK. 
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Enzyme assay of human cytosolic PEPCK (cPEPCK) 
The enzyme assay of human cPEPCK was conducted under identical condition 
used in Mtb PEPCK.  
Whole cell assay for MIC determination on mc27000 strain 
mc2 7000 starting culture in 7H9 containing OADC, Tyloxapol, Pantothenic acid, 
Malachite green was used to grow until OD600 reaches to 1.0.  The growing cell from 
starting culture was added into testing media 7H9 with dextrose and M9 with acetate 
separately. For the dextrose condition, it consists 0.5% dextrose, 0.085%  NaCl, 0.05% 
tyloxapol, 25µg/ml Pantothenic acid, and 0.25µg/ml malachite green. For acetate 
condition, it consists 0.5% acetate, 2mM MgSO4, 0.1 mM CaCl2, 0.05% tyloxapol, 
25µg/ml Pantothenic acid, and 0.25µg/ml malachite green. Incubation with inhibitors 
(50, 25, 12.5, 6.25, 3.12, 1.56, 0.78 µM final concentration) in 96-well plate lasts for 7 
days at 37 °C for dextrose plate, and 14 days for acetate plate.  The each well was 
stained with either alamar blue (MABA assay) or Resazurin (5 µg/ml final) for MIC 
determination.   
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Table 3-7. Data collection and refinement statistics for Mtb PEPCK in complex with 
inhibitors.  
 
 
 
 Mtb PEPCK -
Axon1165 
Mtb PEPCK -
RO4355622 
Mtb PEPCK -
RO4355668 
Mtb PEPCK -
RO4355703 
Mtb PEPCK -
RO505244 
Mtb PEPCK -
RO4355707 
Wavelength (Å) 0.98 0.98 0.98 
 
0.98 
 
0.98 0.98 
Resolution 
range (Å) 
50 - 1.7 
(1.77-1.71) 
50  - 1.73 
(1.79  - 1.73) 
50  - 1.57 
(1.62  - 1.57) 
 
50  - 1.57 
(1.60  - 1.57) 
50  - 1.37 
(1.39  - 1.37) 
 
50  - 2.05 
(2.09  - 2.05) 
Space group C 1 2 1 C 1 2 1 C 1 2 1 C 1 2 1 C 1 2 1 C 1 2 1 
Unit cell 104.667 
122.246 
64.245 
90 
117.15 
90 
105.680 
122.117 
64.869 
90 
117.70 
90 
 
105.655 
122.353 
64.663 
90 
117.43 
90 
105.770 
122.314 
64.868 
90 
117.53 
90 
 
 
105.616 
122.655 
64.788 
90 
117.33 
90 
 
106.297 
121.798 
64.587 
90 
117.56 
90 
Total reflections 327317 75172 99639 
 
390909 
 
532432 
 
151036 
 
Unique 
reflections 
76938 73671 98029 98212 136717 
 
43328 
 
Multiplicity 4.3 (4.0) 1.0 (1.0) 
 
1.0 (1.0) 
 
4.0 (3.0) 
 
3.9 (2.6) 
 
3.5 (2.5) 
 
Completeness 
(%) 
99.75(97.76) 96.71 (75.87) 96.36 (85.14) 
 
96.85 (77.73) 
 
89.38 (61.95) 
 
94.48 (69.29) 
 
Mean I/sigma(I) 27.03 
(9.66) 
21.54 
(0.957) 
 
31.590 
(1.459) 
 
25.560 
(1.559) 
 
18.204 (0.934) 
 
14.475 (1.262) 
 
Wilson B-factor 16.33 25.84 
 
22.17 
 
19.91 
 
15.08 
 
34.62 
R-merge 0.053 (0.161) 0.096 (0.838) 0.076 (0.617) 0.090 (0.509) 
 
0.081 (0.758) 
 
0.134 (0.673) 
R-work 0.1536 
(0.1573) 
0.1638 
(0.2819) 
 
0.1604 
(0.2542) 
0.1639 
(0.2359) 
 
0.1692 
(0.2747) 
 
0.1632 
(0.2581) 
 
R-free 0.1810 
(0.2056) 
0.1921 
(0.3243) 
 
0.1742 
(0.2832) 
 
0.1908 
(0.2650) 
0.1897 
(0.3110) 
 
0.2019 
(0.3132) 
 
Number of 
atoms 
5551 5557 
 
5635 
 
5604 5679 5355 
Macromolecules 4773 4767 
 
4775 
 
4766 4766 4766 
Ligands 51 51 51 51 46 53 
Water 727 739 809 787 867 536 
Protein residues 598 598 599 598 598 598 
RMS (bonds) 0.007 0.009 0.008 0.008 0.008 0.010 
RMS (angles) 1.21 1.37 1.37 1.38 1.23 1.38 
Ramachandran 
favored (%) 
98 98 97 97 98 97 
Ramachandran 
outliers (%) 
0 0 0 0 0.16 0 
Clash score 2.78 3.49 4.32 3.97 3.60 3.32 
Average B-
factor 
18.8 27.40 25.30 22.70 16.90 29.40 
Macromolecules 17.0 25.80 23.30 20.90 14.80 28.50 
Ligands 22.4 32.80 34.80 30.60 21.70 32.50 
Solvent 29.9 37.80 36.50 33.30 27.90 36.90 
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Table 3-7. Continued. 
 Mtb PEPCK- 
RO0506473 
Mtb PEPCK- 
RO0506333 
Mtb PEPCK- 
RO0505787 
Mtb PEPCK- 
RO0504449 
Mtb PEPCK- 
RO0507000 
Wavelength (Å) 0.98674 
 
0.98674 
 
0.97924 0.97949 
 
0.97949 
 
Resolution 
range (Å) 
50  - 1.63  
(1.66  - 1.63) 
 
50  - 1.63  
(1.66  - 1.63) 
50  - 1.62  
(1.65  - 1.62) 
50  - 1.84  
(1.87  - 1.84) 
 
50  - 1.84 
 (1.87  - 1.84) 
Space group C 1 2 1 C 1 2 1 C 1 2 1 
 
C 1 2 1 
 
C 1 2 1 
 
Unit cell 105.273 
121.783 
65.14 
90 
117.91 
90 
106.149 
121.754 
65.031 
90 
117.81 
90 
 
105.829 
121.362 
64.952 
90 
117.94 
90 
106.548 
122.574 
64.882 
90 
117.69 
90 
 
 
105.894 
121.84 
65.265 
90 
118.04 
90 
 
 
Total reflections 366063 
 
372794 
 
374128 
 
233435 236775 
 
Unique 
reflections 
88592 
 
89009 
 
91578 
 
63380 
 
58388 
 
Multiplicity 4.1 (3.4) 4.2 (3.4) 
 
4.1 (3.2) 3.7 (3.6) 4.1 (4.2) 
 
Completeness 
(%) 
99.46 (94.96) 98.40 (94.12) 
 
99.53 (96.17) 
 
99.48 (96.83) 92.87 (83.79) 
 
Mean I/sigma(I) 30.775 (3.11) 
 
22.878 (2.225) 
 
31.221 (3.129) 17.780 (2.108) 43.518 (19.362) 
 
Wilson B-factor 20.28 15.51 
 
20.02 
 
18.24 
 
14.52 
 
R-merge 0.073 (0.336) 
 
0.066 (0.387) 0.104 (0.393) 0.117(0.726) 0.073 (0.138) 
 
R-work 0.1535 (0.2077) 
 
0.1490 (0.2196) 
 
0.1683 (0.2028) 0.1633 (0.2356) 0.1469 (0.1559) 
R-free 0.1730 (0.2666) 
 
0.1676 (0.2488) 
 
0.1805 (0.2345) 
 
0.1988 (0.2967) 
 
0.1767 (0.1974) 
Number of 
atoms 
5678 5724 5494 5612 5702 
Macromolecules 4782 
 
4782 4782 4782 4766 
Ligands 51 56 46 54 49 
Water 845 886 666 785 887 
Protein residues 600 600 600 600 598 
RMS (bonds) 0.017 0.009 0.008 0.008 0.008 
RMS (angles) 2.08 1.39 1.53 1.24 1.36 
Ramachandran 
favored (%) 
98 98 97 98 98 
Ramachandran 
outliers (%) 
0 0 0 0 0 
Clash score 4.57 4.05 3.20 3.52 3.75 
Average B-
factor 
24 19.40 22.90 18.50 16.60 
Macromolecules 21.90 17.20 21.40 16.80 14.30 
Ligands 28.60 20.00 24.10 20.90 15.90 
Solvent 35.70 31.60 33.60 28.80 28.90 
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Table 3-7. Continued. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Mtb PEPCK- 
PEPCK-0057 
Mtb PEPCK- 
PEPCK-0058 
Wavelength (Å) 1.542 0.979 
Resolution 
range (Å) 
23.89  - 1.90  
(1.97  - 1.90) 
 
31.44 - 2.1     
(2.05 -1.98) 
Space group C 1 2 1 C 1 2 1 
Unit cell 104.01 
121.69 
63.95 
90 
116.66 
90 
104.65  
121.74 
 63.92 
 90  
116.59 
 90 
Total reflections 105612 
 
205874 
Unique 
reflections 
48108 45970 
Multiplicity 2.2 (2.1) 4.5 (2.0) 
Completeness 
(%) 
86.30 (82.96) 91.70 (72.15) 
Mean I/sigma(I) 28.00 (3.04) 10.91 (0.17) 
Wilson B-factor 28.59 45.11 
R-merge 0.086 (0.350) 0.197 (3.39) 
R-work 0.1732 (0.2118) 0.1851 (0.3891) 
R-free 0.2106 (0.2668) 0.2449 (0.4005) 
Number of 
atoms 
5190 5062 
Macromolecules 4782 4782 
Ligands 50 41 
Water 357 239 
Protein residues 600 600 
RMS (bonds) 0.009 0.010 
RMS (angles) 1.31 1.37 
Ramachandran 
favored (%) 
97 97 
Ramachandran 
outliers (%) 
0 0 
Clash score 2.93 3.74 
Average B-
factor 
26.00 43.40 
Macromolecules 25.50 43.00 
Ligands 27.40 45.40 
Solvent 33.50 49.80 
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Additional results 
HT screening results from chemical and fragments libraries  
1,131 SRI anti-tuberculosis active compounds were screened against Mtb PEPCK. 
The DSF method is used as an initial screen against Mtb PEPCK to identify any 
molecule that has affinity to the active site. The hits were confirmed using the enzyme 
assay. The summary of the hits, IC50 and ΔTm, are shown in Table 3-8 and their 
chemical structures are shown in Figure 3-22.  
 
 
 
Table 3-8. IC50 and ΔTm value of seven SRI hits against Mtb PEPCK. 
 
Compound ID Name IC50 of Mtb PEPCK (µM) ΔTm (C°) 
333612 
1-(4-(2-bromo-4-
chlorophenoxy)butyl)-
1H-imidazole 
7.19 5.0 
333496 
1-(4-(4-bromo-2-
chlorophenoxy)butyl)-
1H-imidazole 
7.26 5.0 
333360 
1-(4-(4-isopropyl-3-
methylphenoxy)butyl)-
1H-imidazole 
4.94 5.5 
332991 
1-(4-(3-isopropyl-5-
methylphenoxy)butyl)-
1H-imidazole 
5.91 5.5 
332702 
1-(4-(5-isopropyl-2-
methylphenoxy)butyl)-
1H-imidazole 
6.19 5.5 
332657 
1-(3-(3,4-
dichlorophenoxy)propyl)-
1H-imidazole 
4.70 5.6 
309287 
1-(5-(2,4-
dichlorophenoxy)pentyl)-
1H-imidazole 
4.09 5.6 
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Figure 3-22. The chemical structure of the SRI hits from the HT screen against Mtb 
PEPCK by DSF and enzyme inhibition assay.  
 
 
 
The series of phenoxylimidazoles from the SRI compound library show a 
consistent thermal shift of about 5 degrees from the melting point of Mtb PEPCK. These 
compounds are known to possess have about 1-2 µg/mL of anti-tubercular activity, but 
its mechanism of action is unclear 71. As shown in Table 3-1, these compounds show 
IC50s in the low micro molar range against Mtb PEPCK. However, the purchased series 
of phenoxylimidazoles from ChemBridge Corporation (Figure 3-23) shows no thermal 
shift and no inhibition against the Mtb PEPCK enzyme.  
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Figure 3-23. The chemical structure of the phenoxyalkylimidazole compounds 
purchased from ChemBridge Corporation. 
 
 
 
 Despite the high structural similarity of compounds between the SRI libraries and 
the purchased one, the experimental results are not the same. We examined the 
difference between the purchased compounds and SRI compounds in the libraries, and 
found that the SRI compounds, especially the phenoxyalkylimidazole series, contained 
oxalate salt. Comparing the DSF results from the apo enzyme, the apo enzyme with 
Mn2+, the apo enzyme with inhibitors, and the apo enzyme with Mn2+ and inhibitor 
sample (Table 3-9) showed that the inhibitor plus metal causes an approximately 6 
degree thermal shift, while the inhibitor without metal shows no thermal shift, indicating 
that it is the complex of oxalate and metal binding to the active site that causes the 
thermal shift. This is in agreement with the Mtb PEPCK-oxalate complex structure 
discussed in chapter 2, which indicates that the oxalate coordinates directly with 
manganese and binds to the catalytic site (Figure 2-3B). Moreover, it has been reported 
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that oxalate inhibits the PEPCK enzyme in the micromolar range 67. Taken together, the 
contamination of oxalate salt in the phenoxyalkylimidazole compounds in the SRI 
libraries resulted in false positives in the DSF study and enzyme inhibition assay. While 
screening these diverse libraries we learned that the presence of any acidic salt may 
cause false positive results, especially for the enzymes of the TCA cycles due to their 
intermediate structures resemble to the structure of acetate or oxalate. 
 
 
 
Table 3-9. Melting temperature and thermal shift of samples, apo enzyme, apo enzyme 
in the presence of Mn2+, apo enzyme with inhibitors, and apo enzyme with inhibitors in 
presence of Mn2+. The DSF results suggest that the combination of metal and inhibitors 
cause a greater temperature shift. 
 
Sample Tm ΔTm 
Apo 50 - 
Apo +Mn2+ 52 +2 
Apo+ Inhibitors 50 0 
Apo + Mn2+ + Inhibitors 56 +6 
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Table 3-10. Chemical structure and thermal shift (ΔTm with Mn) of fragment hits. 
 
Molecule name Structure ΔTm with Mn 
Cambridge Frag Lib10-E2 
 
+ 20 
Cambridge Frag Lib10-F6 
 
+ 2.5 
EN:T5267544 
 
+ 3.0 
CB:4012315 
 
+ 2.0 
Cambridge Frag Lib 
15-G9 
 
 
+ 3.0 
 
 
 
A fragment library of 591 small molecules was screened against Mtb PEPCK, 
and five hits with thermal shifts with a range of 2.0 - 20 degrees were found (Table 3-
10), but only one exhibited enzyme inhibition activity, EN:T5267544 (IC50 = 50µM). 
We were unable to conduct complex crystal trials for these hits due to the weak binding 
characteristics of the fragments.  
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HT screening of Sac1 diverse libraries (1667 compounds) 
 Our lab selected anti-tuberculosis active molecules from among 51K drug-like 
molecules, based on inhibition of TB growth on different carbon sources (such as 
dextrose vs. acetate). Since Mtb PEPCK is essential for TB growth on acetate as a 
carbon source in in vitro studies, 1667 anti-TB compounds active on acetate conditions 
were screened against Mtb PEPCK using an enzyme inhibition assay. Two compounds, 
EN: T5251690 and 5292830, exhibited enzyme inhibition with IC50s of 58 µM and 38 
µM, respectively (Figure 3-24). We could not obtain a complex structure of Mtb PECPK 
with either of these inhibitors, likely due to low potency. However, these compounds 
could provide opportunities for further lead design and optimization.  
 
 
 
 
Figure 3-24. The chemical structure of two hits (EN:T5251690, EN:T5292830) from 
Sac1 libraries, and IC50 value and dose-response curve. 
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CHAPTER IV                                                                                                           
STRUCTURAL STUDY OF PYRUVATE KINASE FROM MYCOBACTERIUM 
TUBERCULOSIS 
  
Introduction 
Pyruvate kinase (PykA) has a regulatory role in central carbon metabolism as the 
rate-limiting enzyme in the final step of the glycolysis pathway. Its kinetic and 
regulatory properties have been well characterized with three-dimensional structures in 
divergent species, but little is known about the PykA from Mycobacterium tuberculosis. 
TraSH analyses have shown that Mtb PykA is essential for in vitro growth of Mtb on 
glycerol and fatty acids 30, indicating it may be a potential target for anti-TB 
chemotherapy.  
PykA reaction  
Pyruvate kinase (EC 2.7.1.40) (PykA) is involved in the junction of the 
gluconeogenic and glycolytic pathways. It controls the metabolic flux from fructose-1,6-
bisphosphate to pyruvate, by acting as a rate-limiting enzyme in the last step of the 
glycolytic pathway. It catalyzes an irreversible reaction (Keq = 103 to 104) under 
physiological conditions; the production of ATP from ADP by converting 
phosphoenolpyruvate (PEP) into pyruvate in the presence of either monovalent or 
divalent cations 72 (Scheme 4-1).  
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4 4 	  
Scheme 4-1. Pyruvate kinase (PykA) reaction.  
 
 
 
PykA regulation by allosteric effector  
PykA’s position at the junction of the gluconeogenesis and glycolysis pathways 
makes it play a role in changing metabolic flux 73. Thus, the intracellular level of ATP, 
GTP, and glycolytic intermediates are controlled by PykA 74. The enzyme is regulated in 
mutiple ways, via gene expression, allosteric regulation by small metabolites, and post-
translational modification. Specially, levels of intracellular intermediates  are commonly 
regulated by non-genetic mechanisms 75. Most PykA enzymes are allosteric enzymes 
that are regulated by glycolytic intermediates (Figure 4-1). PykA enzymes from diverse 
species display different allosteric regulatory properties. For example, type 1 pyruvate 
kinase (PykF) from Escherichia coli (E. coli) is allosterically regulated by fructose 1,6-
bisphosphate (F1,6BP) and type 2 E. coli PykA is activated by adenosine 
monophosphate (AMP). In addition, L. mexicana and Trypanosoma cruzi are regulated 
by fructose 2,6-bisphosphate (F2,6-BP), and both Saccharomyces carlsbergensis and 
yeast pyruvate kinase are regulated by F1,6BP 76,77, 78, 79. In addition, mammalian 
pyruvate kinase enzymes existed as four different isoforms, representing different 
regulatory properties. The R and L isoforms are found in erythrocytes and the liver, the 
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M1 isoform is found in skeletal muscle, and the M2 form is widely spread with a low 
level of expression under normal cellular conditions, but is highly expressed in tumors. 
The M1 isoform is an unregulated enzyme, but R, L and M2 are allosterically regulated 
by F1,6-BP 80. Some bacilli including M. tuberculosis, Geobacillus stearothermophilus, 
and B. stearothermophilus are thought to be regulated by AMP and pentose 
monophosphates, such as ribose 5-phosphate 81-83. The variety of allosteric regulators for 
the pyruvate kinase enzyme across species implies that it has different regulatory 
mechanisms and different roles in different species. Moreover, the different allosteric 
molecule binding sites could offer an opportunity for the design of organism-specific 
drugs. A putative AMP-binding site has been proposed based on sequence alignment and 
mutation studies 83, but direct crystallographic evidence for the binding site of AMP has 
yet to be established.  
 
 
 
 
Figure 4-1. Chemical structure of common allosteric effectors for pyruvate kinase from 
diverse species. 
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Structural study of pyruvate kinase from divergent species 
The three-dimensional structure of pyruvate kinase has been studied in many 
species including the human M2 84, 85 and R isozymes 84, as well as in E. coli 86, 
Saccharomyces cerevisiae 74, Leishmannia mexicana 77, and Trypanosoma brucei 87. 
Most pyruvate kinase enzymes are homo-tetramers (each monomer contains about 500 
residues) under physiological conditions, and have also been shown to be tetramers in 
the crystal lattice. Most of the pyruvate kinase structure has a highly conserved amino 
acid sequence in the active site and possess similar overall folds. Each subunit has three 
or four distinct domains, depending on the organism. In the human and yeast pyruvate 
kinase enzyme, each monomer consists of four domains, N (α-helical stretch N-terminal 
domain), A (the common parallel α/β8 barrel motive), B (nine-stranded β barrel motif), 
and C (regulatory domain, α/β open-sheet motif) 74,85. Two A-domains contact to form a 
dimer and then tetramerization occurs between interfaces of the C-domains of the 
dimers. In the E. coli pyruvate kinase enzyme the N domain is not present it consists of 
only three domain, the A- ((α/β)8 barrel), B- (a flexible β barrel), and C-terminal 
domains 86. The catalytic site is located between the A- and B- domains, and residues 
from both domains are involved in substrate binding. The B-domain displays flexibility 
in many crystal structures, and is involved in the catalytic reaction. Upon PEP and ADP 
binding to the catalytic site, the B-domain moves like a hinge to start catalysis. The C-
domain includes an allosteric effector binding site, that is 40 Å from the active site 86, 74.  
Pyruvate kinase is one of the housekeeping metabolic enzymes which is present 
in humans, thus a detailed structural comparison between the host and pathogen pyruvate 
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kinase structures is necessary to develop selective anti-TB drugs. As discussed 
previously, human pyruvate kinase has 4 different isozymes, M1, M2, L, and R. The 
sequence identity between Mtb PEPCK and the human isozyme is in the range of 35-
37%. In Figure 4-2, multiple sequence alignment between Mtb pyruvate kinase and 
human isozymes reveals that the α-helical stretch of the N-terminal domain found in 
human pyruvate kinase is absent in Mtb.  
We have determined the crystal structure of Mtb PykA in complex with a co-
purified allosteric effector, AMP. Structural evidence for the AMP binding site has not 
been reported, all the available allosteric binding sites are for the F1,6BP and F2,6BP. 
The structural explanation of the activator specificity of Mtb PykA and the activator 
binding site compared with human M2 pyruvate kinase are discussed in this chapter. The 
difference between the effector binding sites provides another therapeutic approach for 
the design of selective anti-TB drugs targeting Mtb PykA.  
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Figure 4-2. Multiple sequence alignment of Mtb PykA with all four human isozymes 
(M1, M2, L, R). The stars mark the directly interacting residues with AMP in Mtb PykA, 
indicating the differences between human orthologs and Mtb PykA.  
 
 
 
 
  
 
142 
Result and discussion 
Overall structure of Mtb PykA 
To determine the Mtb PykA structure, we cloned and expressed Mtb PykA 
(Rv1617) from E. coli, then purified it using affinity chromatography (Ni-column) and 
size exclusion chromatography (Superdex 200). Size exclusion chromatography 
confirmed that Mtb PykA (472 residues) is a functional tetramer in the solution. Mtb 
PykA was crystallized in 15-18% PEG3350 and 0.15-0.30 M ammonium acetate, and the 
resulting crystal belonged to space group P1 with unit cell parameters a = 93.7, b = 
110.5, c = 135.1, α = 85.9, β = 87.9, γ = 83.7. It was impossible to solve the structure 
with a higher symmetry space group than P1, the molecular replacement solution only 
resulted in a correct structure solution in that space group. The crystal structure of Mtb 
PykA was solved at 2.1 Å, and refined to an overall crystallographic R-factor of 19% 
and a free R-factor of 23%. Data collection and refinement statistics for Mtb PykA are 
shown in Table 4-1. The asymmetric unit contains eight monomeric molecules, forming 
two homotetramers as shown in Figure 4-3. The inter-subunit interactions define two 
(large and small) contact areas. The A/A' interface is constructed by Aα6, Aα7, and Aα8 
helices of the (α/β)8 barrel of adjacent subunits with a vertical twofold axis. The C/C' 
interface is maintained by hydrogen bonds from the adjacent Cα1 helices and Cβ5 
strands of the C-domains.  
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Figure 4-3.  Mtb PykA structure. (A) homo-tetramer, B-domain was not built due to lack 
of electron density in subunit II. A/A' and C/C' interfaces between monomers are shown 
as lines, and (B) Each subunit has an A- (pink), B- (blue), and C- (green) domain. The 
catalytic site is located between the A and B domains, and the allosteric effector binding 
site is located in the C-domain.  
 
 
 
The overall Mtb PykA architecture was similar to reported other species pyruvate 
kinase structures, having each a subunit composed of three A-, B-, and C-domains 
(Figure 4-3). The A-domain (residues 2-70 and 168-338) constitutes the central eight 
stranded α/β barrels. The B-domain (residues 71-167) consists of antiparallel β-sheets, 
and is known as a flexible domain. While electron density was fully observed for the A- 
and C-domains, density for the B-domain was completely disordered in the subunit II 
and we were unable to build it. Similar observation of the flexibility of the B-domain has 
been reported in many pyruvate kinase crystal structures, including E. coli, human and L. 
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mexicana. This flexibility of the B-domain is important for catalysis 85,86,88. The C-
domain (residues 339-472) is composed of five β-strands surrounded by four α-helices.  
The allosteric activator binding site is located in the C-domain. In the Mtb PykA 
structure, a co-purified AMP molecule and a PO42- ion were observed in the allosteric 
effector binding pocket of each subunit, according to the Fo-Fc electronic density map 
(Figure 4-4). The Mtb PykA -ADP bound structure was determined in this study to 
explore the catalytic site. The complex crystal was obtained by soaking the apo-crystal 
into 10 mM ADP and Mg2+ in the mother liquid (15-18% PEG 3350 and 0.15-0.30 M 
ammonium acetate). The crystal space group is P1 with cell parameters a = 93.6, b = 
110.7, c = 136.1, α = 85.6, β = 81.5, γ = 83.5. The electron density of ADP and Mg2+ 
only appears in subunit G, which was used as a ‘reference subunit’ for the analysis of the 
ADP complex Mtb PykA structure in this chapter. The data collection and refinement 
statistics for AMP-PO42-bound complex structure and ADP-Mg2+-AMP-PO42- complex 
structure are shown in Table 4-1. They did not show notable differences as similar cell 
parameters, indicating that conformational changes do not occur between subunits.  
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Table 4-1. Data collection and refinement statistics for Mtb pyruvate kinase (PykA) in 
complex with AMP-PO42- and AMP-ADP-PO42-. 
 
 Mtb PykA-AMP-PO42- -
complex 
Mtb PykA-AMP-ADP- PO42- 
-complex 
Wavelength (Å) 1.54 0.98 
 
Resolution range (Å)1 50 - 2.1 (2.14 - 2.1) 
 
42.69 - 2.13 (2.21 - 2.13) 
Space group P1 P 1 
Unit cell 93.714  
110.496 
 135.075 
 85.87 
 81.49 
 83.65 
93.634 
 110.753 
 136.071 
 85.59 
 81.52 
 83.47 
Total reflections 913375 
 
881730 
Unique reflections 203637 
 
288351 (24036) 
 
Multiplicity1 3.3 (2.0) 
 
3.9(3.6) 
Completeness (%)1 97.88 (91.76) 96.33 (80.58) 
Mean I/sigma(I) 5.58 (0.42) 7.56 (0.65) 
Wilson B-factor 49.53 
 
39.36 
R-merge1 0.129 (0.709) 
 
0.159 (0.00) 
R-work1 0.1891 (0.2886) 0.2167 (0.3375) 
 
R-free1 0.2291 (0.3407) 
 
0.2624 (0.3592) 
 
Number of atoms 28051 28998 
 
Macromolecules 26471 
 
27155 
 
Ligands 41 67 
Water 1539 
 
1776 
 
Protein residues 3486 
 
3580 
RMS (bonds) 0.009 0.009 
 
RMS (angles) 1.40 
 
1.40 
 
Ramachandran 
favored (%) 
95 96 
Ramachandran 
outliers (%) 
1.8 1.6 
 
Clashscore 8.74 8.97 
 
Average B-factor 43.80 48.30 
 
Macromolecules 43.80 48.30 
 
Ligands 46.60 62.90 
 
Solvent 43.60 47.30 
 
1.  Numbers in parenthesis indicates data for highest-resolution shell. 
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Figure 4-4. AMP molecule found in the allosteric effector binding site. (A) Refinement 
without ligand shows Fo-Fc density (green) contoured at 4.2 σ for the AMP (blue) 
molecule. The same quality maps are observed in all four allosteric activator sites of the 
tetramer in the asymmetric unit. (B) The 2Fo-Fc map of AMP contoured at 3.0 σ with 
residues involved in direct interaction. (C) Detailed interaction of AMP in allosteric 
binding site.  
    
 
 
Allosteric effector site in Mtb PykA 
The Fo-Fc difference electron density map shown in Figure 4-4 produced strong 
positive features that were indicative of an adenosine monophosphate (AMP) molecule 
in the allosteric site in the Mtb PykA structure. The crystal structure of Mtb PykA 
revealed the AMP binding site for the first time, opening windows for designing 
organism-specific inhibitors targeting Mtb PykA enzyme. All eight subunits have one 
AMP molecule in the same location in each C-domain. The detailed interactions between 
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AMP and the Mtb PykA enzyme are shown in Figure 4-4C. The adenine ring lies on 
several hydrophobic residues pocket including W398, F373, and M425 for π-π 
interactions at 4.0, 3.5, and 4.1 Å, respectively. The C(6)NH2 forms a hydrogen bond 
with the backbone carbonyl oxygen of P417. The 1N of adenine interacts with the 
backbone amide nitrogen of M419 (bond distance of 2.9 Å) and 3N hydrogen bonds to 
the backbone amide nitrogen of G454 at 2.9 Å. The ribose ring 2`-OH hydrogen bonds 
to the backbone carbonyl oxygen of G450 and the oxygen of the 3`-OH group forms a 
hydrogen bond with the hydroxyl group of side chain S458 at 2.5 Å. The phosphate 
C(5)O picks hydrogen from the backbone amide of Q375 at 2.9 Å. The oxygen from the 
phosphate group forms a hydrogen bond with the backbone amide nitrogen of G457, and 
the hydroxyl group of side chains of S376, T379, and T374 at 2.6, 2.6, 2.5, and 2.5 Å, 
respectively. Interestingly, it has been proposed that the W398 residue is not essential for 
binding allosteric activator, ribose-5 phosphate in E.coli type II PK 82, but our structure 
reveals that the aromatic ring of the W398 side chain interacts with the adenosine ring of 
AMP through π-π interactions in a face-to-edge configuration, indicating it is likely 
essential for AMP binding.  
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Figure 4-5. The effect of AMP and FBP on Mtb PykA. Graph of percent enzyme 
activity against PEP concentration. (A) 0.5 mM and 2 mM AMP treated in Mtb PykA 
enzyme reaction and compared to untreated enzyme (apo), resulting in enzyme 
activation by AMP, (B) 2 mM F1, 6BP treated in the reaction, it did not activate the 
enzyme. 
 
 
 
The effect of AMP on the Mtb PykA enzymatic activity was shown in Figure 4-5. 
The Mtb PykA enzyme is activated by AMP, but not FBP. Mtb PykA exhibits a 
sigmodal kinetic response to the binding of PEP in the apo sample, indicating the 
enzyme is allosterically regulated. In the presence of AMP, the enzyme reaction was 
activated at a low concentration of PEP. However, F1,6BP did not increase enzyme 
activity, it showed decreased enzyme activity compared to the apo sample in the absence 
of F1,6BP. Therefore, the structural evidence of AMP binding in allosteric effector site 
and the kinetic data are in agreement with the AMP as an allosteric activator of Mtb 
PykA enzyme.  
The allosteric activation mechanism of PykA proposes that the activator induces 
conformational changes to shift the conformational equilibrium of this tetrameric 
enzyme from the T state (inactive) to the R state (active) 89. Unfortunately, the apo 
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structure of Mtb PykA was not obtained in this study, thus the T and R states were not 
compared. 
 
 
 
 
Figure 4-6. Comparison of the allosteric binding site in the Mtb PykA (gray) structure 
with those of the human M2 pyruvate kinase structure (sky blue) (PDB: 4G1N). It 
reveals the site is not conserved. 
 
 
 
Comparison of the allosteric activator binding pocket between human M2 and Mtb 
pyruvate kinase 
The difference in allosteric effectors used by the human (F1,6BP) and Mtb 
(AMP) PykA implies that there is a difference between the effector binding sites. 
Superimposing the effector binding site of Mtb PykA with human M2 shows that several 
different residues support direct interactions. In Mtb PykA the adenine ring binding 
pocket is surrounded by hydrophobic residues such as M425, A397, and W398, while 
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the site in human pyruvate kinase contains charged residues like R455 and N453. The 
AMP phosphate binding pocket also contains different residues, R351 and T379, but 
they are substituent with the T409 and S437 residues in human M2. A structural 
alignment of Mtb PykA with all four human isozymes (M1, M2, L, R) is shown in 
Figure 4-2. The blue box represents the sequence of the effector binding site and the 
stars indicate the residues that directly interact with AMP in Mtb PykA, indicating a 
difference between the human orthologs and Mtb enzymes. The differences in the 
regulatory properties between the pathogen and human create another potential avenue 
for the development of selective drugs, the unique effector binding pocket of Mtb PykA 
should be explored in future studies.  
 PO42- binding site 
Phosphate ions are bound at identical pockets near to the effector binding sites in 
all eight subunits of the asymmetric unit and have peak heights of greater than 6 σ in Fo-
Fc map. The phosphate ion interacts with the R385 (2.8 Å), R382 (3.0 Å), H345 (2.7 Å), 
T349 (2.6 Å) side chain and the backbone amide of the R348 residue (2.7 Å) (Figure 4-
7). This phosphate ion binding site is not observed in other species, but is unique to Mtb 
PykA. The site is located 13.2 Å from the phosphate of AMP. The residues, T349, R348, 
and H345 lie in the loop between the A-domain and the Cα1 helices, which maintains 
the C/C' interface, and may possibly affect the regulatory mechanism. Unfortunately, 
due to the lack of an apo Mtb PykA structure, we could not further explore the role of the 
site in this study.  
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Figure 4-7. Phosphate binding pocket in Mtb PykA. (A) Phosphate ion interacting with 
R382, R385, H345, and T349 side chains and the backbone amide of R348. (B) The 
distance between the phosphate binding site and allosteric binding site is 13.2Å.   
 
 
 
Catalytic site – ADP-Mg2+ binding site  
The active site in each subunit is located in the cavity between the A- and B-
domains. The electron density of the ADP molecule appeared only in the G subunit 
among eight monomers. In Figure 4-8, the Fo-Fc density map shows the ADP molecule 
contoured at 3.1 σ. The adenine ring is surrounded by hydrophobic residues H38, P13, 
and V315. The imidazole ring of H38 residue makes a π-π interaction with the adenine 
ring of ADP at a distance of 3.3 Å in a face-to-edge configuration. The P13 and V315 
side chains provide hydrophobic interactions with the adenine ring. The C-6 amine 
group of the adenine ring has a water-mediated interaction with the backbone carbonyl 
oxygen at a distance of 2.7 Å. The N-7 atom of the adenine ring functions as a hydrogen 
bond acceptor interacting with a water molecule (2.7 Å), and the water interacts with the 
carbonyl group of the N35 side chain (3.1 Å). The ADP phosphate oxygen forms a 
hydrogen bond with the carbonyl group of N35 (3.2 Å). Both divalent and monovalent 
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cations are required for pyruvate kinase activity 72. Though the soaking solution 
contained 10 mM Mg2+, no electron density was observed in the active site. The ADP 
binding geometry in Mtb PykA is identical to that observed in the L. mexicana pyruvate 
kinase-ATP complex (PDB code: 3HQP), as the active sites are highly conserved among 
the pyruvate kinase enzymes from different species. It has been reported that the B-
domain moves closer to the A-domain upon the binding of the two substrates, oxalate 
and ATP in pyruvate kinase enzyme from rabbit muscle 90, but the ADP-Mtb PykA 
crystal structure showed ADP binding does not cause conformational changes in the B-
domain, it remains in the same position as it is seen in the structure without ADP.  
 
 
 
 
Figure 4-8. The Fo-Fc density map (green) for the ADP bound in the active site of 
subunit G is shown contoured at 3.1 σ.  
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Figure 4-9. ADP bound to the active site of the Mtb PykA enzyme. (A) ADP interacting 
residues. (B) Ligplot of ADP binding with water molecules.  
 
 
 
Conclusion 
The complex Mtb PykA structure with ADP as a substrate and AMP as an 
allosteric effector were determined. Structural and biochemical study of Mtb PykA 
demonstrated that its activity is regulated by AMP molecule. Despite of highly 
conserved active site, detailed structural studies of Mtb PykA reveals considerable 
difference in an allosteric effector binding site between host and pathogen pyruvate 
kinase enzyme. The binding mode of AMP molecule was identified for the first time, 
structural evidence of Mtb PykA suggests optimistic avenues for the design species-
specific drug of new TB chemotheraphy.  
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Experimental procedures 
Cloning, protein expression, and purification of M. tuberculosis  PykA (Rv1617) 
The M. tuberculosis Pyruvate Kinase (PykA) (Rv1617) gene was amplified by 
PCR, ligated into restriction site NdeI and HindIII of the pET28a vector and then 
transformed into Escherichia coli BL21 (DE3) cells (Novagen) for over-expression. The 
cells were grown to an OD600 of 0.7-0.8 at 37 °C in Luria-Bertani medium containing 50 
µg ml-1 kanamycin. Mtb PykA expression was induced with 0.5 mM isopropyl 1-thio-β-
D-galactopyranoside (IPTG). Cell growth continued at 293 K for 18 h after IPTG 
induction, and the cells were harvested by centrifugation at 4200 g for 15 min at 277 K. 
The cell pellet was resuspended with lysis buffer (20 mM Tris-HCl pH 7.0, 500 mM 
sodium chloride, 5 mM imidazole and 1 mM phenylmethylsulfonyl fluoride (PMSF)) 
and the cells were lysed by French press. The cell debris was centrifuged at 36000 g for 
50 min at 277 K. The M. tuberculosis PykA with an N-terminal poly-His tag in the 
supernatant fraction was purified by nickel affinity chromatography (Ni-NTA resin 
(Qiagen)) followed by gel filtration (HiLoad 26/60 Superdex 200 prep-grade column 
(GE Healthcare)). The buffer used during gel filtration was 20 mM Potassium phosphate 
(pH 7.0), 50 mM KCl, 2mM DTT, 5% glycerol and 0.1mM EDTA. The protein was then 
concentrated to 12 mg/ml in using a Spin-X UF concentrator (Corning). The protein 
concentration was estimated by measuring absorbance at 280 nm by using the Nano drop 
(Thermo Science), employing the calculated extinction coefficient of 26600 M-1 cm-1 
(SWISS-PROT; http://www.expasy.ch/).  
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Crystallization and data collection of M. tuberculosis PykA 
Mtb PykA was crystallized by hanging drop vapor diffusion at 16 °C. 
Crystallization was achieved in a 4 µl drop consisting of 2 µl well solution [15% (w/v) 
PEG 3350, 0.2-0.4 M Ammonium Acetate] and 2 µl of protein. Mtb PykA -ADP 
complex was co-crystallized in condition of 10 mM ADP and 10 mM MgCl2 with 
protein sample, after 30 min incubation on ice. Diffraction quality crystals were obtained 
in a 4 µl drop consisting of 2 µl well solution [15% (w/v) PEG 3350, 0.2-0.4 M 
Ammonium Acetate] and 2 µl of protein. Crystals were cryo-protected through soaking 
for a second in solution [10% (w/v) PEG3350, 0.1M Ammonium Acetate] containing 
20% glycerol (v/v). Diffraction data were collected at a wavelength of 1.542 Å using a 
Rigaku R-Axix IV ++ at home source and at the Advanced Photon Source beamline 23-
ID using a MAR 300 CCD detector (MarMosaic from Marresearch Charged Coupled 
Device) (Rayonix LLC, Evanston, IL). The HKL2000 program package (HKL Research, 
Inc., Charlottesville, VA) was used for integration and scaling.  
Structure determination and refinement of M. tuberculosis PykA 
The structure of Mtb PykA was solved by molecular replacement (MR) with 
PHASER program (University of Cambridge, Cambridge, U.K.).  The coordinates of 
pyruvate kinase from E.coli (PDB entry 1PKY) were used as a search model. Rigid body 
refinement, followed by simulated annealing refinement at 5000 K, was conducted using 
PHENIX (Python-based Hierachical Environment for Integrated Xtallography). 
Subsequently, refinement was conducted in alternating cycles of manual model building 
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in COOT (Crystallographic Object Orientated Toolkit), followed by refinement in 
PHENIX until the R factors converged.  
In vitro acetylation assay of M. tuberculosis PykA 
Acetylation assay was performed in buffer condition of 25 mM Tris-HCl pH 7.5, 
100 mM NaCl contained 100 µM Acetyl CoA and 0.67 mg/ml Mtb-PatA in the presence 
of 200 µM cAMP. Reactions were started by the addition of 20 µM Mtb PykA and 
incubated for 10 min at 25 °C.  After the reaction was quenched by boiling in SDS 
loading dye, it was analyzed in parallel with SDS-PAGE and western blotting with 
antibody to acetylated lysine (Cell Signaling Technology, cat. no. 9441S; 1:2,000 
dilution) detected by chemiluminescence.  
Trypsin digestion in solution 
Trypsin was used for the protein disgestion of M. tuberculosis PykA to find out 
acetaylated peptides. The protein was diluted in the buffer of 50mM Ammonium 
Bicarbonate and incubated 5min at 95°C. Then 0.1µg/µl trypsin was added to the buffer 
contained Mtb PK and incubated overnight at 37°C.   
Mass-spectroscopy of M. tuberculosis pyruvate kinase to identify acetylated peptides 
Digested samples were concentrated and desalted by using ziptip with C18 resin 
(EMD Millipore). Samples were spotted on MALDI plate with matrix (α-Cyano-4-
hydroxycinnamic acid 7mg/ml 70% acetonitrile and 0.1% Trifluoroacetic acid). MS and 
MS/MS spectra were collected by AB SCIEX 4800 Plus MALDI TOF/TOF™ Analyzer. 
The analysis of searching acetylated peptides were performed using Protein Prospector 
(http://prospector.ucsf.edu/prospector/)  
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CD spectroscopy 
The CD spectra of Mtb PK proteins, wild-type, K110Q, K110R, and K110A 
mutants were analyzed between 180-260nm at 0.5-nm intervals by using a Chirascan TM 
CD Spectrometer (Applied photophysics). The solution contains 8µM proteins and 
distilled water.  
Enzyme assay of M. tuberculosis PykA used for HTS 
The pyruvate kinase activity can be measured with coupled the lactate 
dehydrogenase (LDH) reaction. Mtb PykA catalyzes pyruvate production from PEP by 
converting ADP to ATP in presence of divalent metal, Mg2+. Then lactate 
dehydrogenase (LDH) produces lactate from pyruvate by converting NADH to NAD+. 
Therefore, a decrease in NADH absorbance was monitored at 340nm for PykA enzyme 
activity (Figure 4-10).   
 
 
 
 
Figure 4-10. Schematic of the Mtb PykA enzyme assay coupled LDH enzyme reaction. 
The PykA activity was measured in decrease of NADH absorbance at 340nm.  
 
 
 
The 4nM purified Mtb PykA enzyme was used for measuring enzyme assay in 
solution contained 0.5mM ADP, 0.25 mM NADH, 2.5 mM MgCl2 and 1unit of LDH. 
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The reaction was initiated by addition of 0.5mM PEP after pre-incubated with inhibitors 
for 20min at room temperature.    
 
Additional results 
Lysine acetylation of Mtb PykA – identification of acetylated lysine 
The pyruvate kinase enzyme is regulated in multiple ways, including gene 
expression, allosteric regulation by small metabolites, and post-translational 
modification. Major post-translational modification, lysine acetylation, is commonly 
found in metabolic enzymes 91. Rv0998, is a cAMP–regulated PAT of Mtb (Mtb PatA) 
that is a key enzyme in the adaptation to different carbon sources and shifting to slow 
growth 75,92. It has been proposed that acetyl coenzyme A (acetyl-CoA) synthetase 
(ACS) is acetylated by Mtb PatA 93, but the true substrates of Mtb PatA have not yet 
been determined. Christopher M. Sassetti’s group identified acetylated peptide 
(VSTTYk(ac)QLAQDAAR) on M. smegmatis pyruvate kinase (M. smeg PykA) when 
incubating with recombinant Mtb PatA (data not published).  
We attempted to investigate whether Mtb PykA is the substrate for Mtb PAT, we 
incubated Mtb PykA with Mtb PAT (Rv0998) (Method in chapter x) and digested the 
sample with trypsin. We analyzed the resulting peptide fragments using LC/MS/MS. 
However, the expected lysine acetylated peptide fragment (VSTTYK*R) was not found 
in the digested sample though it had been in the unmodified sample, as shown in figure 
4-11. Trypsin preferentially cleaves positively charged residues such as lysine or 
arginine. However, trypsin digestion is limited to acetylated lysines due to both steric 
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effects and the loss of positive charge on the Ɛ-amine group of lysine, which disrupts 
interaction with the aspartate residue of the trypsin catalytic center 94. Therefore, the 
VSTTYKR fragment could have been acetylated resulting in the missing peak in the 
modified sample. Many trials to identify the acetylated fragment were unsuccessful, 
further analysis is required for this study.  
 
 
 
 
Figure 4-11. Trypsin digested peptide sequence identified from an LC/MS/MS 
comparison of unmodified and modified samples. Unmodified sample ran in the absence 
of acetylase (Mtb PAT), while modified sample ran in the presence of acetylase (Mtb 
PAT).  The peptide fragments, VSTTYK(110), and SQLAMTWGTSTFIVPK(418) are 
not present in the LC/MS/MS result of modified sample. 
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Lysine acetylation of Mtb PykA – site-directed mutagenesis at the K110 site 
K112 in M. smegmatis is identical to the K110 residue in the B-domain of Mtb 
PykA. To establish the role of K110 in Mtb PykA, we performed site-directed 
mutagenesis to make K110A, K110Q, and K110R mutants. As shown in figure 4-12, the 
K110A mutant exhibits about 25% decreased activity and the K110Q and K110R 
mutants show 60% decreased activity compared to the wild-type. The CD analysis of 
each mutant revealed that no significant structural changes occurred (Figure 4-13). In 
figure 4-14, K110 was located in B-domain and pointed to solvent area without 
interaction with vicinity residues. This suggests that acetylated K110 might affect B-
domain flexibility inducing loss of substrate affinity. However, the mutants did not 
completely impair enzyme activity, thus, further study is required to conclude whether 
Mtb PykA is one of the substrates for Mtb PAT or not.  
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Figure 4-12. The enzyme activity of wild-type (blue) and mutants of Mtb PykA, K110A 
(red), K110Q (green), and K110R (purple).  K110A mutant exhibits about 25% 
decreased activity and the K110Q and K110R mutants show 60% decreased activity 
compared to the wild-type. 
 
 
  
 
162 
 
Figure 4-13. CD result of wild-type and mutants of Mtb PykA, K110Q, K110R, and 
K110A. The table shows no major conformational changes occur in mutants.  
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Figure 4-14. Location of K110 in the B-domain. K110 residue is pointing to solvent 
area, no major interaction found with adjacent residues.   
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CHAPTER V                                                                                                             
IDENTIFICATION OF POTENTIAL INHIBITORS TARGETING PYRUVATE 
KINASE FROM MYCOBACTERIUM TUBERCULOSIS 
 
Introduction 
The pyruvate kinase enzyme is ubiquitous to most of living cells as it is a critical 
enzyme in the glycolytic pathway.  Pyruvate kinase is an essential gene in methicillin-
resistant Staphylococcus aureus (MRSA), Haemophilus influenzea, and Streptococcus 
pneumonia 95, 96, 97 and has been studied as a potential drug target against Trypanosoma 
brucei and Leishmania Mexicana pyruvate kinase enzyme 98 due to they rely on 
glycolytic pathway to produce catabolic source of ATP. The pyruvate kinase isoenzyme 
M2 (PKM2) is an anti-cancer drug target due to its role in controlling glycolysis speed 
and reprogramming the glycolytic flux to provide the special metabolic needs of 
proliferating cancer cells 99, 100.  
The successful examples in the development of species-specific inhibitors against 
pyruvate kinase enzyme have been reported to date. The C-C' interface site of the 
pyruvate kinase enzyme from methicillin-resistant Staphylococcus aureus (MRSA) has 
been targeted as a druggable site. The C-C' interface site is formed by the interaction of 
the Cα1 helices and the Cβ5 strands in each subunit’s C-domain (Figure 4-3).  Bis-indole 
alkaloid inhibitors show nano-molar IC50 values for MRSA pyruvate kinase, where they 
bind to the C-C' interface causing tetramer rigidity and ineffective catalysis 101. Another 
example, dye-like molecules, suramin and the trypan blue mimetics, inhibit Leishmania 
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mexicana (Lm) pyruvate kinase through binding in ATP binding site, these inhibitors 
selectively inhibits PKs from humans 102.  These previous results indicate positive view 
of the development of selective inhibitors against Mtb PykA. The sequence alignment 
(Figure 5-1) compares the Cα1 helices and Cβ5 strands in the C-domain of the Mtb and 
human pyruvate kinase isoforms, indicating which amino acids in this region are not 
highly conserved among species. Therefore, the C- C' interface can also be exploited for 
the design of pathogen-specific inhibitors. In addition, as discussed in Chapter 4, we 
highlighted the sequence divergence of pyruvate kinase between the bacterial and 
mammalian enzymes, especially the allosteric regulator binding site. This also provides 
an opportunity for the design of Mtb PykA specific inhibitors which would not disturb 
human glycolysis. 
5 	  
 
 
 
Figure 5-1. Sequence alignment of the C- C' interface composed of Cα1 helices (349-
366, numbering in Mtb PykA (or PK) and Cβ5 strands (458-466 residues) of each 
subunit in the Mtb and human pyruvate kinase isozymes.  
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Transposon mutagenesis of the H37Rv strain showed that Mtb PykA (Rv1617) is 
an essential gene for in vitro growth of Mtb on glycerol and fatty acids 30, indicating that 
the Mtb PykA enzyme might be related to TB pathogenesis. A knock-out mutant of the 
Mtb PykA gene failed to grow in vitro on glycerol as the sole carbon source 103. Despite 
the importance of Mtb PykA for TB growth and numerous inhibitor studies for the 
pyruvate kinase enzyme across divergent species, no inhibitor studies have been done 
against Mtb PykA. As is common for multi-species housekeeping enzymes, pyruvate 
kinase exhibits a conserved architecture and active site. The presence of highly 
conserved pyruvate kinase homologue in host may hamper development of inhibitors 
targeting on Mtb PykA. To search for Mtb PykA inhibitors, a chemical library of 1428 
compounds (Sac2 hits library) that inhibit Mtb (mc2 7000), and the predicted pyruvate 
kinase inhibitors from in silico screening were tested against Mtb PykA. Several hits 
were found to inhibit M. tuberculosis growth with low micromolar range MICs and with 
IC50s in the nanomolar range. One of the hits bound to the ATP/ADP binding site, this 
result provides potential scaffolds for the development of more potent inhibitor targeting 
on Mtb PykA. 
 
Result and discussion 
In vitro HT screening of the anti-tuberculosis active compounds library 
To identify lead molecules inhibiting Mtb PykA, 1428 anti-tuberculosis active 
compounds (TB growth inhibition on dextrose and acetate as dual carbon sources) were 
screened against the enzyme from our libraries (Sac2 hit libraries). Twelve hits exhibited 
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more than 60% enzyme inhibition at 20 µM. Four compounds among 12 hits showed an 
inhibitory activity against both whole-cell and enzyme. Binding test against enzyme for 
these four hits was tested via DSF.  The chemical structures of compounds, IC50, MIC, 
and ΔTm values are listed in Table 5-1.   
 
 
  
Table 5-1. Distinct structural classes of four hits were identified that exhibit inhibition 
of both the Mtb PykA enzyme and the whole-cell (mc27000). 
 
ID Structure ΔTm IC50 (µM) 
MIC 
(mc27000) 
(µM) 
LC:F0808-1900 
 
 
2 0.76 10 
MB_P:KM04416 
 
 
-3 0.04 5-10 
LC:F2147-0563 
 
 
 
1 0.23 5-10 
LC:F3284-4918 
 
 
2 0.06 10 
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LC:F3284-4918 (5,6-dimethylthieno[2,3-d][1,2,3]triazin-4(3H)-one) caused a 
two degree shift in the DSF assay with an IC50 value of 0.06 µM and an MIC value of 10 
µM. LC:F2147-0563 (5-amino-4-phenylthiazole-2-thiolate) showed a one degree shift in 
the thermal shift assay, and an IC50 value of 0.23 µM. MB_P:KM04416 (ethyl 4-(3-
oxoisothiazol-2(3H)-yl)benzoate) caused a negative shift of about three degrees, with an 
IC50 of 0.04 µM. LC:F0808-1900(N-(3-bromo-4-hydroxynaphthalen-1-yl)-4-
ethylbenzenesulfonamide) resulted in a two degree shift with an IC50 value of 0.76 µM 
and an MIC value of 10 µM. Two compounds, KM01446 and F0808-1900 compounds 
were tested on human fibroblasts cell for testing cytotoxicity with compound 
conconcetration in range of from 0 to 50µM. While KM01446 compound showed 
toxicity at 12.5µM of compound, F0808-1900 is non-toxic to cells up to 25µM range. 
However, trials (soaking and co-crystallization) in obtaining a complex structure to 
determine the binding mode of these compounds were unsuccessful.  
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Figure 5-2. Predicted binding mode of F0808-1900 (N-(3-bromo-4-hydroxynaphthalen-
1-yl)-4-ethylbenzenesulfonamide) with Mtb PykA discovered in docking. Docking 
structure with F0808-1900 was colored in light purple, and ADP complex structure of 
Mtb PykA was colored in grey. F0808-1900 binds to ADP/ATP binding pocket in the 
active site.  
 
 
 
F0808-1900 bound to the ATP-binding site 
The interactions of F0808-1900 with the Mtb PykA enzyme were analyzed using 
a molecular docking approach, Glide (grid-based ligand docking) 104, was done by Dr. 
Charles Hutchins from Abbvie. The docking result shows the F0808-1900 molecule 
binds to the ATP binding site, the naphthalene ring has a π-π interaction with the 
imidazole ring of the H38 side chain (3.6 Å), the site overlaps with the adenine ring as 
shown in the ADP-complex in the Mtb PykA structure (Figure 5-2). The two oxygens of 
the sulfonamide linker accept hydrogen atoms from the backbone amide of the N35 and 
H38 residues to form hydrogen bonds at 2.0 Å and 2.9 Å, respectively. The benzyl ring 
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interacts with the H44 side chain at a distance of 3.8 Å. The interactions of the F0808-
1900 ethyl benzyl ring with enzyme are supported by hydrophobic interactions, such as 
the side chain of the H44 residue (3.8 Å) and the peptide bonds of G12 and P13 (3.2 Å). 
Four compounds having similar structure with F0808-1900 purchased from ChemBrige 
vendor were tested against Mtb PykA to check which parts of compounds are important 
for interaction. The results revealed that the naphthalene ring of this compound is critical 
to inhibit enzyme activity (Figure 5-3).    
 
 
 
 
Figure 5-3. Four purchased compounds which are similar to “hit” structure (F0808-
1900) with IC50 values. These suggest the naphthalene ring is important to maintain 
enzyme inhibition. (A) N-(3-bromo-4-hydroxy-1-naphthyl)-4-fluorobenzenesulfonamide 
(B) N-(3-bromo-4-hydroxy-1-naphthyl)-2-naphthalenesulfonamide (C) N-(3-bromo-4-
hydroxyphenyl)-4-fluorobenzenesulfonamide (D) N-(4-chlorobenzyl)quinolin-5-amine 
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Comparison ADP binding site of Mtb and human pyruvate kinase  
Despite the conservation of the ADP binding area among species, the ethylbenzyl 
ring sulfonamide of F0808-1900 binding site is different in the host enzyme as shown in 
the superposed structure of human and Mtb pyruvate kinase. Notably, as shown in Figure 
5-4, Y83 in human M2 pyruvate kinase will cause steric hindrance with the ethylbenzyl 
ring, while D43 residue in Mtb PykA does not, indicating that this compound may not 
inhibit the human enzyme. Adjacent to that, there are two more residue differences; M34 
and A47 residues in Mtb PykA are substituent with L74 and T87 residues in human M2 
PK. This structural evidence of docked F0808-1900 with Mtb PykA implies that this 
adjacent pocket can be exploited for the design of selective inhibitors against Mtb PykA. 
 
 
 
 
Figure 5-4. Comparison of the docked F0808-1900 compound in the Mtb PykA 
structure (pink) with the human M2 PK (tan; PDB 3GR4). The inhibitor binding site 
indicates different residues between the human and Mtb PykA enzymes, indicating a 
potential site for selective inhibitor development.  
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Virtual screening hits were experimentally validated against Mtb PykA 
The Abbvie Company conducted virtual screening to identify molecules with 
inhibition potential against Mtb PykA using computational drug discovery tools to 
generate 531 potential Mtb PykA inhibitors. Virtual screening (VS) was based on the 
ADP binding site in the Mtb PykA -ADP complex crystal structure. Glide was applied to 
predict which molecules would potentially bind to the active site 104. The 531 
compounds were tested against the Mtb PykA enzyme, resulting in 10 hits showing a 
more than 75% inhibition. We eliminated six hits due to conflicts with the other 
institute’s projects, leaving us with four hits for further study. The chemical structure of 
the four hits, the IC50, and MIC90 values are represented in Figure 5-5. A-1261670 (5-
(2,5-dimethyl-1H-pyrrol-1-yl)-2-hydroxybenzoic acid) exhibited potent activity against 
the enzyme (IC50 = 1.2 µM), but it was not effective in the whole-cell assay (MIC90 > 
100 µM). Interestingly, this compound shares a notable structural similarity with 
MB_P:KM04416 and LC:F2147-0563 (a benzene and a five membered ring) (Table 5-
1), which were previous hits. These results suggest that a scaffold including benzene and 
a five membered ring could be modified to increase potency against both the enzyme 
and the cell.  
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Figure 5-5. The chemical structure of the four identified active compounds from the 
virtual screen done by AbbVie with IC50 and MIC90 values for each compound. 
 
 
 
A-1476021, 4-(4-(1-hydroxy-2-(3-(trifluoromethyl)phenoxy)ethyl)-1H-1,2,3-
triazol-1-yl)-5-phenylpentanoic acid, has a very potent enzyme inhibition, showing an 
IC50 value of 0.27 µM and mild activity against the cell with an MIC90 value of 25 µM. 
Two hits with a close structural resemblance, A-335500 and A-340049, had IC50 values 
of 0.8 and 1.1 µM, respectively, but their whole-cell activities were not quite as strong as 
A-1476021, perhaps because its larger size might make it difficult to enter the cell. In 
this study, we used virtual screening and anti-Mtb active compounds to search for novel 
Mtb PykA inhibitors. We are conducting trials to obtain complex structures for all the 
hits to determine their binding mode. Binding orientations and optimization should be 
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investigated further. These results will provide potential scaffolds for further 
development of more potent and selective Mtb PykA inhibitors.  
 
Conclusion 
The screening of our chemical compound libraries (Sac2) resulted in identify 
four hits which showed potent activity on enzyme at nano-molar range and whole cell at 
micro-molar range. Docking of F0808-1900 hit into the active site of Mtb PykA revealed 
its binding site was slightly overlapped with the ADP/ATP binding site, but different 
residues were involved in contact of F0808-1900. Thus, this site could be explored 
further for the design of selective inhibitors. Also, the naphthalene ring of F0808-1900 is 
critical for having potent inhibitory activity against enzyme. Hits from virtual screening 
using Mtb PykA structure were screened Mtb PykA enzyme, and four hits show very 
potent inhibitory effect on enzyme. These works provides promising directions for the 
lead modification and design selective inhibitor strategy.      
 
Experimental procedures 
Enzyme assay of M. tuberculosis pyruvate kinase used for HTS 
The pyruvate kinase activity can be measured with coupled the lactate 
dehydrogenase (LDH) reaction. Mtb PykA catalyzes pyruvate production from PEP by 
converting ADP to ATP in presence of divalent metal, Mg2+. Then lactate 
dehydrogenase (LDH) produces lactate from pyruvate by converting NADH to NAD+. 
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Therefore, a decrease in NADH absorbance was monitored at 340nm for PykA enzyme 
activity.  
The 4nM purified Mtb PykA enzyme was used for measuring enzyme assay in 
solution contained 0.5mM ADP, 0.25 mM NADH, 2.5 mM MgCl2 and 1unit of LDH. 
The reaction was initiated by addition of 0.5mM PEP after pre-incubated with inhibitors 
for 20min at room temperature.   The enzyme assay was monitored the decreased NADH 
absorbance at 340 nm during 5min. The % inhibition was calculated from this equation, 
%inhibition = (1- (decreased absorbance slope)/control slope (no inhibitor, only 
DMSO)))*100. The value of IC50 was calculated by using Collaborative Drug Discovery 
(CDD) database. Activity assays were performed with a Thermo Scientific Multiskan 
GO spectrometer. The plate used in the enzyme assay was a 96-well, half area, UV-star 
plate, (Greiner bio-one). 
Differential Scanning Fluorimetry (DSF) assay of M. tuberculosis PykA  
The real time (RT)-PCR machine (Stratagene Mx3005P) was set to equilibrate 
samples at 25°C for 5minutes and then gradually increase temperature to 95°C at a rate 
of 1°C/minute. The excitation and emission of SYPRO orange can be monitored using 
filters: FAM (492nm) and ROX (610nm). The RT-PCR instrument (MxPro software) 
calculated  first derivative plot, indicating the lowest point is melting point of the protein 
105 106. The master mix contained 20µg/ml protein in buffer (20mM Tris-HCl pH 7.5, 
50mM NaCl) and 5X SYPRO orange (diluted from 5000X concentrate). Each well of a 
96-well plate has 10µl solution contained 9µl master mix and 1µl of 1mM inhibitors 
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stock (final concentration 100 µM). It is not recommended exceed DMSO amount not 
over 2% (v/v), but this case, 10% DMSO does not influence the results.  
Whole cell assay for MIC determination on mc27000 strain 
mc2 7000 starting culture in 7H9 containing OADC, Tyloxapol, Pantothenic acid, 
Malachite green was used to grow until OD600 reaches to 1.0.  The growing cell from 
starting culture was added into testing media 7H9 with dextrose. The media consists 0.5% 
dextrose, 0.085%  NaCl, 0.05% tyloxapol, 25µg/ml Pantothenic acid, and 0.25µg/ml 
malachite green. Incubation with inhibitors in 96-well plate lasts for 7 days at 37 °C and 
then the each well was stained with resazurin (5 µg/ml final) for viability testing.  
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CHAPTER VI                                                                                                    
SUMMARY 
 
New anti-TB drugs are urgently needed to eradicate M. tuberculosis from the 
human population. The Mtb PEPCK and PykA enzymes are involved in the CCM, 
which is a major determinant of the pathogenicity of Mtb, but drug development has 
traditionally shied away from targeting enzymes with human orthologs. I have 
dedicated the years of my Ph.D to the challenging topic of making progressive effort in 
targeting the Mtb PEPCK and PykA enzymes for the development of efficient anti-TB 
drugs. In CHAPTER 1, the literature review on TB drug discovery, and the problem of 
currently used TB drugs were discussed. Also, the prospect of the Mtb CCM as target 
for anti-tubercular drug design was addressed. In CHAPTER 2, I presented the crystal 
structures of Mtb PEPCK in apo and complex forms. Despite a highly conserved active 
site between the human and Mtb enzymes, distinct movements of the flexible loops 
were observed. A functional study of Mtb PEPCK revealed that a unique interaction 
between the P-loop and the Ω-loop in Mtb PEPCK is required to allow efficacious the 
anaplerotic reaction (PEP to OAA) of PEPCK, which is important to Mtb’s 
pathogenicity. Comparing the structural differences between the human enzyme and 
Mtb PEPCK supported its viability as a target for the design of selective inhibitors. In 
CHAPTER 3, GTP-competitive inhibitors were introduced and optimized based on 
structural evidence for inhibitor interaction with Mtb PEPCK. This work has created a 
positive outlook on the success of designing a pathogen-specific anti-tuberculosis 
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drug. We developed selective inhibitors against Mtb PEPCK enzyme. In CHAPTER 4, 
crystal structures of the Mtb PykA enzyme were determined, and the binding mode of 
an allosteric effecotor, AMP was identified for the first time. Comparison of the 
allosteric effector binding site between Mtb and human revealed important differences 
in the residues present in the site that could be exploited for the development of 
selective inhibitors. In CHAPTER 5, identification of inhibitors from HT screening of 
diverse compound libraries was addressed. The hits were active against both the 
enzyme and whole-cell in nanomolar and low micromolar ranges, respectively. This 
works provide potential scaffolds that can be used for further rounds of inhibitor 
optimization. Structural studies of Mtb PEPCK and PykA have provided a better 
understanding of their role in the gluconeogenesis/glycolysis pathway. The inhibitor 
studies presented in this dissertation of two important enzymes in the Mtb CCM not 
only reinforce the structure guided inhibitor design strategy but also provide better 
direction for lead optimization.  
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